A Study on the effects of Intravenous Dexmedetomidine on the Haemodynamic Stress Response to Laryngoscopy and Endotracheal Intubation during General Anaesthesia by Rakhi, S P
A STUDY ON THE EFFECTS OF INTRAVENOUS 
DEXMEDETOMIDINE ON THE HAEMODYNAMIC 
STRESS RESPONSE TO LARYNGOSCOPY 
AND ENDOTRACHEAL INTUBATION 
DURING GENERAL  
ANAESTHESIA 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation 
Submitted to 
THE TAMILNADU Dr. M.G.R MEDICAL 
UNIVERSITY 
 
In partial fulfilment of the requirements for the award 
of the degree of 
 
M.D ANAESTHESIOLOGY 
Branch X 
April 2015 
CERTIFICATE 
 
This is to certify that this dissertation entitled “A study 
on the effects of intravenous dexmedetomidine on the 
haemodynamic stress response to laryngoscopy and 
endotracheal intubation during general anaesthesia” is a 
bonafide record of the work done by Dr. Rakhi S.P under my 
guidance and supervision in the Department of Anaesthesiology 
during the period of her postgraduate study for M.D 
Anaesthesiology [Branch-X] from 2012-2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. V.G.Jayaprakash, MD 
[Guide] 
Professor 
Department of Anaesthesiology                   
Sree Mookambika Institute of 
Medical Science                                                                          
Kulasekharam                                                                          
Kanyakumari (Dist) – 629161 
Mobile: 9447833999 
Dr. Rema. V. Nair, M.D., D.G.O.,  
Director  
Sree Mookambika Institute of  
Medical Sciences [SMIMS] 
Kulasekharam [K.K District] 
Tamil Nadu -629161 
 
Dr. G.Parvathy , DNB, DA 
Professor and Head 
Department of Anaesthesiology                    
Sree Mookambika Institute of   
Medical Science                                                                          
Kulasekharam                                                                          
Kanyakumari (Dist) – 629161 
 
DECLARATION 
 
In the following pages is presented a consolidated report 
of the study “A study on the effects of intravenous 
dexmedetomidine on the haemodynamic stress response to 
laryngoscopy and endotracheal intubation during general 
anaesthesia” a randomized clinical trial, on cases studied and 
followed up by me at Sree Mookambika Institute of Medical 
Sciences, Kulasekharam from 2013-2014. This thesis is 
submitted to the Dr.M.G.R. Medical University, Chennai in 
partial fulfilment of the rules and regulations for the award of 
MD Degree examination in Anaesthesiology. 
Dr.Rakhi S.P, 
Junior Resident in Anaesthesiology, 
Department of Anaesthesiology,  
Sree Mookambika Institute of Medical Sciences,  
Kulasekharam, Kanyakumari District. 
 
 
 
 
 
 
PLAGIARISM SCREENING REPORT 
ACKNOWLEDGEMENT 
I thank God almighty, for all his blessings, without which this work 
would not have been possible. 
I express my heartfelt gratitude our Director Dr. Rema V. Nair and our 
Chairman Dr. Velayudhan Nair who provided me the infrastructure and for 
permitting me to carry out this study. They are the foundation pillars of the 
various activities that have been initiated in our institution. 
I thank my HOD Dr. G.Parvathy whose suggestions, help, critical views 
and constant motivation was present throughout the study period. She lent her 
full support in times of difficulties that I encountered during this study period. 
She is the answer to our prayers when we post graduates were straying during 
our study times. It has been a tremendous and wonderful experience to work 
under her guidance.  
I thank my guide Dr V.G. Jayaprakash for his valuable help, suggestions 
and supervision throughout the study. His encouragement from the inception of 
this research to its culmination has been profound. He gave me constant 
support throughout my post-graduation days without which this dissertation 
would not have been completed on time.  
I humbly thank Dr.Gopalakrishnan whose support, guidance, help, 
critical views and comments kept me in full swing throughout my study period. 
His suggestions were very valuable at each stage of my dissertation work. I am 
indebted to him for his guidance and support throughout my initial post 
graduate days.   
I am also grateful to Dr.Subramaniam for his valuable support and 
constant encouragement. 
I also thank Dr. Rommy Geever, Dr.Prashanthan, Dr.Mahilamani and all 
the staff members of Anaesthesiology for their valuable support. 
I thank Dr.Mohsina Basheer, my co-pg, for her valuable and timely help 
which made me complete my study on time. 
I am grateful to my junior post graduates Dr.Suzanne and Dr.Jisha for 
the various technical aspects of my study. 
I am grateful to my family members for relieving me of my social 
responsibilities so that I could fully focus my attention on this study. 
Without the whole hearted cooperation of my patients, this thesis would 
not have reached a conclusion. I express my sincere gratitude to all my patients 
at Sree Mookambika Institute of Medical Sciences, Kulasekharam. 
Dr.Rakhi S.P. 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF CONTENTS 
 
Sl.No. Contents Page No 
1. Introduction  1 
2. Aims and Objectives 2 
3. Hypothesis and Scientific Justification 3 
4. Review of Literature 4-75 
5.  Materials and Methods 76-80 
6.  Statistical Analysis 81-97 
7. Discussion  98-103 
8. Conclusion 104 
9.  Summary  105-106 
10. References  107-138 
11. Annexures  i-xxii 
 
 
 
 
 
 
LIST OF TABLES 
Sl. No Tables Page No 
1 Distribution of Sample according to Age 81 
2 Distribution of sample according to gender of 
patients 
82 
3 Comparison of mean body weight between controls 
and study group  
83 
4 Comparion of American Society of 
Anaesthesiology score between controls and study 
group 
84 
5 Comparison of number of patients who underwent 
different types of surgery in group-I and group-II 
85 
6 Comparison of heart rate changes between groups 
at various time intervals 
87 
7 Comparison of mean systolic blood pressure 
changes between groups at various time intervals 
89 
8 Comparison of mean diastolic blood pressure 
changes between groups at various time intervals 
91 
9 Comparison of mean arterial pressure changes 
between groups at various time intervals 
93 
10 Comparison of Isoflurane concentration used in 
Study and Control Groups 
95 
11 No. of patients receiving supplemental Opioid in 
intraoperative period 
95 
 
 
LIST OF FIGURES 
Sl. No Figures Page No 
1 Chemical  structure  of dexmedetomidine 49 
2 Dexmedetomidine Vial and Ampoule 51 
3 The  different  α2  adrenoreceptors 53 
4 Physiology of dexmedetomidine 61 
5 Distribution of Sample according to Age of patients 82 
6 Distribution of sample according to gender of 
patients 
83 
7 Comparison of mean body weight between controls 
and study group 
84 
8 Comparion of American Society of 
Anaesthesiology score between control and study 
group 
85 
9 Time dependent changes in heart rate of group-I 
and group II patients  
88 
10 Time dependent changes in systolic blood pressure 
in group-I and II patients 
90 
11 Time dependent changes in diastolic blood pressure 
in group-I and II patients 
92 
12 Comparison of mean arterial pressure changes 
between groups at various time intervals 
94 
13 No. of patients receiving supplemental Opioid in 
intraoperative period in Study Group 
96 
14 No. of patients receiving supplemental Opioid in 
intraoperative period in Control Group 
96 
 
LIST OF ABBREVIATIONS 
ANP  : Atrial Natriuretic Peptide 
ASA  :   American Society of Anaesthesiologists 
ATP  : Adenosine Triphosphate 
AVP  : Arginine Vasopressin 
BIS  : Bispectral Index 
CABG : Coronary Artery Bypass Grafting 
cAMP : Cyclic Adenosine Monophosphate 
CBF  :  Cerebral Blood Flow 
CMRO2 :  Cerebral Metabolic Rate of Oxygen 
CNS  :    Central nervous system 
CPB  : Cardio Pulmonary Bypass 
CSF  : Cerebro Spinal Fluid 
ECG  :      Electrocardiogram 
ERCP : Endoscopic Retrograde Cholangio Pancreatography 
FDA  : Food and Drug Administration 
GABA :       Gamma amino butyric acid 
ICP  : Intra Cranial Pressure 
ICU  : Intensive Care Unit 
IM           :         Intramuscular 
IOP  : Intra Ocular Pressure 
IV           :         Intravenous 
LC  : Locus Coeruleus 
MAC  : Monitored Anaesthesia Care 
MAP            :         Mean Arterial Pressure 
NS  : Normal Saline 
PaCO2 : Partial Pressure of Carbon-di-oxide 
PACU : Post Anaesthesia Care Unit 
VAS  : Visual Analogue Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
 
Background and Objectives: 
During induction of general anaesthesia, hypertension and tachycardia caused 
by endotracheal intubation may lead to cardiac ischemia and arrhythmias. 
Dexmedetomidine attenuates the hemodynamic response to endotracheal intubation 
and reduces anaesthetic requirement. The purpose of this study was to evaluate the 
effect of intravenous dexmedetomidine 1μg/kg given over 10 minutes before 
induction of anaesthesia and 0.4mcg/kg/hour as maintenance during the surgery, on 
haemodynamic stress response resulting from laryngoscopy and endotracheal 
intubation and the haemodynamic stability during surgery. 
Materials and Methods:  
Seventy patients scheduled for elective surgery were randomized into two 
groups each having thirty five patients-dexmedetomidine group (Group 1) and control 
group (Group 2). Heart rate, systolic blood pressure, and diastolic blood pressure were 
recorded at just before intubation, immediately after intubation, 1, 2, 3, 4, 5 minutes 
after intubation followed by every 5 minutes till the first 45 minutes of surgery.  
Anaesthesia was induced with inj.Propofol 2mg/kg IV followed by succinyl choline 
2mg/kg for endotracheal intubation.  Anaesthesia was maintained with oxygen, 
nitrous oxide, isoflurane, atracurium.  Any further need for analgesia was 
supplemented by IV fentanyl.  
Statistical Analysis:  
The data was analysed by SPSS 16.0 with independent t-test. 
 
 
Results:  
Pretreatment with dexmedetomidine 1 ug/kg attenuated the cardiovascular and 
catecholamine responses to tracheal intubation after induction of anaesthesia. In our 
present study, the rise in heart rate, systolic blood pressure and diastolic blood 
pressure after intubation, 1, 2, 3, 4, 5 and 10 minutes after intubation was significantly 
less in the dexmedetomidine group. The patients in dexmedetomidine group also had 
better haemodynamic stability during surgery. The requirement of opioids and 
isoflurane were significantly less in the dexmedetomidine group. 
Conclusions:  
Intravenous dexmedetomidine significantly attenuates sympathoadrenal 
response to laryngoscopy and endotracheal intubation and also cause reduction in 
intra operative anaesthetic requirement, without affecting intraoperative 
cardiovascular stability 
Keywords:  
Dexmedetomidine, endotracheal intubation, premedication, sedation, α2 
adrenergic 
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INTRODUCTION 
Balanced anaesthesia protocols include  combination of  drugs of 
different classes used with specific purpose so as to create  
unconsciousness, muscle relaxation, analgesia and amnesia. As the 
drugs are used in low to moderate doses, the adverse effects are 
reduced. So anaesthesia induction, maintenance and emergence are 
safer,  smoother and comfortable. Maintenance of heart  rate,  blood 
pressure and depth of anaesthesia are important in the intra-operative 
period. Laryngoscopy and intubation can lead to hemodynamic stress 
response which can be controlled by suitable agents. Various drugs like 
lignocaine,  nifedipine, Beta blockers, nitro glycerine etc. are used to 
reduce hemodynamic stress response to laryngoscopy and  intubation.  
Dexmedetomidine is a high selective centrally acting, potent 
alpha2 adrenergic agonist with less duration of action.  Alpha 2 to alpha 
1 selectivity for  dexmedetomidine is 1620:1 compared to 220:1 for 
clonidine.  Dexmedetomidine has sedative,  anxiolytic,  analgesic and 
sympatholytic propert ies.  
Various studies have been done using intravenous  
dexmedetomidine for analgesia,  anxiolysis and sedation during surgery. 
In our study we are analysing the effect  of intravenous  
dexmedetomidine1microgm/kg given over 10 minutes  before induction 
of anaesthesia  and then as continuous infusion at 0.4microgm/kg/hr 
during the maintenance of anaesthesia .  
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AIMS AND OBJECTIVES 
1.  To study if  dexmedetomidine can reduce hemodynamic stress 
response to laryngoscopy and tracheal intubation.  
2.  Assess hemodynamic stability during the surgery when  
dexmedetomidine is used.  
3.  To study the complications when dexmedetomidine is used.  
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HYPOTHESIS AND JUSTIFICATIONS OF THE STUDY 
Hypothesis  
Intravenous Dexmedetomidine decreases haemodynamic stress 
response during laryngoscopy and endotracheal intubation . 
 Scientific Justification of the Study 
 It  is  very important to maintain stable haemodynamic s 
throughout the surgery. Laryngoscopy and endotracheal intubation 
leads to haemodynamic instability.  This leads to increase in cardiac 
workload and myocardial oxygen consumption. This is deleterious  in 
patients with pre-existing cardiovascular disease. So it is important to 
find a suitable drug for reducing the haemodynamic stress response 
during laryngoscopy .  Various drugs l ike lignocaine, nifedipine,  beta 
blockers,  nitro glycerine etc .  are used to reduce haemodynamic stress 
response to laryngoscopy and intubation. Dexmedetomidine has 
additional analgesic,  anxiolytic, sedative and sympatholytic properties 
which are useful in general anaesthesia. So the dose  of other drugs and 
their adverse effects can be reduced along with reduct ion of hospital 
expenditure and maintenance of stable haemodynamics.  
 
 
 
 
 
4 
 
REVIEW OF LITERATURE 
Two predictors of perioperative cardiac morbidity are  increase in 
heart rate and blood pressure .  Increase in heart rate and acute 
hypertension deleteriously affect  myocardial  oxygen supply and 
demand. Different  techniques are being tried  to prevent or at tenuate the 
hemodynamic effects following laryngoscopy and tracheal intubation, 
like deepening of anaesthesia, avoiding anticholinergic drugs prior to 
surgery,  pre-treatment with lignocaine, vasodilators like nitroglycerin ,  
beta blockers, calcium channel blockers and opioids.  
Reid and Brace, first explained the hemodynamic effects to 
direct laryngoscopy and endotracheal  intubation
(6 )
.These hemodynamic 
changes were noticed after the emergence of muscle relaxants such as 
tubocurarine and succinylcholine for facilitating endotracheal 
intubation during anaesthesia induction.  King et  al
(7 )
 studied the 
hemodynamic changes to laryngoscopy in the year 1951. They proposed 
that  the cardiac dysrhythmias,  tachycardia and hypertension  related to 
laryngoscopy and tracheal intubation were the result of reduced vagal 
tone or a rise in sympatho-adrenal activity.  They noted that  
laryngoscopy alone can cause an elevated blood pressure.  Intubation 
amplified this  effect  and was capable of causing arrhythmias.  Wycoff
(8 )
 
compared laryngoscopy and endotracheal intubation under general  
anaesthesia with the same under cricothyroid block.  The block 
produced smaller  changes in blood pressure and  heart  rate.  Dingle
(9 )
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observed a rise in systolic  blood  pressure of more than  100mm Hg 
following endotracheal intubation.  
Bedford described the relation of CNS to the cardiovascular 
response
(1 0 )
.  During laryngoscopy and endotracheal intubation, 
hemodynamic instability ensues as larynx, trachea and carina  are 
having sympathetic nervous system reflexes which  respond to 
substances or objects which they com e in contact  with. Other elements 
such as a lighter plane of anaesthesia are also contributory to this  
stress response.  
C Prys Roberts et  al
(1 0 )  
demonstrated the electrocardiographic 
and hemodynamic responses to induction of anaesthesia  followed by 
laryngoscopy and endotracheal intubation. Takashima K et  al
(1 1 )
 
conducted a  study to find out the real  cause for cardiovascular response 
to rapid anaesthesia induction  and endotracheal intubation and showed 
that  the cardiovascular response during endotracheal intubation was 
mainly the result of insertion of the laryngoscope blade.  The variations 
in ECG found during intubation result s from stimulation of vagus nerve 
by laryngoscopy. The reason for these cardiovascular fluctuations was 
studied and concluded that  pressure exerted by the laryngoscope blade 
on the soft  tissues adjacent to the epiglott is probably contributed to the 
electrocardiographic findings.  
Cardiovascular response  to laryngoscopy and endotracheal 
intubation is  mediated by autonomic nervous system. The 
parasympathetic response which is sinus bradycardia is more common 
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in infants and small  children, but infrequently seen in adults also.  As 
this reflex is mediated by an increase in vagal tone at sino-atrial node, 
it  is considered as a monosynaptic response to a painful st imulus.  
Sinus tachycardia  is  the sympathetic response to laryngoscopy 
and intubation. Derbyshire et  al
(1 2 ,1 3 )
 suggested that tracheal intubation 
is accompanied by both increased sympathetic activity and an increased 
adreno-medullary catecholamine activity.  The common cardiovascular  
responses to tracheal intubation are produced by these sympathetic 
efferents.  These pathways are polysynaptic and traverse from the vagal 
and glossopharyngeal afferents to the sympathetic systems through the 
brain and spinal cord causing a diffuse autonomic response , including 
an increased firing of the cardio -accelerator fibres and the release of 
norepinephrine from adrenergic nerve endings in many vascular beds,  
and release of adrenaline from the adrenal medulla.  As renin released 
from the juxtaglomerular apparatus of kidney has β  adrenergic activity,  
renin angiotensin system activation also plays a role in the 
hypertensive change to intubation.  
In studying the cardiovascular responses to laryngoscopy and 
endotracheal intubation, the effect  of laryngoscopy has been studied 
separately from intubation.  To avoid the stimulus of rigid laryngoscopy 
and succinylcholine , Ovassapian et al
(1 4 )  
used awake fiberoptic  
nasotracheal intubation and reported that the highest rise in blood 
pressure happened during the introduction of  endotracheal tube 
through the  passage.  The maximum rise in heart rate occurred when 
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the endotracheal tube was placed in the trachea. Shribman et al
(1 5 )
 also 
studied the cardiovascular changes to laryngoscopy with or without 
intubation.  They demonstrated significant and similar ri se of blood 
pressure and circulating catecholamine concentrations with or without 
intubation. Intubation causes a higher increase in heart  rate , which was 
not seen with laryngoscopy only.  Finfer et  al
(1 6 )  
compared direct  
laryngoscopy with  fiberoptic intubation and found out that both 
laryngoscopic and bronchoscopic intubat ion resulted in significant 
increase in blood pressure and heart  rate without any d ifference 
between the groups. It  seems that maximum increase in blood pres sure 
occurs with laryngoscopy and the maximum rise in heart rate occurs 
with endotracheal intubation.  
Elderly patients constitute a high percentage of both inpatient 
and outpatient hospital  population  and have an greater incidence of 
coronary artery disease,  cerebrovascular disease and  a higher baseline 
blood pressure which makes them particularly susceptible to 
fluctuations  in blood pressure and heart  rate during laryngoscopy and 
endotracheal intubation leading to increased  risk of cerebro vascular  
accident, myocardial  infarction,  congestive cardiac failure or sudden 
death.
(1 7 ,1 8 )
 
 The prevalence of cardiovascular diseases significantly affects 
both cardiac and non-cardiac surgeries . As more patients are 
undergoing non-cardiac surgery, the impact of cardiovascular disease 
on such patients is  higher than in the cardiac surgery group. The 
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number of non-cardiac surgical patients at risk of cardiac morbidity is  
found to be 7 to 8 million patients per annum.
(1 9 )
 
Mangano stated that it  is difficult to assess the incidence of 
perioperative cardiac morbidity.  In the elderly group the range is        
2-15%.
(2 0 )
 
 Rose and Tinker
(2 1 )
 stated that final outcome (i.e.  perioperative 
myocardial  infarction, patient alive or dead), should be differentiated 
from process outcome (i.e.  myocardial ischemia, hypertension, 
tachycardia during surgery). When process outcome is considered, 
reduction of these different  physiologic disturbances during 
anaesthesia and surgery will  be better for the patient. It is not yet  
proved that reducing such physiological  changes actually improves 
final outcome, as a very large population study is needed to show 
relatively small but significant  differences.  
 Goldman  and Caldera
(2 2 )
  concluded  that  hypertension  and the  
history  of  cardiac  dysrhythmias  were  important risk  factors in  the  
issue  of  whether  preoperative  ischemia  can be  a  predictor  of  
negative  outcome.  Raby  et al
(2 3 )
  stated  that   preoperative  ischemia  
was  a  more  important  risk  factor,   which  was in contrast to 
Mongano  et  al 
(2 4 )
  whose study  concluded  that   postoperative  
ischemia  was  more  important.  
 The  time  during  which  intubation  is  done  is   principally  a  
high  risk  interval
(2 4 ,2 5 )
.   Known  or  suspected  cardiac  disease  is  
one  among  the commonest   indications for modifications of   
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haemodynamic  effect.  Patients  requiring  stable  haemodynamics  
include  patients  with  a  symptomatic  aortic  aneurysm,  ischemic  
heart  disease,  recent  myocardial   infarction, intracranial hypertension 
and cerebral  aneurysm.  Slogoff  and  Keats 
(2 6 )  
stated  that  most  of 
the  ischemic  episodes  during  anaesthesia  were  related  to 
intubation  and  surgical  stimulation,  particularly  if  tachycardia  
occurs.  Similarly  Kleinman  et al
(2 5 )
  stated  that  increase in heart  
rate and an increase in afterload  due to  laryngoscopy  and  
endotracheal  intubation  can  be  related  with  myocardial  ischemia 
occurring secondary  to  coronary  artery  vasoconstriction.  
 The  study  by  Goldman  and  Caldera  and  editorial  by Prys  
Roberts
(2 7 )
  give  rat ionale  for  delaying surgery  in  patients  whose  
blood pressure control  is   not  optimal.  Moreover,  Steen et  al
(2 8 )
,   
concluded that   almost   double  the  reinfarction  rate  is  seen 
perioperatively  in  patients  who  had   hypertension preoperatively.  
Stone et al
(2 9 )
 s tated  that  substantial   risk  of  developing  myocardi al   
ischemia is more in  hypertensive  patients  untreated  before  induction  
and  that  the  ischemia  occurring  during  the  stress  of  induction  
and  intubation  was  always  associated with rise in heart rate .  
 Two  academic  interpretors  of  perioperative  cardiac  
morbidity  are  rise in heart rate  and  rise in blood pressure
(3 0 ,3 1 )
.  The 
haemodynamic  changes  due to intubation  result ing  from  
sympathetic  nervous  stimulation  which  predispose  patients  to  
ischemia  comprise of increase  in heart  rate,  blood  pressure,   
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pulmonary  capillary  wedge  pressure  and  reduced  ejection  fraction. 
An  increase  in  heart   rate  deleteriously  affect  myocardial  oxygen  
supply  ( reduced  diastolic  fill ing  t ime)  and    demand  (increased 
cardiac  work load).  Blood  pressure  has  direct  relat ion  with  
cardiac  output  and  systemic  vascular  resistance.  Acute increase in 
blood pressure affects both myocardial  oxygen supply and  oxygen 
demand.  During  systemic  hypertension,  peak  systolic  ventricular  
wall  tension occurs,  which  increases  myocardial   oxygen  
consumption.  
 Cardiac  output  and  systemic  vascular  resistance  are  related 
to each other with  variations   in  one  resulting  in a  compensatory  
response  in  the  other.  Both  heart  rate  and  blood  pressure  are   
primary  determinants  of   balance  between  myocardial   oxygen  
supply  and  oxygen demand.  Heart  rate  is  there  on  both  oxygen  
supply  and  oxygen demand  sides  of  the  myocardial  equation.  
Myocardial  oxygen  supply  can  increase  by  a  reduction  in  heart   
rate  and  rise in  diastolic  blood  pressure,  both  within  
physiological  limi ts.  They  act by  allowing   a  prolonged  diastolic  
filling  time  and  a greater coronary  perfusion  pressure  respectively.   
Myocardial  oxygen  demand  increases  according to rise  in  heart  
rate,  result ing in a  less  diastolic  filling time and  myocardial   
perfusion  time. 
 It   has  been  recognized  that   there  are  six  determinants  of   
myocardial   work  i .e.  myocardial oxygen  consumption.  They  are:  
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Minor factors  (which are more or less fixed):   
1.  Metabolism (20%) 
2.  External work (17%) 
3.  Activation energy (3%) 
Major factors  (can be altered by pharmacological or physical  methods):  
1.  Systolic wall tension (30-40%) 
2.  Contractili ty (10-15%) 
3.  Heart  rate  
Systolic  wall  tension  is  the  most  significant   determinant  of  
left  ventricular  work,  accounting  for  30 -40%  of  the  energy  needs  
of the  beating  heart .  It   is  directly  proportional  to  the  product  of  
arterial  blood  pressure  (afterload)  and  left   ventricular  fil ling  
pressure  (preload).   Therefore  an  increase  in  either  of  these  
beyond  their  normal  range  will  cause an  increased  myocardial   
work  by  increasing  systolic  wall  tension.  This  also has a linear  
relation with the myocardial oxygen consumption. The concept  of  rate  
pressure  product  (heart  rate  x  systemic  blo od  pressure),  introduced  
by  Georta  et  al   (1957)  has  been  found  to effectively  reflect  
changes  in  myocardial  oxygen  consumption.  
 Myocardial contractility accounts for 10 -15% of myocardial  
oxygen consumption and cardiac work. Increase in heart rate is  
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associated with a rise in myocardial  contractil ity.   Therefore  rise  in  
heart  rate  means  rise  in  myocardial   work load  i .e.  increase in   
oxygen  demand.  
 On  the  other  side  of  the  scale  is   the  myocardial   oxygen  
supply. Supply  is   regula ted  by  adjusting  coronary  blood  flow ,  
which  is   dependent  on  coronary  vascular  resistance.  As  
myocardial  blood  flow  occurs  in  diastole,  diastolic  blood  pressure 
gives  an  estimate  of   the perfusion  pressure.  A diastolic  blood  
pressure  of  60mm Hg  is  generally  accepted  as  a  lower limit,  
below  which the perfusion  is likely  to  be  compromised.  Duration 
of diastole  is   another  important  factor  affecting  myocardial  oxygen  
supply.  At  a  normal  heart  rate  of 75/m inute,   diastole  occupies  
more  than  60  percentage  of  the  cardiac  cycle.  When  the  heart   
rate  increases,  systolic  intervals  change  little   while  diastolic  
intervals  decreases  significantly.   At  a  maximum  heart   rate  of   
180/minute,   diastole  occupies  only  40 percentage   of  the  cardiac  
cycle.  Here,  an  increase  in  rate  impairs  the  myocardial  supply  
and  can  lead  to  ischemia  or  infarction   when  the  balance  between  
oxygen  supply  and  demand  is  alr eady  compromised.  These facts  
show the importance of at tenuating the stress response .  
 Various techniques are available for haemodynamic modification 
and the selection of one may be difficult.   Thomson
(3 2 )
  stated  that  the 
method for obtaining  desired  haemodynamic  result  depends  on  the  
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clinical  scenario  and  anaesthesiologist’s preference.  Methods may 
be less significant compared  to final result . 
 During  general  anaesthesia ,  it   is  difficult  to  detect   periods of  
inadequate  myocardial oxygenation  because  angina  pectoris,  the  
most  reliable  indicator  of  myocardial  ischemia  cannot  be  
identified.  Hence  other  indices  have  to  be  used  to  assess  the  
adequacy  of  myocardial  oxygenation.  The  rate  pressure  product  
reflects  the  myocardial  oxygen  demand  and  is  obtained  by  
multiplying  systolic  blood  pressure  and  heart   rate.  Rate  pressure  
product  has  a  constant  association  with  the  onset  of  angina  pain.   
Patients  whose  rate  pressure  product  w ere  over  12000  showed  
ischemic  changes  in  V5  lead  during  the  pre -bypass  period  of  
coronary  artery  surgery  (Kaplan  1975).   Thus   i t   is   better  to 
monitor  the  rate  pressure  product  in  all   patients  with  coronary  
artery  disease and  maintain  it   less  than  12000  during  surgery,   
particularly  during  periods  of  stress  such  as  intubation.  
 Some regimens reduce the resulting hypertension , but fewer 
reduce resulting tachycardia.  Each of those methods has their own 
advantages,  disadvantages and risks .  It  is  difficult  to  compare  most 
of the studies as  methodological  differences   exist  in  size  and  type  
of  patient  populations , use  of  preoperative  and  concomitant  drugs,   
induction  agents,   dosage  and  t iming  of  study, duration  of  
laryngoscopy, maintenance  drugs,  frequency  and  methods  of  blood  
pressure  monitoring. 
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 Duration  of  laryngoscopy  has  bee n  shown  to  exert  an  
important   effect  on the severity  of  cardiovascular  response.  
Attempts  to  reduce stress  changes  to  laryngoscopy  and  
endotracheal  intubation  could  seem  to  be  the  most  suitable  when  
intubation  is   likely  to  take  greater   than  30  seconds.  This  is   
particularly  significant   in  coronary  artery  disease  or  intracranial   
hypertension.   Prolonging  laryngoscopy  greater   than  60  seconds  
produces  more  rise  in  pulse  rate  and  blood  pressure  (Stoelting, 
1977).  
 Different   methods  have  been described  in  literature  to  
supress  the  cardiovascular  responses  to  laryngoscopy  and  
endotracheal  intubation.  Some of them are:  
1.  Prophylactic  use  of  Beta  blockers  prior  to  laryngoscopy  and 
endotracheal  intubation  (acebutolol
(3 3 )
,   propranolol
(3 4 )
,   
atenolol
(3 5 )
,   metoprolol
(3 6 )
,   labetolol
( 3 7 ,3 8 )
  and  esmolol
(3 9 )
.   
Side  effects  of  beta  blockers  include  bronchospasm,  
bradycardia,   hypotension,    cardiac  dysrhythmias  and heart  
fai lure.  
2.  Thoracic  epidural  anaesthesia  (Watwill et al (4 0 )) 
3.  Inducing deeper plane of anaesthesia using volati le  anaesthetic 
agents.  (King  et al
( 7 )
) 
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4.  Use  of  calcium  channel  blockers (4 1 -4 3 )   (intravenous  
verapamil,   10mg  nifedipine  sublingually).  They may not be 
able to prevent tachycardia .  
5.  Magnesium sulfate  i.v (4 4 -4 6 )   inhibits  catecholamine  release.  
6.  Vasodilators  such  as  sodium  nitroprusside  1 -2mcg/kg  i.v  
15seconds  prior  to  laryngoscopy
( 4 7 )
,   hydralazine,   
phentolamine,  nitroglycerine
(4 8 -5 0 )
.  
7.  2ml nitroglycerine solution 60mg, 1 minute prior to induction .  
(Fassoulaki and Kaniaris
(5 0 )
).  
8.  Nitroglycerine  ointment  2%  applied  to  skin  12  minutes  
before  laryngoscopy  (Elkayam  U,  Aronow  WS)  
9.  Buprenorphine  i .v (5 1 )  
10.Fentanyl  1-2mcg/kg  2-4  minutes  before  laryngoscopy
(5 2 )
 
11.Alfentanil  15-30mcg/kg  (Black  et  al
(5 3 )
 
12.Sufentanil   0.5-1mcg/kg  (Kay  et   al
(5 4 )
)  
13.ATP
(5 5 ,5 6 )
  iv  0.05  and  0.1mg/kg  given  simultaneously  with  
start  of  laryngoscopy  (Mikawa  et   al
(5 7 )
) 
14.IV  Esmolol  infusion  of  500mcg/kg  started  3  minutes  prior  
to  laryngoscopy  and   intubation,  followed  by  a  continuous  
infusion  of  either  100mck/kg/min,  200mcg/kg/min  or  
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300mcg/kg/min  found  that   all  three  doses  significantly  
reduced  the  stress  response.  (Menkhaus  et  al
(5 8 )
) 
15.IV  Lidocaine  1.5mg/kg  3  minutes  before  intubation  
minimizes  blood  pressure  fluctuations  after  endotracheal  
intubation.  (Lev  &  Rosen
(5 9 )
) 
16.Lidocaine gargles  prior to laryngoscopy and intubation.  
(Stoelting
(6 0 )
) 
17.Lignocaine 4% spray into larynx  and trachea  before  intubation.  
(Delinker  et  al
(6 1 )
) 
18.Fentanyl  6mcg/kg  completely  abolished  haemodynamic  stress  
response  compared  to  attenuation  by  2mcg/kg.  (Kautto  U.M  
et  al
(6 2 )
) 
The  most  recent  studies which aim in control or  attenuation  
of  haemodynamic stress  effects  to laryngoscopy and intubation  
focused  on  the  effect  of  remifentanyl  at  various  dosing  regimens.  
Remifentanil  in  a  dose  of  1mcg/kg  bolus  over  30  seconds  
followed  by  an  infusion  of  0.5mcg/kg/min  was  found  to  
efficiently  attenuate  the  stress   response  to  intubation  in  a  study  
by  Thompson  et   al
( 6 3 )
.  
The use of alpha-2-adrenoreceptor agonists  as anaesthetics is not 
new.  Veterinarians used to employ  xylazine  and  medetomidine  for  
analgesia  and  sedation  in  animals  and  much  of  our  knowledge    
was gained from  this  application.  It  is  evident now that  complete  
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anaesthesia  is  possible  by  use of new,  more  potent  alpha-2-
adrenoreceptor  agonists,  like  medetomidine  and  i ts  stereoisomer ,   
Dexmedetomidine.  The  initial  movement   for  the  use  of  α -2-
adrenoreceptor  agonists  in  anaesthesia  was a result of   observation  
made  in  patients  who  were  receiv ed  clonidine  therapy
( 6 4 )
 during 
anaesthesia.   Kaukinen  S  et  al
(6 5 )
  demonstrated  the  preoperative  
and  postoperat ive  use  of  clonidine  with  neurolept  anaesthesia.   
This  was  soon  followed  by  description  of  M inimum Alveolar 
Concentration  requirement  of  halothane  by  clonidine  by  Bloor  BC  
et  al
(6 6 )
.  
Dexmedetomidine  is   a  far  more  selective  α -2-adrenoreceptor  
agonist ,  with a 1600  fold  greater  selectivity  for  the  alpha  2 than  
alpha  1  receptor
(6 7 )
.   Dexmedetomidine  possesses  sedative,   
anxiolytic,  sympatholytic,  analgesic  and  hypno tic  properties   
without  causing  significant   respiratory  depression
(6 8 -7 1 )
.   The  
sympatholytic  effect  reduces  mean  arterial  pressure   and  heart   
rate   by  reduction in   noradrenaline  secretion
(7 2 ,7 3 )
.   Moreover,   
Dexmedetomidine  has  the  ability  to  decrease   both  the  anaesthetic   
and  opioid  analgesic  requirements  in   the  perioperative  
period
(7 4 ,7 5 )
.   It   was  introduced  in  clinical  practice  in  the  United  
States  in  1999  and was approved  by  the  FDA  only  for use as   
short  term  (<24hrs)  sedative  for  adult   ICU  patients  who are under 
mechanical   ventilat ion.  Since  Dexmedetomidine shows an opioid-
sparing  effect  without  any  respiratory  depression,  it   is  
increasingly  used  “off  label”  during  different   types  of  surgeries.   
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Off-label use of dexmedetomidine  outside  the  ICU  include  sedation  
and  adjunct  analgesia  in  the   operating  room,  sedation  for   
diagnostic  and  procedure  units ,  and  for  other  uses   such  as  
withdrawal  detoxification/amelioration  i n  adult  and  paediatric  
patients
(7 6 ,7 7 )
.  
Dexmedetomidine is an imidazole compound. It is  the  
pharmacologically  active  dextroisomer  of  medetomidine   which has  
specific  and  selective  alpha -2-adrenoreceptor  agonism.  It  has a  
unique  mechanism  of  action  and i t  differs  from  those  other  
currently  used  sedatives  including  clonidine.  Activation  of   
receptors  in  brain  and  spinal  c ord  inhibits  neuronal  firing   
resulting in   hypotension,  bradycardia,    analgesia and sedation.  The  
responses  to  activation  of   receptors  in  other  areas  include  
reduction in  salivation, bowel  motility and secretion in  the  
gastrointestinal  tract;  contraction  of  vascular  and  other  smooth  
muscles;  inhibition  of  renin  release,  rise in  glomerular  filtrat ion  
and  rise in  secretion  of  sodium  and  water  in  the  kidney,   
reduction in  intraocular  pressure  and  reduction in   insulin  release  
from   pancreas.  In  general ,  presynaptic  activation  of  alpha -2-
adrenoreceptor  inhibits  the  secretion  of  noradrenaline,  terminating  
the  transmission  of  pain  signals.  Postsynaptic  activation  of  alpha -
2-adrenoreceptors  in  CNS causes   inhibition of sympathetic  activity  
resulting in  reduction in  blood  pressure  and  heart  rate.  These 
effects when combined can produce analgesia, sedation  and  anxiolysis.  
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Dexmedetomidine  exhibits  all  these  effects,  which helps in   
avoidance of  some  of  the  adverse  effects  of  multiagent  therapy. 
One  of  the  highest   densities  of  alpha -2-adrenoreceptors  has  
been  found  in  locus  coeruleus, main  noradrenergic  nucleus  in  
brain  and  a  key  modulator  of  vigilance.  Sedative and  hypnotic 
effects  of  alpha-2-adrenoreceptor  activation  is  at tributed  to  this  
site  of  origin  for  the  descending  medullo -spinal  noradrenergic  
pathway,  which is  known to  be  a significant   modulator  of  
nociceptive  neurotransmission .  In  LC,  alpha-2-adrenergic  and  
opioidergic  systems  are having common  effector  mechanisms,  
demonstrating  that   dexmedetomidine  has  supraspinal  site  of  
action.  
It  can be concluded from these findings   that  the  major  
antinociceptive and sedative  effects  of  dexmedetomidine  can be 
attributed  to  stimulation  of  alpha-2-adrenoreceptors  in  locus  
coerulus.   Moreover,   studies  in  transgenic  mice  have  demonstrated  
that  the  alpha-2-adrenoreceptors    subtype  is  liable  for  relaying  
the analgesic and  sedative properties  of  dexmedetomidine.  
Bloor  BC  et  al
(7 8 ,7 9 )
  studied  the  effect  of  dexmedetomidine  
in  humans  and  concluded  that   lower  doses  (0.25mcg/kg  and  
0.5mcg/kg)  resulted  in  monophasic   reduction  in  mean arterial 
blood pressure  response.  The  transient  pressor  phase  is   
unimportant  in  anaesthesia  and  should  probably  be  avoided  by  
slow  infusion  rate,   particularly  in  patients  with  impaired  cardiac  
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function.  The  second  phase  of  the  biphasic  response  i s  longer  
lasting  reduction of  mean arterial blood pressure   and  concomitant  
decrease  in  heart  rate.   They proved that  dexmedetomidine is well 
tolerated by all  subjects.   In  another  study  they  concluded  that   i .v  
dexmedetomidine  caused  marked  sedation,  mild  hypercapnia  and  
hypoventilation,  and  an  early  transient  ri se  in  oxygen  
consumption.  The  minimal  effect   of  dexmedetomidine  in 
ventilation indicates  that  alpha-2-adrenoreceptor  agonis ts  may  be  
useful   in  providing analgesia and  sedation  without  ventilatory  
depression. 
The  effects  of  dexmedetomidine  for  perioperative  control   of  
haemodynamics  were  investigated  by  many.  Villela  NR  et   al
(8 0 )
  
concluded  that  dexmedetomidine use as premedication,  infusion  
during  anaesthesia  or  in  the  postoperative  period  improves  
haemodynamic  stability.  Anaesthetic consumption is  reduced during 
anaesthesia.   Patients  sedated  with  dexmedetomidine  may  awaken  
when  requested  and  become  cooperative.  Even high doses of 
dexmedetomidine do not cause respiratory depression.  Bradycardia  is   
a  frequent  side  effect  which  may  be  minimized  by  slow  drug  
infusion.  Therefore,  dexmedetomidine is  an  important  additional  
resource  to  anaesthetic  practice  that   may  be  used  in  different  
patients  and  surgical   procedures.  Kall io  A  et   al
(8 1 )
  in  their  study  
concluded  that   the  administration  of  single  i .v  dose  of  
dexmedetomidine  results   in  almost  complete  inhibition  of  
noradrenaline  release  from the sympathetic  nerves.  This  decrease of  
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sympathetic  tone  was  associated with   reduction  in heart   rate and 
blood  pressure,   without any compensatory  changes  found  in  the  
monitored  endocrine  s ystems, release of AVP  and  ANP  or  plasma  
renin  activity.  
As  an  intravenous   premedicant,  dexmedetomidine  reduces  
thiopental   requirements  (by  ±  30%)  for  short   procedures,  reduces  
the  requirements  of  the  volatile  anaesthetics  (by  ±  25%),  and  
more  effectively  attenuates  the  haemodynamic stress  response  to  
endotracheal  intubation  compared  with  2mcg/kg  of  fentanyl.  
Yildiz  et  al
(8 2 )
  conducted  study  to  see  the  effect iveness  of  
dexmedetomidine  on reducing  haemodynamic stress changes to  
laryngoscopy  and tracheal  intubation.  They  concluded  that  a  single  
dose  of  dexmedetomidine administered preoperatively results  in  
blunting of haemodynamic stress response during  l aryngoscopy, causes 
progressive  increases  in  sedation  and  decreases requirement of  
opioids  and  anaesthetics.  Moreover,   dexmedetomidine reduced  not 
only blood  pressure  and  heart   rate  but also  recovery  time  after  
the  surgery.  
Scheinin  et  al
(8 3 )
  showed  that   dexmedetomidine reduces  
sympathoadrenal  responses  to  endotracheal  intubation  and  
decreases  the  requirement of   thiopentone  and  perioperative  
fentanyl.  This  was  studied  in  a  randomised ,  placebo  controlled,   
double  blind  trial  in  24  American Society of Anaesthesiology  1  
patients.  Dexmedetomidine 0.6mcg/kg or saline was administered 
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intravenously 10minutes prior to induction of anaesthesia.  The   dose  
of  thiopentone  sodium required was  significantly  less in the 
dexmedetomidine  group  than  in   control  group  and  the  drug  
reduced  the  haemodynamic  responses  to  laryngoscopy  and  
endotracheal  intubation.  Concentration  of  noradrenaline  in  the  
mixed  venous  plasma  was  lesser  in  the  dexmedetomidine  group  
throughout the phases  of  induction.  
In  the  study  conducted  by  Hulya   et  al
(8 4 )
,   a  single  dose  of  
0.5mcg/kg  of  dexmedetomidine  administered  preoperatively  
10minutes  before  induction  caused  significant  sedation,  reduction 
in dose of  thiopentone  and  blunted  haemodynamic  re sponse  to  
intubation  without any  change  in  recovery  characteristics.   Jaakola  
et  al
(8 5 )
,   demonstrated  that  dexmedetomidine  reduced  the  increase  
in  heart  rate  and blood pressure   during  intubation.  Varshali   et   
al
(8 6 )
  showed  that  dexmedetomidine causes attenuation of  
sympathoadrenal  response  to  endotracheal  intubation  and  decreases  
the amount of perioperative  anaesthetics required.  Sixty  patients ,   
scheduled  for  elective  surgery  of   more  than  three  hours duration 
is  randomly  selected.  Control  group received isoflurane-opioid- 
dexmedetomidine anaesthesia.   The  need  for  thiopentone  and  
isoflurane reduced  by  30%  and  32%  respectively  in  
dexmedetomidine group  compared  to   control  group.  After  the  
endotracheal  intubation,  maximal  average  increase  was  8%  in   
systolic  BP  and  11%  in  diastolic  BP  in  dexmedetomidine group   
compared  to  40%  and  25%  respectively  in  the  control group. 
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Similarly,   average  increase  in  heart   rate  was  7%  and  21%  in  
dexmedetomidine group  and  control  group  respectively.  Lawrence  
et  al
(8 7 ) `
  found  that  a  single  dose  of  d exmedetomidine prior to 
induction  of  anaesthesia  reduced the  haemodynamic stress  response  
to both intubation  and  extubation.  
Bajwa  et   al
(8 8 )
  showed that  the pressor  response  to  
laryngoscopy,  intubation,  surgery  and  extubation  were  efficiently  
decreased  by  dexmedetomidine.  One  hundred  patients  posted   for  
elective  general  surgery  were  divided  into  two  groups.   Group  D  
were  given  1mcg/kg  of  dexmedetomidine  and  fentanyl  while  
Group  F  received  2mcg/kg  of  fentanyl  preoperatively.   Anaesthesia  
was  induced  using   thiopental  and was  maintained  with  oxygen-
nitrous  oxide  and  Isoflurane.  The  mean  dose  of  fentanyl  and  
isoflurane  were  also  reduced   significantly (50%). The  mean recovery  
time  was  also  shorter  in the dexmedetomidine  group.  
Turan  et  al
(8 9 )
  demonstrated  that  without  interfering  with the  
recovery  time,  dexmedetomidine  0.5mcg/kg  given  5minutes  before  
the  end  of  surgery causes stabilization of  haemodynamics,  allows  
easy  extubation,  provides  a  smoother  recovery  and allows early  
neurological  assessment   after  intracranial  surgeries.  
Alex  Bekker  et  al
( 9 0 )
  conducted  a study  to  see  outcome  of  
dexmedetomidine  on  perioperative  haemodynamics  in  patients  
undergoing  craniotomy.  They demonstrat ed  that  a  continuous  
infusion  of  dexmedetomidine  provided the  haemodynamic  stability  
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in  patients  undergoing  intracranial  surgery  without causing any 
increase in  the  incidence  of  hypotensive  episodes  and  bradycardia.  
Similarly  Zerrin  Ozkose  et   al
(9 1 )
  concluded  that  combination  
of  preoperative  loading  and  in traoperative  intravenous   infusion  of  
dexmedetomidine  caused blunting of  pressor  response  to  tracheal 
intubation  and  surgery,  reduced requirement of desflurane  shortened  
the recovery  time,  improved  haemodynamic  stability  and  reduced  
postoperative  pain  levels  in  patients  who  underwent  lumbar  
discectomy  under  desflurane  anaesthesia.   In  a  prospective ,  
randomized,  double  blind  trial,   dexmedetomidine  infusion  
(1mcg/kg  or  saline  placebo)  before  induction  was  used  to  reduce  
the  haemodynamic stress change  to  intubation  along with  low  dose  
fentanyl  and  etomidate  in  30  patients  who underwent  myocardial   
revascularization  receiving  beta  blocker  treatment.   After  induction  
the  drop  in  heart   rate  was  higher  in  the  dexmedetomidine  group 
as compared  with  placebo  group.  One  minute  after  intubation  
heart  rate  s ignificantly  raised  in   placebo  group  while  i t   reduced  
in  dexmedetomidine group.  Incidence  of  hypertension  which 
required  treatment  was  significantly  higher  in  the  placebo  
group
(9 2 )
.  
Pekka  Talke  et.al
( 9 3 )
  conducted  a  study  to  find out   the  
haemodynamic  and  adrenergic  effects  of administration of  
perioperative  dexmedetomidine  infusion  for  vascular  surgery.  They  
concluded  that   dexmedetomidine  (plasma  concentration  in  the  
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range  of  0.18  to  0.35ng/ml)  attenuates   increase  in  heart  rate  and  
plasma  noradrenaline  concentration  seen during  emergence  from  
anaesthesia.  Tulfanigullari  B  et  al
(9 4 )
  studied on the  effect of 
dexmedetomidine infusion on  recovery  outcome  variables  during  
laparoscopic  bariatric  surgery.  They  found that,  use  of    
intraoperative  dexmedetomidine infusion  (0.2-0.8mcg/kg/hr)  reduced  
fentanyl  use,  antiemetic  therapy  and  the  total  duration  of  stay  in  
PACU.  Likewise  Hassan  S
(9 5 )
  also  concluded  in  his  study  that 
Infusion  of  dexmedetomidine  intraoperatively reduced  the  total   
amount  of  propofol  and  fentanyl  necessary  to  maintain  
anaesthesia,  offered a better  control   on the intraoperative  and  
postoperative  haemodynamics,  reduced  postoperative  pain  levels,  
reduced  the  total  amount  of  morphine  used  and  showed a better  
recovery  profile  compared  to   placebo.   
Jeongmin Kim  et al
( 1 8 1 )
 (2014), conducted a study on agitation 
during emergence following desflurane anaesthesia in paediatrics. They 
found out that  infusion of low dose dexmedetomidine intraoperatively 
along with fentanyl decreases emergence agitation occurring after 
desflurane anaesthesia in paediatric patients  undergoing strabismus 
surgeries.  
Dhara A. Vyas,  et  al,
(1 8 2 )
 in 2013 compared dexmedetomidine 
with midazolam for sedation and cardiovascular  changes occurring 
during tympanoplasty and modified radical mastoidectomy. They 
selected 50 patients of age group 15 to 50 years of American Society of 
 
 
26 
 
Anaesthesiology grade 1 and 2.  They divided them in to two groups: 
First group received Inj. Dexmedetomidine 1µg/kg over 15min, which 
was followed by 0.5µg/kg/hr infusion and the other group received Inj . 
Midazolam 0.05 mg/kg slow i.v,  followed by an infusion of  
0.01mg/kg/hr. Their arterial heart rat e,  blood pressure and sedation 
level were monitored. They concluded that  Dexmedetomidine could be 
a better alternative over Midazolam for MAC in ENT surgeries done 
under local anaesthesia.  
Tanuja,  Shobha Purohit , Amit Kulshreshtha, 2014,
(1 8 3 )
 conducted 
a study on effects of dexmedetomidine on intraocular pressure and 
haemodynamic changes in response to laryngoscopy and tracheal 
intubation. Fifty American Society of Anaesthesiolog y -1 / 2  patients 
of 20-50 years, undergoing elective intracranial  tumour surgery were 
selected and were divided into two groups, Group D (Dexmedetomidine 
group) and Group C (Control group).  Dexmedetomidine 0.8 mcg/kg i.v. 
(in 20-ml saline) or placebo (normal sal ine 20 ml IV) were given 
slowly over 10 minutes in groups D and group C, respectively.  
Haemodynamic parameters and IOP were measured  1 minute after 
induction of anaesthesia, after intubation and then at 1, 3, 5 and 10 
minutes of intubation. They concluded that  the preinduction 
administration of single dose dexmedetomidine in the dose of 0.8 
mcg/kg decreases the magnitude of stress -induced sympathoadrenal  
effect on intra ocular pressure and on haemodynamic parameters during 
laryngoscopy and intubation and i t also decreases the requirement of 
dose of propofol for induction of general anaesthesia.  
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Dalia Abdelhamid Nasr , et al,
(1 8 4 )
 in 2013, conducted study on 
the effectiveness of  dexmedetomidine administered caudaly on the 
stress response and postoperative pain in cardiac surgery  in children.  
Forty patients, (American Society of Anaesthesiology  2,3), 1-3-years 
of age were randomly divided into 2 groups; group I received caudal 
bupivacaine 0.25%, 2.5 mg/kg and dexmedetomidine 0.5 μg/kg and 
group II received bupivacaine 2.5 mg/kg and fentanyl 1 μg/kg. They 
concluded that caudal dexmedetomidine is a useful adjuvant in 
anaesthesia for children undergoing cardiac surgeries , it  reduces the 
cardiovascular and neuroendocrine stress responses caused by trauma 
and CPB, and it also provides adequate postoperative analgesia and 
short time to extubation.  
Kwon-Hui Seo1, et  al,
(1 8 5 )
  in 2014 conducted a study on 
effective dose of dexmedetomidine for reducing haemodynamic 
response during emergence in patients who underwent laparoscopic 
total  hysterectomy. Patients undergoing laparoscopic total 
hysterectomy were randomly divided to receive 0.9% normal saline 
(control  group) or dexmedetomidine (0.5 µg/kg, 0.75 µg/kg or 
1.0 µg/kg 30 min) before extubation. Heart rate, systolic blood pressure 
and diastolic blood pressure and extubation time were measured before 
drug administration, immediately after administ ering drug. 10 min after 
administering the drug, immediately after extubation and 5 min after 
extubation. They concluded that  Intravenous infusion of 0.5 µg/kg 
dexmedetomidine 30 minutes prior to the end of surgery attenuated the 
haemodynamic responses during emergence without prolonging the 
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extubation t ime. Dexmedetomidine doses of more than 0.5 µg/kg did 
not exert  any surplus positive effects on cardiovascular responses,  but 
did significantly prolong the extubation time.  
Ashraf M. Eskandr,  et  al, 
(1 8 6 )
 in 2014, conducted a study to 
evaluate the effects of adding dexmedetomidine to local anaesthetics  
on the sensory and motor block of the subtenon block in patients 
undergoing phacoemulsification cataract surgery. 60 patients of 
American Society of Anaesthesiolog y grade 1-3, aged between 18 and 
70 years,  posted for phacoemulsification cataract  surgery were 
randomly assigned to 2 equal groups.  In  control  group, patients were 
given 2 ml mixture containing 2% lignocaine and 0.5% bupivacaine and 
Dexmedetomidine group were given 2 ml of a mixture containing 2% 
lignocaine and 0.5% bupivacaine plus dexmedetomidine(0.5 μg/kg). 
Onset and duration of sensory and motor block was recorded. Pain 
while administering anaesthesia and during surgery was graded and 
recorded. Intraocular pressure, hemodynamic, and sedation parame ters 
were recorded before and after surgery.   The study demonstrated that  
adding dexmedetomidine(0.5 μg/kg) in a mixture of 2% lignocaine and 
0.5% bupivacaine in subtenon block for patients undergoing cataract  
phacoemulsification surgery, resulted in rapid  onset and prolongation 
of analgesia and akinesia with decreased intra ocular pressure and 
stable hemodynamic changes.  
Fuhai Ji, MD,
(1 8 7 )
 in 2013, conducted a study to know if 
perioperative dexmedetomidine use can cause reduction in incidence of 
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complications and mortality following cardiac surgery. The study was 
done on 1134 patients who had coronary artery bypass surgery and 
CABG plus valvular surgery or other procedures .  Among these patients 
568 received dexmedetomidine infusion intravenously while 566 did 
not. Mortality and postoperative major cardiocerebral adverse events  
like stroke, coma, perioperative myocardial  infarction, heart  block, or 
cardiac arrest  were the primary out comes measured . Secondary 
outcomes were kidney failure, septicemia, delirium, ventilat ion hours  
needed postoperatively,  length of stay in hospital  and readmission 
within 30-days. The study demonstrated that cardiac surgical patients 
who received intravenous dexmedetomidine infusion after  
cardiopulmonary bypass had a better in-hospital,  30-day, and 1-year 
survival rate.  The use of dexmedetomidine perioperatively also caused 
significant reduction in incidence of postoperative complications 
including delirium. There were no evidences of adverse hemodynamic 
effects of dexmedetomidine in patients who underwent cardiac surgery.  
Rasha S Bondok, et  al
(1 8 8 )
,  in  2014,  conducted a study for 
investigating the effect of intraoperative equisedative doses of 
dexmedetomidine and propofol on supraclavicular nerve block in 
patients having ischemic heart disease. Patients having ischemic heart  
disease, scheduled for upper-limb orthopaedic surgery after an 
effective ultrasound-guided supraclavicular nerve block were selected. 
Patients were randomly divided for receiving either 
dexmedetomidine0.5 μg/kg or propofol 0.5 mg/kg as an initial loading 
dose for 10 minutes which was followed by a maintenance dose 
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adjusted intraoperatively to a bispectral in dex of 70-80. In the PACU, 
the sedation score was assessed every 10 minutes unti l discharge. The 
degree of pain was assessed hourly for the first  12 hours and at 18 and 
24 hours postoperatively.  Duration of analgesia and need of rescue 
analgesia were calculated. This study concluded that intravenous 
sedative doses of dexmedetomidine can prolong the analgesic effect of  
supraclavicular brachial  plexus nerve block and maintain a constant 
cardiorespiratory status. These properties make it an ideal adjuvant 
especially in patients with ischemic heart disease.  
Kanchan Gupta, et  al 
(1 8 9 )
,  in 2014, conducted a randomised 
double-blind study for comparing the effect  of dexmedetomidine and 
tramadol in peri-operative shivering in surgeries done under sub 
arachnoid block. The study was conducted in 50 American Society of 
Anaesthesiology Grade 1 and 2 patients of either gender of age 
between 18 and 65 years, posted for various surgical procedures under 
spinal  anaesthesia.  The patients were randomised in to 2 groups of 25 
patients, each to receive either dexmedetomidine0.5 μg/kg or tramadol 
0.5 mg/kg as slow intravenous bolus. The grade of shivering, onset of 
shivering, time for cessation of shivering, recurrence, response rate 
and adverse effects were observed at scheduled intervals.  The study 
concluded that both dexmedetomidine(0.5 μg/kg) and tramadol (0.5 
mg/kg) were effective in treating patients with post -spinal anaesthesia 
shivering. But the t ime taken for complete cessation of shivering was 
shorter with dexmedetomidine as compared to tramadol.  Moreover,  
dexmedetomidine causes fewer adverse effects like nausea and 
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vomiting. Sedation caused by dexmedetomidine offers additional  
comfort to the patient.  
Mohamed Essam Abdel -Meguid,  
(1 9 0 )
 in 2013, did a research to 
determine the efficiency of dexmedetomidine to achieve fast  tracking 
and improvement of postoperative pain management  in patients  
undergoing off-pump coronary artery bypass surgery.  30 patients 
posted for off-pump CABG were divided into 2 groups: Group I were 
given dexmedetomidine 0.5 ug/kg/hour  infusion just  after the 
anaesthesia induction followed by 0.3 ug/kg/hour on shifting to the  
ICU which was continued up to 12 hours after extubation. Group II 
patients were given normal saline at  a similar volume and infusion rate  
visual analog scale of 10-100 was informed well  to all the patients at  
the time of pre-anaesthesia check-up. Management of Postoperative 
pain was done using morphine. Extubation time and visual analog scale 
was noted every two hourly for 12 hours after extubation.  In 
conclusion, dexmedetomidine as an adjunct to anaesthetic management 
of off-pump CABG provides a better quality of postoperative analgesia 
with opioid-sparing effect,  while at  achieving the ultimate goal in 
management of off -pump coronary artery bypass which is fast tracking 
of patients.  
Rayner SG, et  al 
(1 9 1 )
,  in 2012, did a retrospective study of 20 
patients in intensive care unit treated with dexmedetomidine for 
alcohol withdrawal  refractory to benzodiazepine . The alcohol 
withdrawal severity scores and medication doses for 24 hours before 
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dexmedetomidine therapy were compared with values during the init ial  
hours of dexmedetomidine administration. Dexmedetomidine is an 
attractive adjunct drug for treating of severe alcohol withdrawal as it  is  
capable of providing sedation and reducing autonomic hyperactivity 
with potentially decreased incidence of respiratory distress and 
delirium than found while using benzodiazepine. It is part icularly 
useful when the symptoms are refractory to  even high doses of 
benzodiazepines,  as it  acts  through pathway independent of GABA. 
Here, adjunct therapy using dexmedetomidine in patients with severe 
alcohol withdrawal who were poorly controlled on, or were 
experiencing significant side effects with traditional treatment led to a 
decrease in alcohol withdrawal scoring, reductions in benzodiazepine 
dosing, and decreases in heart rate and blood pr essure.  
Shailesh Bhadla, et  al  (192),  in 2013, conducted a study on 
comparing dexmedetomidine and midazolam as premedication in  
paediatric patients who underwent ophthalmic day-care surgeries.  60 
patients were allocated to group I and group II and given Inj  
Dexmedetomidine 0.4 μg/kg diluted in 10 ml slowly i .v.  and Inj  
Midazolam 0.05mg/kg i .v.  accordingly. Level of sedation, parent 
separation, response to induction, heart rate, blood pressure, peripheral  
oxygen saturation, post operative agitation and shivering was noted. 
The study concluded that dexmedetomidine is superior than Midazolam 
as premedication in paediatric patients with more intense sedation, 
favourable induction conditions, excellent parent separation, lower 
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incidence of postoperative agitation and shivering along with 
hemodynamic stabili ty and no respiratory depression.  
SS Harsoor,  et  al  (1993),  in 2013, conducted a research to assess  
the effects of intra venous dexmedetomidine on sensory, motor,  
haemodynamic parameters and sedation during subarachnoid block 
procedures. A total of 50 patients undergoing infraumbilical  and lower 
limb surgeries under subarachnoid block were selected. Group I 
received int ra venous dexmedetomidine 0.5 mcg/kg bolus over 10 min 
before subarachnoid block, followed by 0.5 mcg/kg/h infusion 
throughout the surgery. Group II received similar volume of normal  
saline infusion. Time for onset  of sensory and motor blockade, 
cephalad level of analgesia and duration of analgesia were noted. 
Sedation scores using Ramsay Sedation Score and haemodynamic 
parameters were assessed. The study concluded that  intravenous 
supplementation of loading dose of dexmedetomidine 0.5 mcg/kg 
followed by infusion at  0.5 mcg/kg/h hastens the onset  of sensory 
block and prolongs the duration of sensory block, analgesia and motor 
block with lesser incidence of bradycardia. Moreover, intravenous 
dexmedetomidine supplementation during subarachnoid block produces 
adequate arousable sedation without causing respiratory depression.  
Anbarasu Annamalai , et  al (194),  in 2013, conducted a study for 
evaluating the effectiveness  of intravenous dexmedetomidine on 
prolongation of spinal  anaesthesia, level of sedation, post -operative 
analgesic requirement. Ninety adult patients classified as ASA 1 or 2 
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posted for elective surgical  procedures below umbilicus under spinal  
anaesthesia were double blind divided to one of the three groups. All  
patients received 0.5% hyperbaric bupivacaine 2.5 ml spinal 
anaesthesia.  Group I Patient receiving intravenous normal saline 10 ml 
over 10 minutes, 10 minutes before spinal anaesthesia with 0.5% 
hyperbaric bupivacaine 2.5 ml and normal saline 10 ml over 10 minutes  
after 30 minutes of spinal anaesthesia.  Group II Patients were given 
dexmedetomidine 1 μg/kg i .v. over 10 minutes, 10 minutes before 
spinal anaesthesia. Group III patients were given dexmedetomidine 1 
μg/kg  i .v.  over 10 minutes after 30 minutes of spinal  anaesthesia.  The 
study concluded that Intravenous dexmedetomidine prolonged spinal 
bupivacaine sensory blockade in both the groups and also provided 
sedation and additional analgesia.  
Tarek Shams, et al  
( 1 9 5 )
,  in 2013, conducted a comparative study 
of dexmedetomidine versus esmolol on induced hypotension for  
functional endoscopic sinus surgery. Forty patients  scheduled for 
functional endoscopic sinus surgery were randomly divided for 
receiving either dexmedetomidine 1 μg/kg over 10 minute prior to  
induction of anaesthesia followed by an infusion of 0.4-0.8 μg/Kg/h 
during maintenance in Group I,  or esmolol . A loading dose of 1mg/kg 
was infused over one minute followed by an infusion of 0.4-0.8 
mg/kg/h during maintenance in group II .  So that mean arterial blood 
pressure between 55-65 mmHg. Maintenance of general anaesthesia  
was done using sevoflurane 2%-4%. Assessment of surgical  field was 
done to calculate  average blood loss.  Hemodynamic variables,  
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intraoperative fentanyl consumption,  arterial blood gas analysis,  
plasma cortisol  level,  time for emergence and total recovery from 
anaesthesia  were recorded. Sedation score was assessed at 15, 30 and 
60 minutes after extubation and time to complain pain was recorded. 
The study demonstrated that dexmedetomidine or esmolol with 
sevoflurane are safe agents for controlled hypotension and both are 
useful in providing ideal surgical field during functional endoscopic 
sinus surgery. Compared with esmolol,  dexmedetomidine offers the 
benefit of inherent analgesic, sedative and anaesthetic sparing effect.  
Hazra R, et  al 
(1 9 6 )
,  in 2014, conducted a study to compare the 
effects of intravenously administered dexmedetomidine with clonidine 
on hemodynamic responses during laparoscopic cholecystectomy. 60 
patients of age between 18 to 50 years, of both the sex posted for 
elective laparoscopic cholecystectomy were randomly divided  into 3 
groups in a double-blind fashion. They were given either clonidine       
1µg/kg in normal saline, dexmedetomidine 1µg/kg in NS or NS 
intravenous respectively.  Total volume of the study drug was adjusted 
to 50 ml and given over a period of 15 minutes before induction. 
Administration of clonidine or dexmedetomidine prior to 
commencement of pneumoperitoneum was found effective in 
attenuating hemodynamic response to pneumoperitoneum. However,  the 
study concluded that  dexmedetomidine blunts the hemodynamic 
response to pneumoperitoneum more efficiently with a greater chance 
of developing hypotension and bradycardia.  
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Usta B, et  al 
(1 9 7 )
,  in 2011, conducted a study for evaluating the 
effect of dexmedetomidine administration on shivering during spinal 
anaesthesia.  Sixty patients posted for elective minor surg eries under 
subarachnoid block with  hyperbaric bupivacaine, were selected. They 
were given either saline or dexmedetomidine. Motor block was 
assessed. The occurrence of shivering was evaluated by a blinded 
observer after the completion of  injection of drug in the subarachnoid 
space.  They found that  infusion of dexmedetomidine postoperatively 
causes significant reduction of shivering associated with subarachnoid 
block during minor surgeries without causing any major side effect.  So, 
the study concluded that dexmedetomidine infusion is effective for 
prevention of shivering and for providing sedation for patients during 
subarachnoid block . 
Kim YS, et  al, 
(1 9 8 )
 in 2013, conducted a study to find out the 
optimum dose of dexmedetomidine for prevention of postanaesthetic 
shivering. 132 patients posted for elective laparoscopic total  
hysterectomy were selected for this randomized, placebo-controlled 
study. Patients were randomly divided to receive dexmedetomidine in 4 
groups: group I received 0.9% NS, 2
n d
 group received 
dexmedetomidine 0.5 µg/kg, group III received dexmedetomidine     
0.75 µg/kg and group IV received dexmedetomidine 1.0 µg/kg. Time to 
extubation and the tympanic temperature during and after operation 
were measured. Shivering was graded  at the time of arrival  to the post  
anaesthesia care unit and every ten minutes thereafter up to forty 
minutes. Sedation and first rescue analgesic t ime at the post  
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anaesthesia care unit were evaluated. They concluded that  
dexmedetomidine 0.75 or 1.0µg/kg i.v. can provide effective 
prophylaxis for against postoperative shivering as well  as an analgesic 
effect. Although potential for intraoperative requirement for atropine, 
sedation in the immediate recovery period and delayed extubation time 
with dexmedetomidine was observed, there were no major clinical  
impacts on the overall recovery from anaesthesia .  
Suvadeep Sen, et  al,
(1 9 9 )
 in 2013, conducted a study for 
evaluation of the effect of dexmedetomidine on propofol requirement 
for induction and maintenance of desired depth of anaesthesia on the 
basis of targeted bispectral index value in spine surgery on prone 
patients under general anaesthesia. 70 adult patients of age 20-60 years 
undergoing elective spinal surgeries under general anaesthesia were 
selected for this study. They were divided into 2 groups. 1
s t
 group 
received loading dose of dexmedetomidine at 1 mcg/kg over the period 
of 10 minutes, followed by maintenance of dexmedetomidine at a rate 
of 0.2 mcg/kg/h. Heart  rate, saturation of peripheral  oxygen, systolic 
blood pressure, diastolic blood pressure,  MAP, electrocardiogram and 
consciousness level were closely monitored in the patients. Propofol 
was started initially at 5 mg/kg/h and then adjusted to maintain a 
bispectral index value in range of 40-60 and its requirement was 
observed and recorded in each patient. The study concluded that  
infusion of dexmedetomidine in the perioperative period provided 
significant reduction in requirement of propofol for  the induction and 
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maintenance of adequate depth of anaesthesia with stable 
haemodynamics .  
S S Harsoor, et al , 
(2 0 0 )
 in 2014, conducted a study for evaluating 
the effect of intravenous dexmedetomidine infusion during general  
anaesthesia  for abdominal surgeries on blood glucose levels and on 
Sevoflurane requirements during an aesthesia.  40 patients posted for 
abdominal surgery under general  an aesthesia were divided into 
Dexmedetomidine group and Placebo group of 20 each. 
Dexmedetomidine group were given loading dose of Inj.  
Dexmedetomidine at 1 μg/kg/10 minutes diluted to 20 ml,  followed by 
maintenance with 0.5 μg/kg/h.,  till  the end of surgery. Placebo group 
received similar volume of IV normal saline.  An aesthesia was 
maintained using nitrous oxide, oxygen and sevoflurane keeping 
entropy between 40 and 60. The study concluded that  
Dexmedetomidine as a preanaesthetic medication and intraoperative 
infusion was effective in attenuating metabolic stress response to major 
surgeries as indicated by stable blood glucose levels. It  also reduced 
intraoperative anaesthetic requirement and had significant an aesthetic 
sparing property during entropy guided general  an aesthesia.  Moreover,  
continuous intraoperative administration of Dexmedetomidine does not 
affect intraoperative cardiovascular stabil ity.  
Alka Shah, et al,
(2 0 7 )
 in 2013, studied to evaluate the 
intraoperative haemodynamics and postoperative analgesia  of 
intrathecal administration of dexmedetomidine added to ropivacaine.  
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50 patients posted for lower abdominal and lower limb surgery were 
included. Each patient was given 4 ml of 0.75% isobaric ropivacaine + 
5 microgram dexmedetomidine. Pulse rate and blood pressure were 
recorded at intervals of 1, 2, 5, 10, 20, 30 minute s and 1,  2 and 3 
hours.  Postoperative pain scores were assessed  using VAS. The 
patients had excellent hemodynamic stability and good postoperative 
analgesia to the combination of ropivacaine and dexmedetomidine.  
Priyam Saikia
,  
et al,
(2 0 8 )
 in 2014 found the use of 
dexmedetomidine, in the postoperative management of a  transoral  
odontoidectomy patient and required mechanical ventilation. 
Dexmedetomidine at 0.5-0.7 μg/kg/h was used for postoperative 
management and continued until extubation of trachea and provided 
sedation level of Richmond Agitation -Sedation Scale −1 to −2.  He was 
easily arousable and co-operative during neurological  evaluations. 
Dexmedetomidine was stopped 22 h after completion of surgery. 
Within 15 min his Richmond Agitation -Sedation Scale rose to a score 
of 0, and trachea was extubated smoothly.  They concluded that  
dexmedetomidine, by its opioid sparing effect and preserved attentive 
behavior, is a useful adjunct to multimodal analgesic regimen in 
postoperative patients who needs sedoanalgesia for mechanical  
ventilation.  
Mahima Gupta, et al ,
(2 0 9 )
 in 2014 conducted a study to evaluate 
and compare the characteristics of subarachnoid blockade, 
hemodynamic stability and adverse effects of intrathecal 
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dexmedetomidine and intrathecal buprenorphine as an adjuvant to 0.5% 
hyperbaric bupivacaine for lower abdominal surgeries.  Sixty patients 
aged 18-60 years posted for elective lower abdominal surgeries. The 
patients were randomly allotted to 2 groups for receiving intrathecal 
3ml of 0.5% bupivacine with 60µg of buprenorphine in group I or 3ml 
of 0.5% bupivacaine with 5µg of dexmedetomidine in group II.  The 
onset time to peak sensory level,  motor block, duration of motor block, 
sedation, haemodynamic variables, analgesia and any adverse effects 
were noted. The duration of motor and sensory block in 
dexmedetomidine group was 413 minutes and 451 minutes which was 
considerably different from 205 minutes and 226 minutes of 
buprenorphine group. Also duration of analgesia was 493 minutes in 
dexmedetomidine group compared to 289 minutes of buprenorphine 
group. They concluded that intrathecal dexmedetomidine 5µg when 
compared to intrathecal buprenorphine 60µg causes longer duration of  
sensory and motor block. The requirement for additional sedation and 
rescue analgesia was less in dexmedetomidine group and the 
haemodynamics were comparable in both the groups without causing 
any significant side effects.  
MS Saravana Babu, et al,
(2 1 0 )
 in 2013, conducted a study for 
evaluating the efficacy of epidural route  of administration  and for 
comparing the efficacy and clinical characteristics  of dexmedetomidine 
and clonidine as adjuvants to ropivacaine, in epidural analgesia with 
particular importance on the quality of analgesia and the abili ty for 
providing a smooth post-operative course.  60 patients,  aged between 18 
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and 65 years who underwent surgeries of spine were divided into 2 
groups. 1
s t
 group patients were given  20 ml of 0.2% ropivacaine and 1 
μg/kg of dexmedetomidine while 2n d  group were given 20 ml of 0.2% 
ropivacaine and 2 μg/kg of clonidine via the epidural  catheter.  Onset of 
analgesic action, t ime of peak action, duration of analgesia, 
cardiorespiratory parameters, requirement  of rescue I.V analgesics and 
side-effects were noted. They concluded that  the epidural  route 
provided adequate analgesia in spine surgeries in terms of visual 
analogue scale score and overall patient satisfaction and i t eluded the 
requirement of intravenous analgesics in both groups. 
Dexmedetomidine was found to be a better neuraxial  adjuvant to 
ropivacaine as compared to clonidine for provi sion of early onset and 
long lasting post-operative analgesia and stable haemodynamic 
parameters.  
Dalia Abdelhamid Nasr, et  al,
(2 1 1 )
 in 2013, conducted  study to 
evaluate the efficacy of caudal dexmedetomidine on lesser response 
and postoperative pain in children undergoing cardiac surgery. Forty 
patients, 1-3-years old were divided into two groups; group I patients 
were given caudal bupivacaine 0.25%, 2.5 mg/kg and dexmedetomidine 
0.5 μg/kg and group II patients were given bupivacaine 2.5 mg/kg and 
fentanyl 1 μg/kg. They found that Serum cortisol  level and blood 
glucose level  were increased in both groups but increases were 
considerably less  in dexmedetomidine group. They found out that 
caudal dexmedetomidine proves to be a useful adjuvant in paediatric 
cardiac anaesthesia, by attenuating the cardio vascular and 
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neuroendocrinal stress response to surgical trauma and cardio 
pulmonary bypass and in providing adequate postoperative analgesia 
and short  time to extubation.  
Lili Jiang, et  al ,
(2 1 2 )
 in 2014, conducted a study to investigate 
whether dexmedetomidine is capable of attenuating rat pulmonary 
damage induced by ischemia-reperfusion injury, which is a type of 
acute sterile lung injury. From the study, they suggested a potential  
clinical  application of dexmedetomidine for reducing lung ischemia-
reperfusion injury in an experimental model.  
Friesen RH, et al ,
(2 1 3 )
 in 2013, conducted a study for quantifying 
the effects of initial loading doses  of dexmedetomidine on mean 
pulmonary artery pressure in paediatric patients  with and without 
pulmonary arterial  hypertension. Paediatric patients  undergoing cardiac 
catheterization either  for routine surveillance after cardiac 
transplantation or for pulmonary arterial hypertension studies were 
included. After anaesthetic induction using sevoflurane and 
endotracheal intubation, sevoflurane was discontinued and an aesthesia 
maintenance was done using midazolam 0.1 mg/kg IV and remifentanil  
infusion 0.5 to 0.8 μg/kg/min i.v. Patients were mechanically 
ventilated to maintain PCO2 of 35 to 40 mm Hg. When the end-tidal  
concentration of sevoflurane was 0% and fraction of inspired oxygen 
was 0.21, baseline heart rate, MAP, pulmonary arterial pressure,  right 
atrial  pressure, right ventricular end-diastolic pressure, pulmonary 
artery occlusion pressure, cardiac output,  and arterial blood gases were 
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measured, index pulmonary vascular resistance and index systemic 
vascular resistance and cardiac index were calculated. Each patient was 
then given a 10 minute infusion of dexmedetomidine of 1μg/kg, 
0.75μg/kg  or 0.5μg/kg. The same measurements and calculations were 
done again at  the end of the infusion. Initial  loading doses of 
dexmedetomidine were associated with considerable systemic 
vasoconstriction and hypertension, but  analogous response was not 
seen in the pulmonary vasculature, even in paediatric patients  with 
pulmonary arterial hypertension. They concluded that dexmedetomidine 
do not seem to be contraindicated in paediatric patients having 
pulmonary hypertension.  
Siddareddigari  Velayudha Reddy, et al,
(2 1 4 )
 in 2014, conducted a 
study to compare the clinical effects of dexmedetomidine and esmolol 
in attenuating the presser response during laryngoscopy. 90 adult 
scheduled for non-cardiac surgery requiring intubation were selected. 
The patients were allocated into 3 groups. 1
s t
 group received placebo, 
2
n d
 group received 2.0 mg/kg of esmolol and 3
rd
 group received 1.0 
μg/kg of dexmedetomidine, intravenously over 10 min and 3 min before 
induction of general anaesthesia. All  patients were uniformly pre -
medicated, induced and intubated using thiopentone and 
succinylcholine as per the  standard protocol. Heart  rate and systemic 
blood pressures were recorded at  baseline,  after study drug infusion, 
after induction, immediately and 3,  5, 7,  10 minutes after intubation. 
Evaluation of baseline and immediately after intubation values ,  
revealed a greater percentage variation in mean arterial pressure in the 
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esmolol and control  groups as compared to that in dexmedetomidine 
group. They stated that  administration of a single dos e of 
dexmedetomidine prior to general anaesthesia induction was an 
effective method for at tenuating the hemodynamic response to tracheal 
intubation.  
Yu Zhang, et  al,
(2 1 5 )
 in 2014, performed a study to evaluate the 
hypothesis that adding dexmedetomidine to ropivacaine prolongs 
axillary brachial plexus block. Forty-five patients of aged 25-60 years 
who were posted for forearm and hand surgery were randomly allocated 
into 3 equal groups and received 40 ml of 0.33% ropivacaine + 1 ml  
dexmedetomidine (50 μg) (group 1), 40 ml of 0.33% ropivacaine + 1 ml 
dexmedetomidine (100 μg) (group 2) or 40 ml of 0.33% ropivacaine + 1 
ml saline (group 3) in a double-blind fashion. The onset  and duration 
of sensory and motor blocks and adverse effects were noted. Sensory 
and motor block onset times were same in the three groups. Sensory 
and motor blockade durations were found to be prolonged in 2
n d
 group 
compared to group 3. No significant variations in the sensory blockade 
duration were found between group 1 and group 3. Bradycardia,  
hypertension and hypotension were not observed in group 3 and 
occurred more often in group 2 than in group 1. They concluded that  
dexmedetomidine added to ropivacaine for an axillary brachial plexus 
block prolongs the duration of block. Dexmedetomidine can cause  
adverse effects like bradycardia, hypertension, and hypotension.  
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Pant D, et al ,
(2 1 6 )
 in 2014 conducted a study to compare the 
effects of sublingual midazolam and dexmedetomidine used for 
premedicating children. The study enrolled hundred children of age     
1 to 12 years posted for orchidopexy, inguinal hernia repair  or 
circumcision under general anaesthesia.  The selected children were 
divided into two groups of 50 each. Patients  in group I were given 
sublingual midazolam 0.25 mg/kg  as premedication, while those in 
group II received sublingual dexmedetomidine 1.5µg/kg as 
premedication. Sedation was assessed.  They concluded that  sublingual 
dexmedetomidine offers a better  preoperative sedation compared to 
sublingual midazolam in all the age groups and also provides a 
smoother induction of anaesthesia and emergence particularly in the 
preschool children.  
Na Young Kim, et  al,
(2 1 7 )
 in 2014, conducted a study for 
assessing the effect of dexmedetomidine infusion on the requirement of 
sevoflurane, recovery profiles, and emergence agitation in paediatric 
patients undergoing ambulatory surgery. Forty paediatric patients  
undergoing ambulatory hernioplasty or orchiopexy were divided into 2 
groups. Patients in dexmedetomidine group received dexmedetomidine 
1 µg/kg, followed by 0.1 µg/kg/h  i.v. til l  the end of surgery, while the 
saline group was given same volume of normal saline.  Induction and 
maintenance of anaesthesia was done by sevoflurane and caudal block 
was performed in all  the patients .  End-tidal concentration  of 
sevoflurane, the incidence of agitation on emergence, pain scores, and 
sedation scores were noted. Hemodynamic variations and other side 
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effects were evaluated in the perioperative period. End-tidal  
sevoflurane concentration of dexmedetomidine group was significantly 
reduced in 23.8-67% compared to saline group during surgery. 
Incidence of emergence agitation found lower in dexmedetomidine 
group than in saline group. Postoperative pain was similar and 
discharge time did not vary between the groups. MAP and heart rate 
were considerably lower in dexmedetomidine group during surgery.  
They concluded that infusion of dexmedetomidine intraoperatively 
reduced sevoflurane requirements and reduced agitation during 
emergence without any delay in discharging the paediatric patients who  
undergo ambulatory surgery. Anaesthesiologists should be cautious 
about bradycardia and hypotension.  
Shan-Shan Wang, et al,
(2 1 8 )
 in 2013, conducted a study on 
sedative effects and attenuation of haemodynamic and arousal 
responses during induction of anaesthesia and intubation in paediatric 
patients by comparing two differ ent doses of preoperative  
dexmedetomidine.  Forty paediatric patients of  age from 3 to 6 years,  
posted for adenotonsillectomy were administered either  
dexmedetomidine 1 μg·kg− 1  (group 1) or 2 μg·kg−1  (group 2) 
30 minutes before anaesthesia induction. Anaesthesia induction was 
done using sevoflurane in oxygen flow. Heart  Rate and Mean arterial 
pressure were measured and bispectral index was used as an index of 
arousal response and were recorded every 5  minutes after giving 
dexmedetomidine and measured every 1 minute for 5  minutes post 
intubation. Assessment of behaviour scores, sedation status and mask 
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induction scores were done. Dexmedetomidine 2 μg·kg−1  i .v.  given  
30 minutes before induction of anaesthesia provided significant  
attenuation of  increase in mean arterial pressure caused by intubation 
response. Variations in heart rate and bi -spectral  index also show that  
dexmedetomidine premedication causes effective attenuation of 
response to intubation. Preoperative dexmedetomidine 2 μg·kg−1  also 
provides optimal-sedation and smoother anaesthesia induction. 
Premedication of dexmedetomidine is effective in reducing 
cardiovascular and arousal responses to tracheal intubation.  
Gaurav Jain
,  
et al,
(2 1 9 )
 in 2012, conducted a study to analyze the 
effect of perioperative administ ration of dexmedetomidine on the 
incidence of chronic pain in patients who undergo surgery for breast  
cancer.  86 patients were divided to 2 groups and were given either 
dexmedetomidine (2 μg/ml) in group I or sal ine in group II,  in a 
loading dose of 0.5 ml/kg, i.v, 30 minutes before induction, followed 
by 0.25 ml/kg/h i.v. as continuous infusion t ill  the end  of surgery and 
then the dose was reduced to 0.1 ml/kg/h for up to 24 hours.  The 
requirement of isoflurane and fentanyl intra-operatively and 
paracetamol postoperatively was considerably lower in Group I.  They 
concluded that  infusion of dexmedetomidine perioperatively has a 
crucial role in reducing the severity and incidence of chronic pain and 
providing better  quality of life in patients who undergo breast cancer 
surgery.  
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Sukhminder Jit Singh Bajwa , et  al,  
(2 2 0 )
 in 2011, conducted a 
study for comparing the efficiency and clinical characteristics  of 
dexmedetomidine and clonidine, in epidural anaesthesia with special 
attention on their sedative properties and an ability for providing 
smooth intra-operative and post-operative pain relief. The study was 
done in 50 adult  females of age 44 to 65 years posted for vaginal 
hysterectomy. The patients were divided into 2 groups of 25 patients 
each. Group I was given 17 ml of 0.75% epidural  ropivacaine and 1.5 
μg/kg of dexmedetomidine,  whereas group II were given a mixture of 
17 ml of 0.75% ropivacaine and 2 μg/kg of clonidine. Onset and 
duration of analgesia,  sensory and motor block levels,  sedation  and 
adverse effects were noted.  They concluded that dexmedetomidine is a 
better adjuvant for neuraxial anaesthesia when compared with clonidine 
for obtaining early onset of analgesia, optimal sedation and prolonged 
post-operative analgesia.  
Eike Martin, et al,
(2 2 1 )
 in 2003, conducted a study on the role of 
Dexmedetomidine in sedation of postoperative patients in  the ICU. In 
this study, dexmedetomidine was assessed for sedation of 401 
postsurgical patients. Either dexmedetomidine or saline was started 
when the patients arrive in the ICU (1.0 mcg/kg for 10 minutes), then 
titrated at  0.2 to 0.7 mcg/kg/h to effect.  Patients were given propofol 
when needed. Morphine was given for relief of pain.  60% of the 
dexmedetomidine patients did not require any other sedative,  21% 
required < 50 mg propofol.  76% of the control group patients required 
propofol,  59% received ≥ 50 mg. Dexmedetomidine patients needed 
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considerably less morphine for analgesia.  Continuous  administration of 
dexmedetomidine throughout the ICU stay did not affect  oxygen 
saturation, respiratory rate, weaning  duration, or times to extubation. 
Most of the patients who received dexmedetomidine could maintain 
blood pressures in the normal range, without  any rebound. 
Hypertension, rigors and atelectasis occurred more often in the control  
group, whereas hypotension and bradycardia were seen more often in 
the dexmedetomidine group.  
All   these  studies  l ed  to  conclusion  that   dexmedetomidine  a  
highly  specific  alpha2   agonist  drug  possesses sedative,  anxiolytic,   
sympatholytic,   analgesic  and  hypnotic  properties  and  provides  
perioperative  haemodynamic  stability.  
Pharmacology 
Dexmedetomidine 
 
 
 
 
Fig -1:  Chemical  structure  of  dexmedetomidine 
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Physicochemical  Characteristics  
 Dexmedetomidine  is  the  d-enantiomer  of  medetomidine,  a  
substance  that   has  been  used  for  sedation  and  analgesia  in  
veterinary  medicine  for  many  years.  It   is  highly specific   for  the  
α2  receptor  (α2 /α1   200:1),   making  it   a  complete  alpha2   agonist .  
Dexmedetomidine  is included in   imidazole  subclass  of  alpha2   
receptor  agonists  like  clonidine,   and  i ts  structure  is   i llustrated  in  
Fig  1.  It  is freely soluble in water .  
Preparation of  Solution 
 Dexmedetomidine is available as 100mcg/ml. It  must  be  diluted  
in normal saline   to  achieve  the required  concentration before  
administration.  Preparation  of  solution   is  the  same,   for  both  
loading  dose  and  maintenance  infusion.  
Co-administration with other Fluids  
 Dexmedetomidine  hydrochloride  infusion  is  not to be  
administered  via the  same  intravenous   catheter  along with  blood  
or  plasma  as the physical   compatibility  is  not  yet  established.  
 Dexmedetomidine  is  shown  to  be  incompatible  while   given  
with   amphotericin  B and  diazepam. 
Dexmedetomidine  is shown  to  be  compatible  while   given with  
the  following  i.v  fluids:  
 Normal Saline 
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 5%  dextrose  in  water  
 20%  mannitol  
 Ringer’s Lactate solution 
 100mg/ml  magnesium  sulfate  solution  
 0.3%  potassium  chloride  solution  
Compatibility with Natural  Rubber 
 It  is shown that  dexmedetomidine has the potential for 
absorption to  some  types  of  natural  rubber.  So it  is  advisable  to  
use  the administration  components  made  of synthetic,  or  coated  
natural  rubber  gaskets.  
Availability  
 100mcg/ml  in  glass  vials and ampoules  
 
  
 
 
 
Fig  2:  Dexmedetomidine Vial  and Ampoule  
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Storage and Handling 
 Dexmedetomidine 100mcg/ml is  available in 2ml clear glass  
vials and 1ml ampoules.   Vials are intended for single use only.  
 Dexmedetomidine should be stored in  room  temperature,  25 0C  
(77
0
F)  and  variations  allowed  are  15
0
C - 30
0
C  (59
0
F-86
0
F).  
Clinical Pharmacology 
Mechanism of  Action 
 Dexmedetomidine  is  an  imidazole  compound,  d-enantiomer  
of  medetomidine  with  a  highly  selective   alpha2   selective  receptor  
agonism. Alpha2  adrenoreceptors  are membrane-spanning G proteins .   
Intracellular pathways  include  adenylate  cyclase  inhibition  and  ion  
channel  modulation .   Three  subtypes  of  α 2   receptors  are  described  
in  humans:  α2 A ,   α2 B,   α2 C   (Fig. 3)
(1 1 1 )
.   The  α2 A  adrenoceptors  are  
mainly  distributed  in  the  periphery,  wh ile  α2 B   and  α2 C   are  in  the  
brain  and  spinal  cord.  Postsynaptic   alpha2   adrenoreceptors  in  
peripheral  blood  vessels  produce  vasoconstrict ion,  while  
presynaptic  alpha2   adrenoreceptors  inhibit   the  release  of  
noradrenaline,   potentially  attenuating  the  vasoconstriction.  The  
overall   response  to  alpha2   adrenoreceptor  agonists  is  associated  
with  stimulation  of  alpha2   receptors  located  in CNS.  
These  receptors  are  involved  in  the sympatholysis,   sedation  
and  antinociceptive  effects  of  alpha2   adrenoreceptors
(7 0 )
.  
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Fig -3:   The  different  α2   adrenoreceptors  
 Dexmedetomidine  with  selective  alpha2   agonism  has  a  
primary  action  on  locus  coeruleus
(1 1 2 )
.   Neuronal  hyperpolarisation  
is  a  major  component  in  mechanism  of  action  of  alpha2   
adrenergic  receptor  agonist.   Presynaptic  activation  of  the  alpha2   
receptor  inhibit   secretion of  noradrenaline  and  postsynaptic  
activation  of  alpha2   receptor  decreases  sympathetic  activation  of  
CNS. 
 The  mechanisms  of   analgesic  effects  of  alpha2   receptor  
agonists  is  not   completely  understood.  It  is  modulated by 
transmission of   nociceptive  signals  in  the central  nervous system  at  
different  sites including both spinal  and supraspinal sites .   
Dexmedetomidine  has  been  shown  to  stimulate  alpha2   receptor  
presynaptically  and  postsynaptically  and  directly  in  the  spinal   
cord,  hence causing inhibition of   firing  of  nociceptive  neurons
(1 1 3 )
.   
Even peripheral   alpha2   adrenoreceptor  may  mediate  antinociceptive 
action.  Agonists can  act  at  these  si tes  and  decrease transmission 
of nociceptive signals causing pain relief.   G1-protein-gated  potassium  
channels  are activated and  result  in  membrane  hyperpolarisation,  
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reducing rate of firing of  excitable  cells  in  central  nervous system.  
This  becomes important   in  the  inhibitory  neuronal  actions  of  
alpha2   adrenoreceptor  agonists.  An additional   important  physiologic  
action  attributed  to  alpha2  adrenoreceptor  is   the decrease in  
conductance of calcium  into  cells  causing inhibition of secretion  of 
neurotransmitter .  This  is   directly  regulated  by  entry of calcium via 
the voltage-gated N-type calcium  channels  and  it  does not depend  on   
cyclicAMP  and  protein  phosphorylation.  This is facili tated by G0  
proteins.   The above two mechanisms illustrates  two different  means  
of  effective  pain relief.   In  the  first  one,   prevention of nerve     
from  over  firing occurs  while  in  the  next one,  the propagation  of  
signal  to its   neighbour  is affected.  The  receptors in substantia  
gelatinosa  of  dorsal   horn  of  spinal  cord  wh ile  st imulated  inhibits  
nociceptive  neuronal firing  which are stimulated  by the peripheral   
A,  B  and  C  fibres  and  also cause inhibition  of secretion of   
nociceptive  neurotransmitter -  substance  P.  The above  mechanism  is 
the reason for using  clonidine  for  epidural   administ ration in spite of  
its  primary  use  as  an  intravenous   drug.  
Pharmacokinetics  
 Following  IV  administration,  dexmedetomidine  shows  the  
following  pharmacokinetic  characteristics -  a  rapid  distribution  
phase  with  distribution  half-life  of  about  6mins;  context  sensitive  
half  time  ranges  from  4mins  following  10min infusion  to  250min  
following 8hr  infusion;  a  terminal  elimination  half-life of about  
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2hrs;  and  steady-state  volume  of  distribution  (V S S)  of  about  
118litres.   Clearance is found to be about 39L/hr.   The  mean  body  
weight  related  to  the  estimated  clearance  was  72kg
(1 1 4 )
.  
 Dexmedetomidine  shows  l inear  pharmacokinetics  in  dose  
ranging from  0.2-0.7mcg/kg/hour  while  given by  i.v.  infusion upto  
24hrs
(1 1 4 )
.  
Distribution  
 Dexmedetomidine has a steady-state volume of distribution (VSS)  
of about  118  litres.  Protein binding of  dexmedetomidine was 
estimated  in  plasma  of   healthy  adults .  The  average  protein  
binding  was found to be  94%  was  same  in  the  various   plasma  
concentrations  evaluated.  Protein binding was comparable in  both 
gender.  Fraction  of  protein bound dexmedetomidine  hydrochloride  
was  considerably  reduced  in  subjects  having liver  dysfunction  
compared with  healthy  subjects
(1 1 5 )
.  
 The  ability for displacement  of  protein  binding   of  
Dexmedetomidine  by ketorolac, fentanyl ,   theophylline,  digoxin   and  
lignocaine  was  studied  in  vitro,   and  insignificant   variations  in  
protein  binding  displacement  of  warfarin,  ibuprofen, phenytoin,   
propranolol,  theophylline  and  digoxin  by  Dexmedetomidine  was  
studied  in-vitro  and  these  drugs  did not seemed  to  be  
considerably  displaced  by  Dexmedetomidine
(1 1 6 )
.  
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Metabolism 
Dexmedetomidine transforms almost completely and a very small  
amount of dexmedetomidine is eliminated without any change in urine 
and feces. Direct glucuronidation and cytochrome P450 facilitated 
metabolism takes place. The main pathways of dexmedetomidine 
metabolism include direct N-glucuronidation into inactive metabolites ,  
aliphatic hydroxylation ( facilitated mainly by CYP2A6) of 
dexmedetomidine to form 3-hydroxy-dexmedetomidine, the glucuronide 
of 3-hydroxy-dexmedetomidine and 3-carboxy dexmedetomidine; and N 
methylation of dexmedetomidine to form 3-hydroxy N-methyl-
dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and 
dexmedetomidine-N-methyl O-glucuronidation
(1 1 7 )
.  
Elimination 
Terminal elimination half-life of dexmedetomidine is found to be 
about  2 hours and clearance is about  39 L/hour. Dyck and co-workers 
(1 1 8 )
 found that its pharmacokinetics in volunteers is best described by 
a three-compartment model. These pharmacokinetic par ameters 
apparently are unchanged by age or weight or renal failure but 
clearance is a function of height  
(1 1 9 ,  1 2 0 )
.  
Properties  
Sedation 
Dexmedetomidine is approved by the FDA for short  term (<24 
hours) sedation of mechanically ventilated patients in the ICU setting. 
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The alpha2  agonists produce their sedative-hypnotic effect by acting on 
alpha2  receptors in the locus caeruleus and an analgesic action at  
alpha2  receptors within the locus caeruleus and within the spinal cord. 
(1 2 1 )
The quali ty of sedation produced by dexmedetomidine seems 
different compared with that produced by other sedatives acting 
through the GABA systems. In this sett ing, it  appears to offer some 
clinical advantages because it produces a unique type of seda tion-
analgesia with less respiratory depression than the  commonly used 
sedative-hypnotic and opioid analgesic drugs. Patients receiving 
dexmedetomidine infusion as part of their sedation regimen in the 
postoperative ICU setting have been described as being very easy to 
wake up and having the ability to follow commands and cooperate 
while being endotracheally intubated. Undisturbed patients were noted 
to fall asleep right away.
 (1 2 2 )
 Despite good levels of sedation with 
dexmedetomidine, there is l imited respiratory depression,  offering wide 
safety margins.  
(1 2 3 )
 This property allows for “daily wake up” tests to 
be done in a safe manner. This critical test - when ventilated ICU 
patients are taken off al l sedatives to assess their mental  status and 
titrate sedation- shortens their ventilated and ICU length of stay
(1 2 4 )
.  
The alpha2  agonists act  via the endogenous sleep-promoting 
pathways to employ their sedative effect .  Dexmedetomidine produces a 
decrease in activity of the projections of the locus caeruleus to the 
ventrolateral preoptic nucleus. This increases the GABAergic and 
galanin release in the tuberomamillary nucleus,  caus ing a decrease in 
histamine release in cortical  and subcortical projections .  
(1 2 5 )
 The 
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alpha2  agonists seem to inhibit ion conductance through L -type or P-
type cacium channels and facil itate conductance through voltage gated 
calcium-activated potassium channels.
(1 2 6 )
The similari ty between 
natural sleep (non-rapid eye movement) and dexmedetomidine –induced 
hypnosis has been speculated to maintain  the cognitive and 
immunologic function in the sl eep-deprived states (as in the ICU)
(1 2 6 )
.  
Dexmedetomidine can produce profound sedation and it  has been used 
as a total IV anaesthetic when given at  10 times the normal sedation 
concentration range.  
 Dexmedetomidine has been shown to induce a non-rapid eye 
movement sleeping pattern (NREM). The stimulation of the locus 
caeruleus (LC) by dexmedetomidine releases the inhibition the LC has 
over the ventrolateral  preoptic nucleus (VLPO). The VLPO 
subsequently releases  GABA onto the tuberomammillary nucleus 
(TMN). This inhibits the secretion of the arousal-promoting histamine 
on cortex and forebrain, inducing  unconsciousness.  
Dexmedetomidine binds with alpha2  receptors from the locus 
ceruleus inhibiting noradrenal ine release in the ventrolateral prepotic 
nucleus. The disinhibited ventro -lateral  preoptic nucleus decreases  
arousal by means of GABA-mediated and galanin-mediated inhibition 
of hypothalamic, midbrain and pontine arousal nuclei.  
The alpha2  agonists have the advantage that  their effects are 
readily reversible by alpha2-adrenergic antagonists (e.g, atipamezole) .                  
(1 2 8 )
Atipamezole is not currently approved for human use. Similar to 
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other adrenergic receptors, the α 2  agonists also  show tolerance after 
prolonged administration . 
(1 2 9 )
 Because dexmedetomidine is approved 
by the FDA only for short -term sedation (24hours), tolerance, 
dependence, or addiction does not seem to be a problem. 
Dexmedetomidine can be employed for addiction treatment.  
Dexmedetomidine has been described for use in rapid opioid 
detoxification, cocaine withdrawal, and iatrogenic induced  opioid and 
benzodiazepine tolerance after prolonged sedation . 
(1 3 0 )
 In animals,  
dexmedetomidine, in contrast  to opioids,  does not result in  
hyperalgesia or allodynia after its withdrawal . 
(1 3 1 )
 Rats rendered 
tolerant to morphine also showed a decrease in efficacy of hypnotic 
and analgesic effects of dexmedetomidine. As tolerance to opioids 
recovers,  there is  a more rapid recovery of the hypnotic effect of 
dexmedetomidine than its  analgesic efficacy.
(1 3 2 )
The data would tend to 
indicate a possible cross-tolerance between receptors.  
Analgesia 
The analgesic action of dexmedetomidine is complex. Alpha2  
agonists also exert  an analgesic effect when injected intrathecally or 
epidurally.  
(1 3 3 )
Clonidine injected into the neural  axis helps with short  
term pain cancer pain and neuropathic pain . 
(1 3 4 ,  1 3 5 )
 Intrathecally 
injected dexmedetomidine in sleep reduces blood pressure in 1 minute. 
When dexmedetomidine is injected into the epidura l  space, i t  rapidly 
diffuses into the CSF (in one study 
(1 3 6 )
 22% of the injected dose was 
identified in the CSF). The effects on blood pressure are slower in 
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onset with an epidural injection than with an intrathecal 
administration. Epidural effects ar e seen in 5 to 20 minutes.  The 
primary si te of analgesic action appears  to be in the spinal cord.  
(1 3 6 )
 
Systemic use of dexmedetomidine shows reduction in narcotic 
requirement. In the postoperative ICU setting, narcotic requir ements 
were decreased by 50% in patients receiving a dexmedetomidine drip 
compared with placebo
(1 2 2 )
.  
Some of the systemic analgesic effects have been attributed to 
the confounding sedative effects . 
(1 3 7 )
 In human pain studies, the 
results of systemic administration of  dexmedetomidine are not 
consistent . Modest decreases in pain were observed in cold pressor 
tests when patients were receiving dexmedetomidine.  
( 1 3 8 )
 More 
recently,  in a model of heat  and elec trical pain in human volunteers, 
dexmedetomidine was not capable of at tenuating the pain response in 
the clinical dose range when subjects were conscious.  
(1 2 7 )
The 
analgesic effect of dexmedetomidine has been compared with  that of 
remifentanil.  In a noxious heat versus pain intensity graph attained in a 
group of adults, dexmedetomidine was less efficient  in decreasing pain 
(less of a right shift of the curve) than remifentanil . The slope obtained 
was different, which suggests a difference in the mechanism of action 
and an effect of  sedation. 
(1 3 9 ) .
In the clinical  setting, when pain is  
likely to occur and  if dexmedetomidine need to be used, it  is  warranted 
to add a narcotic.  
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Fig. 4: Physiology of dexmedetomidine 
Central Nervous System Protection and other Central Nervous 
System Effects  
The central nervous system protective effects are not well  
defined. In animal models of incomplete cerebral  ischemia and 
reperfusion, dexmedetomidine  decreases  cerebral  necrosis and 
improves the neurologic outcome. In a model of focal ischemia in 
rabbits, dexmedetomidine administered at doses that reduced the MAC 
of halothane by 50%, resulted in less cortical neuronal damage than 
when halothane was administered alone at equieffective MAC 
concentrations
(1 1 6 )
.  In a rat model of unilateral carotid ligation 
accompanied by systemic hypotension, the administration of 
dexmedetomidine provided lower plasma catecholamines with less 
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neurologic and histopathologic damage. 
( 1 4 0 )
The prevalent idea was that  
dexmedetomidine reduced the intracerebral catecholamine outflow 
during injury and resulted in a less neural  tissue damage with be tter 
neurologic outcome. 
(1 4 1 )
Others have found no reduction in cerebral  
catecholamines after receiving dexmedetomidine during injury. 
(1 4 2 )
The 
neuroprotection may be attributed to modulation of proapopto tic and 
antiapoptotic proteins.  Also, decrease in  the excitatory 
neurotransmitter glutamate during injury may explain some of the 
protective effects. 
(1 4 3 )  
The neuroprotective properties of dexmedetomidine in humans 
have not been investigated. Little is  known of the effects of 
dexmedetomidine alone on ICP and CBF. In patients after pituitary 
surgery, a target concentration of 600ng/mL of dexmedetomidine 
resulted in no increase in lumbar CSF pressure.  
(1 4 4 )
In dogs, in the 
presence of volatile anaesthetic agents and dexmedetomidine, CBF 
was decreased, and oxygen consumption was maintained. 
(1 4 5 ,  1 4 6 )  
CBF 
velocity,  as measured by transcranial  Doppler,  decreased with 
increasing concentrations of dexmedetomidine in parallel with 
decreasing MAP and increasing Paco 2 .  
(1 4 7 )
  These reductions  in CBF 
are not accompanied by a reduction in CRM0 2 .  Despite the significant  
reduction in CBF with dexmedetomidine, there was no evidence of 
cerebral ischemia in a dog model. In a preliminary research in 
patients who underwent cerebrovascular surgery using 
dexmedetomidine, there was no evidence of a detrimental  effect on 
local  brain tissue oxygenation. 
(1 4 8 )
 More recently,  in a study in six  
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normal volunteers ,  administration  of dexmedetomidine to achieve 
serum levels of 0.6ng/mL and 1.2ng/mL (with and without 
hyperventilation) produced the predicted reduction of CBF with a 
concomitant reduction in CRM0 2 .  
(1 4 9 )
This finding suggests the 
maintenance of the cerebral oxygen supply-to-demand relationship,  
however, further work in injured brains needs to be done.  
In a rat  seizure model, dexmedetomidine showed significant 
proconvulsant action, which is consistent with formal findings that  
inhibit ion of central  noradrenergic transmission causes facil itat ion of 
seizure expression. 
( 1 5 0
) This finding is in contrast to an anticonvulsant 
effect shown in rats after kainic acid induced seizures. 
(1 5 1 )
As yet there 
have been no reports of seizures in humans. Dexmedetomidine has been 
used in neurosurgical procedures involving neurophysiologic 
monitoring. Cortical  evoked potentials amplitudes and latencies were 
minimally affected when using dexmedetomidine intraoperatively in  
patients who underwent craniotomies.  
(1 4 8 )
Dexmedetomidine is also 
shown to decrease muscle rigidity after administration of high-dose 
opioids.  
(1 5 2 )
In resting volunteers, dexmedetomidine increased growth 
hormone secretion in  a dose-dependent manner,  but  had no effect on 
other pituitary hormones.  
(1 5 3 ,  1 5 4 )
Dexmedetomidine ablates memory in 
a dose-dependent manner. In concentrations used for clinical  sedation 
(i.e., 0.7 ng/mL), recall of picture cards is preserved. Increasing t he 
concentration of dexmedetomidine to 2ng/mL largely ablates recall  and 
recognition of a picture card. 
(1 5 5 )
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Effects on the Respiratory System 
In volunteers,  dexmedetomidine at concentrations causing 
significant  sedation decreases  minute ventilation, but retains the slope 
of the ventilatory response to increasing carbon dioxide. 
(1 5 6 )
The 
changes in venti lat ion were  similar to those observed during natural 
sleep. Ebert  and colleagues, 
(1 5 7 )
 infusing dexmedetomidine to 
concentrations of 15ng/mL in spontaneously breathing adults, did not 
show any variation in arterial  oxygenation or pH. At the maximum 
concentration, Paco2  raised by 20%. Respiratory rate rose with rising 
concentration from 14 breaths  per minute to 25 breaths per minute.  
(1 5 5 )
When dexmedetomidine and propofol were titrated to get equal 
sedative end points (BIS of 85), both did not cause any change in  
respiratory rate.  
(1 5 7 )
 In a research comparing the effects of 
remifentanil and dexmedetomidine on respiratory profiles in normal 
adults,
(1 5 8 )
 the hypercapnic ventilatory response w as not affected even 
at doses which caused unresponsiveness to vigorous stimulation. PaCo2  
showed mild increase with dexmedetomidine, but it  reached a plateau 
following the first  increment. Dexmedetomidine also exhibited a 
hypercarbic arousal phenomenon, which has been described during 
normal sleep and is a safety feature. Intravenous or inhaled 
dexmedetomidine has been shown to block histamine- induced 
bronchoconstrict ion in dogs.  
(1 5 9 )  
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Effects on the Cardiovascular System 
The basic effects of alpha2  agonists on the cardiovascular system 
was reduced heart rate,  reduced systemic vascular resistance,  and 
indirectly reduced myocardial  contracti lity,  systemic blood pressure 
and cardiac output .  By developing highly selective agonists, it  is  hoped 
to reduce some of these adverse cardiovascular effects and to maximize 
the desirable hypnotic-analgesic properties.  The hemodynamic effects 
of a bolus dose of dexmedetomidine in humans show  a biphasic 
response. An acute int ravenous injection of 2 µg/kg resulted in an 
initial rise in blood pressure (22%) and reduction in heart  rate (27%) 
from baseline that happened at 5 minutes after the administration. This 
initial rise in blood pressure is possibly caused by vasoconstrictive 
effects of dexmedetomidine by stimulation of  peripheral alpha2  
receptors. Heart rate returned to baseline in  15 minutes, and blood 
pressure gradually reduced to approximately 15% below baseline in  1 
hour.  After an IM injection of the same dose, the initial  rise in blood 
pressure was not seen;  and heart rate and blood pressure remained 
within 10% of baseline.  
(1 1 8 )
 
Ebert and colleagues 
( l5 5 )  
performed an elegant study in healthy 
subjects using a target-controlled infusion system so as to provide 
rising concentrations (0.7 to l5 ng/mL) of dexmedetomidine. The 
lowest two concentrations caused a reduction in MAP (13%) followed 
by an increase (12%). Rising concentrations of dexmedetomidine also 
produce progressive reduction  in heart  rate and cardiac output (35%). 
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(1 3 6 )
  Infusion of dexmedetomidine in healthy subjects  also resulted in  
compensated decrease in systemic sympathetic tone without causing 
change in baroreflex sensitivity.  It  also blunts the heart  rate and 
systemic sympathet ic activation owing to sweating  but is  less efficient  
in reducing cardiac sympathetic response to shivering. 
(1 6 0 )
The 
incidence of hypotension and b radycardia can be related to 
administration of a loading dose.  Avoid ing the loading dose or not 
giving more than 0.4 mcg/kg decreases the incidence of hypotension, or 
makes it less pronounced. Giving loading dose over 20 minutes also 
reduces the transient hypertension. 
(1 6 1
) In several studies after IM and 
IV administration, dexmedetomidine caused, in a small percentage of 
patients, profound bradycardia (<40 beats/min) and occa sionally sinus 
arrest/pause. These episodes resolved spontaneously or were readily 
treated without adverse outcome by anticholinergics. It  would be 
expected from its profile that  dexmedetomidine would be beneficial  to 
the ischemic myocardium. In animal models  dexmedetomidine showed 
some beneficial effects on the ischemic myocardium through decreased 
oxygen consumption and redistribution of coronary f low from 
nonischemic zones to ischemic zones after acute brief occlusion. 
(1 6 2 )
Dexmedetomidine also decreases serum lactate in a dog model of  
coronary ischemia with an associated reduction  in heart  rate and 
measured catecholamines. It  also produced a ris e in the 
endocardial/epicardial blood flow ratio by 35%. 
(1 6 3 )  
The perioperative use of alpha2  agonists reduces the incidence of 
perioperative myocardial ischemia. 
(6 9 )  
More recently,  Wallace and 
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associates showed that  administration of clonidine in the preoperative 
period reduces the incidence of perioperative cardiac ischemia from 
31% to 14%, and reduces the mortality for 2 years from 20% to 15% 
compared with placebo. The only data on potential benefits in 
perioperative ischemia prevention with dexmedetomidine are provided 
in an underpowered study in vascular surgery patients who received the 
drug in the perioperative period. Blood pressure an d heart rate were 
lower in the dexmedetomidine group. No reductions of ischemic events 
were noted. No rebound effects were  found when discontinuing 
Dexmedetomidine drip, even when i t is  given for more than 24 hours.  
(1 6 6 )
 
Indication 
Labelled:  
 Dexmedetomidine is indicated for sedation of intubated and 
mechanically ventilated patients during treatment in the ICU 
setting.  
 Sedation of non-intubated patients before and / or during 
surgical  or other procedures.   
Off Labelled 
1. Premedication:  
Dexmedetomidine possesses anxiolytic,  analgesic,  sedative,  
antisialogogue and sympatholytic properties, which render it  suitable 
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as a premedication agent.  Dexmedetomidine potentiates the anaesthetic  
effects of all  intra-operative anaesthetic  agents .  
Grant and colleagues 
(1 6 7 )
 described the use of dexmedetomidine 
while securing the airway with a fiberoptic intubation in three patients 
undergoing cervical  spine surgery. The procedure was well  tolerated 
without any hemodynamic compromise or respiratory d epression.  
2. Intra-operative uses:  
Use of dexmedetomidine as adjunct to general anaesthesia: The 
use of intra-operative dexmedetomidine may increase haemodynamic 
stability due to attenuation of the stress -induced sympathoadrenal 
responses to tracheal intubation, during surgery and during emergence 
from anaesthesia.  
In patients given an infusion regimen to achieve a plasma 
concentration of slightly less than 1 ng/mL, combined with 70% nitrous 
oxide, dexmedetomidine decreased isoflurane requirements by 90% 
compared with a control group.
(1 6 8 )
 One retrospective study and two 
prospective, randomized controlled trials in bariatric surgical  patients 
have found that a balanced anaesthesia  with desflurane or propofol plus 
dexmedetomidine (0.5 - 0.8 µg/kg bolus plus 0.4 µg/kg/hr infusion) 
reduces postoperative pain scores and morphine consumption, and 
improves hemodynamics compared to  desflurane-fentanyl or propofol- 
fentanyl anaesthetics. 
(1 6 9 ,  1 7 0 ,  1 71 )  
Dexmedetomidine reduces vasoconstriction threshold and  
increases shivering threshold leading to a lower incidence of shivering.  
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It  is also being used for conscious sedation/ Monitored 
Anaesthesia care.  Because this drug provides good sedation with only 
minimal respiratory depression, it  has been used in patients undergoing 
awake craniotomies with functional testing , and electrocorticograph 
( l7 2 )
 or awake carotid endarterectomies with fewer fluctuations from the 
desired sedation level and a more stable hemodynamics.  
(1 1 7 3 )
 
 Use of dexmedetomidine for regional anaesthesia 
The use of dexmedetomidine as an adjuvant in regional 
anaesthesia is still  not validated. Maarouf 
(1 7 7 )
 explored the effect  of 
epidural dexmedetomidine on the incidence of postoperative shivering 
in 60 patients undergoing orthopedic surgery. He found out that  
patients who received dexmedetomidine at a dose of 100 µg added to 
20 ml 0.5% bupivacaine showed lower incidence  in postoperative 
shivering,  compared to patients who received epidural bupivacaine 
alone (10% vs.  36%). Memis 
(1 7 8 )
 noted that  addition of 0.5 µ.g/kg 
dexmedetomidine to lignocaine for intravenous regional an aesthesia 
improves the quality of anaesthesia and perioperative analgesia without 
causing adverse effects.   
Kanazi et al 
(1 7 9 )
 investigated the effect of adding a small dose of 
3 µg of intrathecal dexmedetomidine to 12 mg bupivacaine. They found 
a significant prolongation of sensory and motor block,  compared to 
bupivacaine alone. In this  study, the effect of 3µg intrathecal 
dexmedetomidine was similar to that produced by the addition of 30 µg 
of intrathecal clonidine.  
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3. Postoperative period:  
In 1999, FDA approved dexmedetomidine as a sedative and 
supplement to sedation in ICU for patients who require mechanical 
ventilation of less than 24 hours duration. Availability of an 
antagonistic agent Atipamezole, 
[ 2 0 1 ] , [ 2 02 ]
 makes it an ideal  drug for 
intravenous titration both as a sole agent and for continuous infusion in 
the intensive care units ,  operating room, and other areas.  Its unique 
sedative action mimics normal sleep, which has  an advantage during 
weaning from mechanical ventilation. Dexmedetomidine need not be 
discontinued and the ongoing sedation can be maintained following 
tracheal extubation,  so as to prevent  emergence delirium and agitation
.  
[ 2 0 3] , [2 0 4]
 
It 's  special  properties favour its use in  the recovery room. In 
addition to its sympatholytic effect s, analgesic effects, reduced rate of 
shivering and the preservation of  respiratory function allows  
continuation of dexmedetomidine infusion in the exubated spontaneous 
breathing patient.  The possibility of ongoing sedation and sympathetic  
block can be useful  in decreasing the high rates of early postoperative 
ischemic events in high risk patient undergoing noncardiac surgery.  
 
4 .  Perioperative administration of dexmedetomidine could be beneficial 
in chronic opioid users and alcoholics, in high - risk patients and also  
in cardiac patients with good to moderately reduced left ventricular 
function.  
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5.  Cocaine poisoning   
Andrew C. Kontak, et  al
(2 0 5 )  
conducted a research in 15 
nontreatment-seeking cocaine-addicted patients and 12 cocaine-naive 
healthy adults to find the dose of intravenous dexmedetomidine that  
lower mean arterial  pressure and heart  rate in the absence of acute -
cocaine challenge. They also conducted a placebo -controlled study in 
26 cocaine-addicted subjects to find out if  dexmedetomidine reverses 
mean arterial  pressure and heart rate increases after cocaine (3 mg/kg).  
They found out that  in a low nonsedating dose, dexmedetomidine can 
be used as a new treatment for cocaine-induced acute hypertension. But 
they found that  higher sedating doses can  cause an unpredictable 
increase in blood pressure during acute -cocaine challenge and should 
be avoided.  
6.  Use in paediatric patients  
Byung Ju Ko et  al 
(2 0 6 )
 in 2012 conducted a study on Procedural  
sedation using dexmedetomidine for paediatric ERCP guided stone 
retraction. As a sedative,  dexmedetomidine can maintain spontaneous 
breathing and preserve oxygenation and ventilation even during deeper 
level of sedation. Here, the total time taken for the procedure  and 
infusion were short  and the child completely recovered from sedation 
within 30 minutes without any adverse events. They came to the 
conclusion that,  when patients are given adequate analgesia,  use of 
dexmedetomidine for sedation for paediatric ERCP would be safe and 
is accompanied by better outcomes than sedation with other drugs.  
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Side Effects  
Hypotension, Bradycardia, and Sinus Arrest  
Episodes of bradycardia and sinus arrest  which are clinically 
significant have been reported when dexmedetomidine is administered 
in young, healthy adults with high vagal tone or with various routes of  
administration  which includes rapid i .v.  or bolus administration.  
Reports of bradycardia and hypotension have been seen with 
dexmedetomidine infusion. If  medical  intervention is needed,  
management includes reducing or stopping the infusion of  
dexmedetomidine, increasing the rate of intravenous fluid 
administration, lower limb elevation and the use of vasopressors. As 
dexmedetomidine can augment the bradycardia induced by st imulation 
of vagus, clinicians should be prepared for intervention . 
Administration of  intravenous anticholinergic agents like 
glycopyrrolate or atropine ought to be considered to modify vagal tone. 
In clinical studies,  glycopyrrolate and atropine were found to be 
effective in treating of most episodes of dexmedetomidine 
hydrochloride-induced bradycardia.  Nevertheless , in some patients with 
considerable cardiovascular dysfunction, more advanced resuscitative 
methods were needed. 
(1 7 4 )  
 
Caution must  be exercised while administering dexmedetomidine 
to patients having advanced heart  block and severe ventricular 
dysfunction. As dexmedetomidine reduces sympathetic nervous system 
activity,  hypotension and  bradycardia are expected to be more marked 
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in patients with hypovolemia, chronic hypertension or diabetes mellitus 
and in geriatric patients.  
In studies where other vasodilators or negat ive chronotropic 
drugs were given along with dexmedetomidine,  an additive 
pharmacodynamic effect was not seen. However, caution should be 
executed when such drugs are used along with dexmedetomidine.  
(1 7 5 )  
Transient Hypertension  
Transient hypertension is seen mainly during the loading dose  
associated with the initial  peripheral  vasoconstrictive effects of 
dexmedetomidine. Treatment of this  transient hypertension is usually 
not necessary, though decreasing the loading infusion rate may be 
desirable.  
(1 5 5 )  
Arousability  
Some patients receiving dexmedetomidine were found to be 
arousable and alert when stimul ated. This alone should not be taken in 
to account as an evidence for lack of efficacy, in the absence of other 
clinical signs and symptoms. 
(1 6 1 )
 
Withdrawal  
While administered up to 7 days  regardless of dose,  12 (5%) 
dexmedetomidine subjects experienced at least 1 event in relation to 
withdrawal within the first 24 hours folowing discontinuation of  the 
drug and 7 (3%) dexmedetomidine subjects experienced at least 1 event 
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24 to 48 hours following the end of drug. The commonest  events were 
nausea, vomiting, and agitation. Tachycardia and hypertension that  
required intervention in the 48 hours after  discontinuation of  
dexmedetomidine occurred at a frequency of < 5%. If tachycardia or 
hypertension occurs after stoppage of dexmedetomidine,  supportive 
treatment is  indicated. 
(1 6 0 )
 
Withdrawal symptoms were not reported following 
discontinuation of short term infusions of dexmedetomidine (< 6 
hours).  
Tolerance and Tachyphylaxis  
Use of dexmedetomidine for more than 24 hours is seen to be 
associated with tolerance and tachyphylaxis , and a dose related rise in 
adverse reactions.  
Hepatic Impairment  
Since dexmedetomidine clearance reduces with severity of liver 
dysfunction, dose reduction must be considered in patients with liver 
dysfunction. 
(1 6 1 )
 
Others  
  Dry mouth 
  Limited amnestic effect  
  Excessive sedation  
  Animal studies show reduction in CBF/CMR0 2  ratio  
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Drug Interaction  
Anaesthetics,  Sedatives, Hypnotics, Opioids  
Administration of dexmedetomidine along with anaesthetics, 
sedatives,  opioids and hypnotics can cause potentiation of their effects.  
Specific studies have established these effects with isoflurane,  
sevoflurane, alfentanil,  propofol, and midazolam. No pharmacokinetic  
interactions have been demonstrated between dexmedetomidine and 
isoflurane, propofol, alfentanil  and midazolam. Though, due to 
possible pharmacodynamic interactions, when administered along with 
dexmedetomidine, a decrease in dosage of dexmedetomidine or the 
concomitant anaesthetic, sedative, hypnotic ,  or opioid may be needed.  
Neuromuscular Blockers  
A study of 10 healthy volunteers  showed that  dexmedetomidine 
administration for 45 minutes at a plasma concentration of  1µg/mL did 
not result  in clinically significant  increase in level  of neuromuscular 
blockade associated with administration  of rocuronium. 
Dexmedetomidine may displace extensively protein bound drugs ,  but 
this is usually not significant .  
Antagonist  
Atipamazole, dose - 50 microgm/kg
(1 7 6 )  
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MATERIALS AND METHODS 
Source of Data:  
 The study was conducted in the Department of Anaesthesiology 
at Sree Mookambika Institute of Medical Sciences, Kulashekharam, 
Kanyakumari district after gett ing permission from the Institutional 
ethical committee. The study was conducted over a period of 14months 
from June 2013 to July 2014.  
Study Design 
Double Blind Randomized clini cal  trial .  
METHOD OF COLLECTION OF DATA 
Inclusion Criteria:  
1.  Patients giving valid consent.  
2.  Patients under American Society of Anaesthesiology physical 
status 1 and 2.  
3.  Patients undergoing elective surgeries under general anaesthesia.  
4.  Patients aged between 18 to 55 years.  
Exclusion Criteria:  
1.  Refusal by the patient.  
2.  Patients with American Society of Anaesthesiolog y physical  
status 3 or more.  
3.  Patients posted for emergency surgeries.  
 
 
77 
 
4.  Patients with history of alcohol or drug abuse.  
5.  Patients who are allergic to any of the test drugs.  
6.  Contraindication to general anaesthesia.  
Sample Size:  
Sample size of each group:  35  
Total sample size of the study: 70  
Scientific basis of sample size used in the study:  
Non-randomised purposive sampling technique.  
Procedures in Detail:  
The study was conducted on 70 patients between 18 and 55 years 
of age belonging to American Society of Anaesthesiolog y physical 
status 1 and 2 of ei ther sex undergoing a variety of elective surgeries 
under general anaesthesia  in Sree Mookambika Institute of Medical  
Sciences, Kulasekharam.  
Pre-operative Check-up 
 A thorough pre-anaesthetic check-up was carried out. Detailed 
history was taken and systems were examined. Pulse,  blood pressure 
and respiratory rate were noted. Height and weight were recorded. 
Routine investigations like haemogram, bleeding time, clotting time, 
chest  X-ray, ECG were obtained before taking up for surgery. After 
applying the exclusion criteria,  70 patients about to undergo general 
anaesthesia with endotracheal intubations were selected.  
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Pre-operative Preparation  
 All the selected patients were visited on the day prior to surgery,  
explained in detail  about the anaesthetic procedure and informed 
writ ten consent was obtained. All patients were kept NPO 6 hours prior 
to surgery. They received Tablet  Ranitidine 150mg and Tablet  
metoclopramide 10mg on the previous night and on the mornin g of 
surgery and injection glycopyrrolate 0.2mg iv and injection midazolam 
2mg iv 30 minutes before surgery as premedication. 
 Intra-operative monitoring included- Pulse oximetry,  non-
invasive blood pressure, ECG, Capnography.  
Preparation of drug for infusion  
Dexmedetomidine 1ml containing 100mcg is added to 50ml 
normal saline to make a solution containing dexmedetomidine 2mcg/ml 
and taken in a 50ml syringe to be administered using a syringe pump.   
Patients were divided randomly into 2 groups.  
Group I:Dexmedetomidine Group; patients received 
dexmedetomidine1µg/kg over 10minutes before the induction of 
anaesthesia and thereafter 0.4µg/kg as continuous infusion  ti ll  the end 
of surgery.  
Group II:Control Group; patients received normal saline 
intravenously administered in the same manner.  
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In operation theatre all  monitors were attached  and baseline 
values recorded. Patients were pre-oxygenated with 100% oxygen for 3 
minutes followed by inj .Fentanyl 1.5mcg/kg IV. Anaesthesia was 
induced with inj .Propofol 2mg/kg IV. This was followed by succinyl 
choline 2mg/kg and endotracheal intubation was done with appropriate 
size endotracheal tube. Patients requiring more than 20 seconds to 
achieve successful tracheal intubation were excluded from the study.  
Maintenance of anaesthesia was done with nitrous oxide: oxygen 2:1 
and atracurium for muscle relaxation after intubation. Heart rate,  
systolic and diastolic blood pressures were recorded just before 
intubation, immediately after intubation, 1, 2, 3,  4,  5 minutes after 
intubation followed by every 5 minutes till  the first 45 minutes  of 
surgery. Any further need for analgesia was supplemen ted by IV 
fentanyl. At the end of surgery neuro -muscular blockade was reversed 
using inj.neostigmine 0.05mg/kg and inj.glycopyrrolate 0.008mg/kg 
and the patients were observed in the post anaesthesia care room for 2 
hours.  Side effects if  any were noted.  
Observations  
Pulse rate and blood pressure were recorded as per the proforma.  
Main arterial Pressure was calculated by the formula  
MAP = DBP + 1/3 (SBP-DBP)  
Where DBP –  diastolic blood pressure ,  SBP –  systolic blood 
pressure.  
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 Change in pulse rate 20% of base line value was considered 
bradycardia or tachycardia.  Patients whose heart  rate fell  below 50 
were given inj.atropine 0.6mg IV.  
Statistical methods of analysis:  
All parameters to be entered in Microsoft excel spread sheet and 
statistically analysed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). 
Statist ical analysis of demographic data, heart rate changes,  blood 
pressure changes were done by unpaired ‘t’  test.  Stud ent’s t  test  was 
used for comparing means of two populations.  
A p value of  >0.05 is not significant  
   <0.05 is significant  
   <0.001 is highly significant.  
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STATISTICAL ANALYSIS 
The data is  expressed in mean and standard error of mean. The 
data was analysed by SPSS (16.0) version. Significant between group -I 
and group-II was analysed by independent t test . P values less than 
0.05 (P<0.05) are considered significant at 95% confidence interval.  
Comparison of Demographic Data  
Table-1: Distribution of Sample according to Age  
 
Age 
(years)  
Group-I (Study) Group-II (Control)  
Number 
Percentage 
(%) 
Number 
Percentage 
(%) 
18-30 11 31.43 13 37.14 
31-40 5 14.29 8 22.88 
41-50 8 22.86 7 20.00 
>50 11 31.43 7 20.00 
 
In the study group, 31.43% patients each were of the age groups 
18-30 and 51-55, 22.86% patients were of the age group 41 -50 and 
14.29% patients were of the age group 31 -40 years. In the control  
group, 37.14% patients were of the age group 18-30, 22.88% patients 
were of the age group 31-40, 20% patients each were of age group 41 -
50 and 51-55 years. (This is shown in the below graph).  
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Fig-5: Distribution of Sample according to Age  of patients  
 
Table-2: Distribution of sample according to  gender of patients  
 
Gender  Group-I (Study)  Group-II (Control) 
Number Percentage 
(%) 
Number Percentage 
(%) 
Male 19  54.28 14  40 
Female 16  45.72 21  60 
 
In the study group, 54.28% patients were males and 45.72% 
patients were females. In the control  group 60% patients were females 
and 40% patients were males. (This is shown in the below graph).  
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Fig-6: Distribution of sample according to gender  of patients  
 
Table-3: Comparison of mean body weight between controls and 
study group  
 
Groups Body weight (Kg) (MEAN±SEM) 
Group-I 62.57±1.14 
Group-II 60.57±6.59 
 
The mean body weight of group I patients were  62.57±1.14 and 
the mean body weight of group II patients were 60.57±6.59.  
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Fig-7: Comparison of mean body weight between controls and study 
group 
Table-4: Comparion of American Society of Anaesthesiologists 
score between controls and study group 
ASA physical status  Group-I (Study) Group-II (Control)  
ASA 1 25 27 
ASA 2 10 8 
 
In the study group 25 patients were ASA 1 and 10 patients were 
ASA 2. In the control group 27 patients were ASA 1 and 8 patients  
were ASA 2. This is  shown in the below graph.  
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Fig-8: Comparion of American Society of Anaesthesiologists score 
between control  and study group 
Table-5: Comparison of number of patients who underwent 
different types of surgery in group-I and group-II 
Type of surgery Group-I (Study) Group-II (Control)  
Urology 02 02  
Head & Neck Surgery  09 11 
Laparoscopic Surgery  06 08 
Orthopaedic Surgery 09 09 
Lower Abdominal Surgery  04 02 
Laparotomy  03 01 
Breast Surgery 02 02 
Total  35 35 
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The above table shows the number of patients who underwent 
different types of surgery in group-I and group-II.  In the 
dexmedetomidine group 9 patients each underwent head and neck 
surgery and orthopaedic surgery, 6 patients underwent laparoscopic 
surgery, 4 patients underwent lower abdominal surgery, 3 patients 
underwent laparotomy and 2 patients each underwent urologic and 
breast surgeries.  In the control group, 11 patients underwent head and 
neck surgery, 9 patients underwent orthopaedic surgery, 8 patients 
underwent laparoscopic surgery, 2 patients each underwent urologic,  
lower abdominal and breast surgeries and 1 patient underwent 
laparotomy.  
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Heart Rate Changes 
Table-6: Comparison of  heart rate changes between groups at 
various time intervals  
Time (min) 
Heart rate (MEAN±SEM) 
P value Group-I 
(Study) 
Group-II 
(Control)  
Base line 83.54±1.03 81.34±1.26 0.279 
Before 
intubation 
67.80±7.71* 88.20±1.14 0.042 
After intubation  76.77±7.63* 100.37±1.31 0.002 
1 min 76.11±8.13* 98.46±1.29 0.030 
2 min 73.82±7.07* 94.48±1.18 0.005 
3 min 71.03±7.09* 90.26±1.18 0.005 
4 min 69.14±6.62* 86.60±1.22 0.000 
5 min 70.00±5.98* 86.51±1.10 0.001 
10 min 69.91±6.12* 86.29±1.08 0.001 
15 min 70.14±6.05* 87.00±1.05 0.003 
20 min 69.94±6.21 87.48±9.66 0.050 
25 min 70.20±5.95 86.06±16.23 0.031 
30 min 70.03±6.21 88.79±9.09 0.047 
35 min 70.08±6.14 87.31±1.00 0.046 
40 min 71.28±6.47 85.63±9.39 0.226 
45 min  70.71±5.94 84.11±9.49 0.114 
 
(*P<0.05 which represents significant  reduction in heart rate at 
different time intervals between group -I and II)  
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Above table shows that there was no significant difference in the 
baseline heart  rate values. Statistically significant reduction in heart  
rate occurred in dexmedetomidine group patients before intubation , 
after intubation, 1 min, 2 min, 3 min, 4 min, 5 min, 10 min and 15 min.  
After 15 min there was no significant difference in heart rates between 
the two groups.  (The same is represented in the following graph).  
 
Fig-9: Time depend changes in heart rate of group -I and group II 
patients  
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Systolic Blood Pressure Changes  
Table-7: Comparison of mean systolic blood pressure changes 
between groups at various  time intervals 
Time (min) 
Systolic blood pressure  
(MEAN±SEM) 
P value 
Group-I   
(Study) 
Group-II 
(Control)  
Base line 128.17±1.73 127.66±1.53 0.825 
Before 
intubation 
105.54±1.59* 
123.23±1.42 
0.000  
After 
intubation 
112.80±1.43* 
147.31±1.66 
0.000  
1 min 113.54±1.47* 143.94±2.03 0.000  
2 min 113.69±1.45* 140.40±1.89 0.000  
3 min 113.33±1.56* 137.09±1.74 0.000  
4 min 112.57±1.52* 137.14±1.79 0.000  
5 min 112.57±1.49* 135.43±1.64 0.000  
10 min 111.71 ±1.38* 131.77±1.67 0.000  
15 min 110.17 ±1.37* 127.71±1.30 0.000  
20 min 107.14 ±3.28* 125.66±1.20 0.000  
25 min 109.40±1.70* 125.94±1.22 0.000  
30 min 108.69 ±1.71* 128.69±1.25 0.000  
35 min 108.74 ±1.60* 130.63±1.07 0.000  
40 min 109.26 ±1.44* 130.57±1.14 0.000  
45 min 110.29 ±1.38* 129.77±1.24 0.000  
(*P<0.05 represents significant reduction in mean systolic blood 
pressure at different time intervals between group -I and II)  
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The above table shows that  there was no significant difference in 
the baseline systolic blood pressure.  Statist ically highly significant 
reduction in systolic blood pressure occurred in dexmedetomidine  
group patients  for all  other readings from before intubation t ill  45 
minutes.  (The same is represented in the following graph).  
 
Fig-10: Time dependent changes in systolic blood pressure in 
group-I and II patients  
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Table-8: Comparison of mean diastolic blood pressure changes 
between groups at various time intervals 
Time (min) Diastolic blood pressure  
(MEAN±SEM) 
P value 
Group-I Group-II 
Base line 82.62±1`.08 82.31±1.01 0.768 
Before 
intubation 
68.17±0.70* 79.33±0.88 0.000  
After 
intubation 
74.85±0.73* 90.05±0.89 0.000  
1 min 74.80±0.72* 86.85±0.98 0.000  
2 min 74.40±0.68* 85.94±1.10 0.000  
3 min 74.97±0.78* 84.62±1.07 0.000  
4 min 74.51±0.84* 83.65±1.05 0.000  
5 min 73.88±0.79* 83.08±0.99 0.000  
10 min 76.05±0.78* 82.74±0.87 0.000  
15 min 72.68±0.84* 82.05±0.85 0.000  
20 min 73.94±0.89* 82.28±1.06 0.000  
25 min 72.68±0.79*  82.74±1.11 0.000  
30 min 71.42±0.76* 84.57±1.18 0.000  
35 min 71.37±0.75* 84.05±1.01 0.000  
40 min 72.00±0.76* 82.68±0.85 0.000  
45 min  72.62±0.79* 82.51±0.77 0.000  
 
(*P<0.05 significant compared mean diastolic blood pressure at 
different time intervals between group -I and II)  
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The above table shows that  there was no significant difference in 
the baseline diastolic blood pressure. Statist ically highly significant 
reduction in diastolic blood pressure occurred in dexmedetomidine 
group patients for all  other readings from before intubation t ill  45 
minutes.  (The same is represented in the following graph).  
 
 
 
Fig-11: Time dependent changes in diastolic blood pressure in 
group-I and II patients  
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Table-9: Comparison of mean arterial pressure changes between 
groups at various  time intervals  
Time (min) Mean arterial pressure 
(MEAN±SEM) 
P value 
Group-I Group-II 
Base line 
97.80±1.15 97.46±7.03 0.834 
Before 
intubation 
80.62±0.75* 93.56±5.63 0.000 
After 
intubation 
87.50±0.75* 108.85±5.68 0.000 
1 min 
87.71±0.82* 105.86±6.63 0.000 
2 min 
87.49±0.75* 103.28±1.84 0.000 
3 min 
87.75±0.86* 101.60±7.44 0.000 
4 min 
87.20±0.87* 99.47±7.45 0.000 
5 min 
86.78±0.792* 100.78±7.24 0.000 
10 min 
87.94±0.87
#  
98.51±5.71 0.001 
15 min 
85.18±0.816
#  
97.27±4.79 0.001 
20 min 
85.00±1.40* 96.80±5.30 0.000 
25 min 
84.92±0.89* 96.79±5.70 0.000 
30 min 
83.84±0.89* 99.22±6.20 0.000 
35 min 
83.8±0.89* 99.34±5.14 0.000 
40 min 
84.41±.844* 97.90±3.70 0.000 
45 min  
84.41±0.76* 98.27±4.56 0.000 
(*P<0.05 significant compared mean arterial  pressure at different 
time intervals between group -I and II)  
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The above table shows that  there was no significant difference in 
the baseline mean arterial pressure. Statistically highly significant  
reduction in mean arterial pressure occurred in dexmedetomidine group 
patients for all other readings from before intuba tion til l  45 minutes.  
(The same is represented in the following graph).  
 
 
 
Fig-12: Comparison of mean arterial pressure changes between 
groups at various time intervals  
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Table No-10 : Comparison of Isoflurane concentration used in 
Study and Control Groups 
Concentration 
of Isoflurane 
Group-I (Study) Group-II (Control)  
Number 
Percentage 
(%) 
Number 
Percentage 
(%) 
0.0.5% 29 82.85 2 5.71 
0.6-1% 6 17.14 15 42.85 
>1% 0 0 18 57.43 
 
 
 
 
Supplemental opioid requirement in the intraoperative period  
 
Table No-11: No. of patients receiving supplemental Opioid in 
intraoperative period 
Study Group Control Group 
N % N % 
5 14.28 35 100 
All patients in the control group required supplemental opioids,  
while 5 out of 35 patients in the study group required supplemental  
opioids.  
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Fig-13: No. of patients receiving supplemental Opioid in  
intraoperative period 
 
Fig-14: No. of patients receiving supplemental Opioid in  
intraoperative period 
 
100 
14.28 
Study Group 
Patients without Opioid
supplementation
Patients with Opioid
supplementation
0 
100 
Control Group 
Patients without Opioid
supplementation
Patients with Opioid
supplementation
 
 
97 
 
Side Effects  
 Two patients developed bradycardia in the study group but  it  
settled without intervention.  
 None of the patients developed hypotension, hypertension or 
respiratory depression.  
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DISCUSSION 
Laryngoscopy and tracheal intubation are considered as the most 
cri tical events during general anaesthesia , as they provoke a transient 
but significant , sympathetic and sympathoadrenal response. Various 
antihypertensive drugs are available for treating perioperative 
hypertension. Beta blockers l ike esmolol and metoprolol is  commonly 
used to treat  hypertensive episode, its use is complicated by 
bradycardia and conduction delays.  Calcium channel blockers cause 
dose dependent cerebral vasodilatation, inhibit ion of auto regulation 
and higher incidence of hypotension. The final common pathway which 
leads to perioperative hypertension appears to be sympathetic nervous 
system activation. Alpha2–adrenergic drugs like clonidine or 
dexmedetomidine reduce these potentially harmful cardiovascular 
responses during anaesthesia  induction.  
This prospective, randomized, double blind placebo controlled 
study was conducted to know whether dexmedetomidine, a newer alfa 
2  -agonist,  with additional properties such as sedation, anxiolysis and 
sympatholysis is effective for attenuating the hemodynamic response 
to laryngoscopy and endotracheal intubation. The study demonstrated 
that a loading dose of 1 mcg/kg of intravenous dexmedetomidine 
followed by continuous infusion of 0.4mcg/kg dexmedetomidine 
caused significant attenuation of heart rate and blood pressure 
response to laryngoscopy and intubation and also reduced 
intraoperative isoflurane and opioid requirement compared to control  
group receiving placebo. 
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Dexmedetomidine exhibits a unique pharmacological  profile 
with sedation, sympatholysis, analgesia and  haemodynamic stability 
along with the great advantage of avoiding respiratory depression. 
Dexmedetomidine offers a dose-dependent cooperative sedation 
which allows interaction with the patient.  These above-said aspects of  
the pharmacological  profile of dexmedetomidine render it  suitable as 
an anaesthetic  adjuvant and also for intensive care unit sedation.  
In our study the two groups were comparable in terms of age, 
gender and weight . The pre-operative heart rate and blood pressure of 
the two groups were having no significant difference (p > 0.05). After 
infusion of dexmedetomidine, there was a fall  in heart  rate and blood 
pressure in the study group. Patients were sedated but arousable.  
Lawrence et  al,
(8 7 )
 found that  a single dose of 2 mcg/kg of 
dexmedetomidine before induction of anaesthesia reduced the 
hemodynamic response to intubation as well  as that to extubation. 
Bradycardia was seen at  the 1
s t
 and 5
t h
 min after administration. This 
might have been due to relatively higher dose given as bolus 
administration. A former study evaluated different bolus doses of 
dexmedetomidine for premedication
(1 1 0 )
 and as recommended in 
literature we selected 1 ug/kg bolus dose. Given the prope rty of the 
drug to cause hypotension or bradycardia when administered to 
patients, it  is important to find out  an infusion rate that would 
maximize the anaesthetic effect and analgesic sparing effect while 
minimizing the incidence of adverse cardiovascular effects which 
require therapeutic intervention.  
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During our study two patients developed bradycardia , which was 
self-l imiting and did not require atropine.  
Dexmedetomidine increases the cardiovascular  stability by 
altering the stress -induced sympathoadrenal responses to endotracheal 
intubation, during surgery and during emergence from anaesthesia.
(8 3 )
 
Jaakola et al
. (8 5 )
 in a study concluded that dexmedetomidine attenuates  
the increase in heart rate and blood pressure during endotracheal 
intubation.  
Scheinin et al  
(8 3 )
,  studied the effect of dexmedetomidine on 
endotracheal intubation, required dose of induction agent and 
perioperative analgesic requirements. They concluded that the required 
dose of thiopentone was considerably lower in the dexmedetomidine 
group and the drug reduced the hemodynamic effects to endotracheal 
intubation. The concentration of noradrenaline in mixed venous plasma 
was lesser in the dexmedetomidine group. Varshali et al 
(8 6 )  
showed 
that  dexmedetomidine reduces sympathoadrenal response to 
endotracheal intubation and decreases perioperative anaesthetic  
requirements.  The need for thiopentone and isoflurane reduced by 30% 
and 32% respectively in the dexmedetomidine group compared to 
control group.  
Villela NR et al
(8 0 ) )
 observed that anaesthetic consumption is 
reduced in the group given dexmedetomidine. Yildiz M et al  
( 8 2 )
 found 
out that  preoperative administration of a single dose of 
dexmedetomidine reduced opioid and anaesthetic requirements. 
Hassan S
(9 5 )
 also observed in his study that the intra -operative 
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infusion of dexmedetomidine reduced the total dose of propofol and 
fentanyl required to maintain anaesthesia, offered a better control of 
intra-operative and postoperative hemodynamics,  reduced 
postoperative pain level, reduced the total dose of morphine used and 
showed a better recovery profile compared to placebo.  
In our study the concentration of isoflurane required during 
surgery was significantly lower in the study group compared to the 
control group.  The intraoperative requirement of opioids was also 
significantly reduced in the study group. Only 5 out of 35 patients in 
the study group required supplemental opioid while all patients in 
control group required supplemental opioid.  
In a prospective,  randomized study by Menda F et  al
(2 9 )
,  
dexmedetomidine was used for attenuation of hemodynamic response to 
tracheal intubation with low dose fentanyl and etomidate in patients 
undergoing myocardial revascularization receiving beta blocker 
treatment.  In the dexmedetomidine group systolic, diastolic and mean 
arterial pressures were lower at  all  times compared to baseline values.  
After induction of anaesthesia , the decrease in heart rate was higher in 
dexmedetomidine group compared to placebo group. One minute after  
intubation, heart rate considerably increased in placebo group while, i t  
reduced in the dexmedetomidine group. The incidence of hypertension 
requiring treatment was considerably higher in the placebo group. It is  
concluded that dexmedetomidine can be safely used to reduce the 
hemodynamic response to intubation in patients undergoing myocardial  
revascularization receiving beta blockers.  
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Sulaiman et  al
(1 8 1 )
 conducted a similar study regarding the 
efficacy of intravenous dexmedetomidine for attenuation of 
haemodynamic responses to laryngoscopy and endotracheal intubation 
in patients having coronary artery disease. Dexmedetomidine at a dose 
of 0.5 mcg/kg as 10 minutes infusion administered before induction of 
general anaesthesia  reduces the sympathetic response to laryngoscopy 
and endotracheal intubation in patients undergoing myocardial  
revascularization.  The authors suggest that it  can be  administered even 
in patients receiving beta blockers. This confirms the observations in 
our study though we chose ASA I & II patients.  
Similarly,  Bajwa et al
(8 8 )
 demonstrated that the pressor response 
to laryngoscopy, intubation, surgery and extubation were effectively 
reduced by dexmedetomidine. The mean dose of fentanyl and isoflurane 
were also decreased significantly (>50%). The mean recovery time was 
also shorter in the dexmedetomidine group.  
In our study the baseline values of heart rate and blood pressure 
were comparable  in both groups. The maximal rise in heart rate and 
blood pressure occurred immediately after tracheal intubation when 
compared to the values  before intubation in both groups . The 
dexmedetomidine group had a significantly lower mean heart rate 
76.77± 7.63 after intubation compared to control group with mean heart  
rate of 100.37±1.31 (p<0.002).  The study group also had lower heart  
rates at 1, 2,  3,  4,  5, 10 and 15  minutes after  intubation compared to 
control group.  
In comparison with the control group, the study group had a 
 
 
103 
 
smaller rise in systolic blood pressure after intubation with mean 
112.80 ±1.43mm Hg in study group and mean of 147.31±6.6mm Hg in 
the control group.  The values of systolic blood pressure returned to the 
values before intubation  earlier in the study group.  The mean systolic  
blood pressure was also maintained stable during the surgery in the 
dexmedetomidine group compared to placebo group.  
Likewise the diastolic blood pressure and mean arterial pressure 
of both groups were having comparabl e baseline values. The values for 
both these parameters were near the value before intubation at all -time 
intervals for patients given dexmedetomidine. For the control group 
there was a significant rise in diastolic blood pressure and mean 
arterial pressure soon after intubation. Thus in our study pretreatment 
with dexmedetomidine 1mcg/kg over 10 minutes followed by 
continuous infusion of 0.4mcg/kg attenuated but not totally obtunded 
the cardiovascular response to tracheal intubation after induction of 
anaesthesia.  It also maintained the haemodynamic stability during the 
surgery.  
The present study findings corroborate  with those of previous 
studies. No adverse cardiovascular effects  from the drug were seen in 
our study.  
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CONCLUSION 
Intravenous Dexmedetomidine can be used for at tenuation of 
haemodynamic stress response to laryngoscopy and endotracheal 
intubation. It also causes reduction in intra operative anaesthetic 
requirement, without affecting intraoperative cardiovascular stabili ty.   
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SUMMARY  
This study was done to evaluate the effectiveness of intravenous 
dexmedetomidine in attenuating the haemodynamic stress response 
during laryngoscopy and intubation and haemodynamic stabil ity during 
the surgery. 70 patients belonging to American Society of 
Anaesthesiology physical status classification 1 and 2  for ei ther sex, 
between 18-55 years scheduled for elective surgeries were divided in to 
two groups each consisting of 35 patients. After premedication, group I 
patients were given dexmedetomidine 1mcg/kg 10 minutes prior to 
induction followed by continuous infusion of 0.4mcg/kg  
dexmedetomidine til l  the end of surgery .  All patients were induced 
with propofol,  intubated using succinyl choline and  were maintained 
with atracurium and isoflurane. Analgesic used was fentanyl.  Group II 
patients received intravenous normal saline instead of 
dexmedetomidine.  
Based on the results obtained in the study it can be concluded 
that  dexmedetomidine causes statistically significant attenuation of the 
haemodynamic stress response to laryngoscopy and intubation and 
maintains the haemodynamic stability during surgery. Administration 
of dexmedetomidine also caused a significant reduction in isoflurane 
requirement during surgery. All  patients in the study group wer e better 
sedated and cardiostable . The study group also had lesser requirement 
of intraoperative opioids.   
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In conclusion, intravenous dexmedetomidine significantly  
attenuates sympathoadrenal response to laryngoscopy and endotracheal 
intubation and also cause reduction in intra operat ive anaesthetic 
requirement, without affecting intraoperative cardiovascular stabili ty  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
BIBLIOGRAPHY 
 
1.  Prys-Roberts C, Greene LT, Meloche R et al. Studies of anaesthesia 
in relation to hypertension II:  Haemodynamic consequences of 
induction and endotracheal intubation. Brit. J .  Anaesth.  1971; 
43:531-547.  
2.  Masson AHB. Pulmonary edema during or after surgery. Anesth. 
Analg. Current Researches 1964; 43: 440 -51.  
3.  Braunwald E. Control of myocardial oxygen consumption 
physiological  and clinical  consideration. Am. J. Cardiol .  1971; 27:  
416-432.  
4.  Maze M, Tranquilli W: Alpha-2 adrenoreceptor agonists:  Defining 
the role in clinical  anaesthesia . Anesthesiology 1991; 74:581-605.  
5.  Gerlach AT, Dasta JF: Dexmedetomidine: An updated review. Ann 
Pharmacother 2007;41:245-252.  
6.  Reid LC, Brace DE. Irritation of the respiratory tract and its reflex 
effect upon heart.  Surg Gynaec & Obst; 1940; 70: 157 -62. 
7.  King BD, Harris LC Jr, Brefenstein FE et al.  Reflex circulatory 
response to direct laryngoscopy and tracheal intubation performed 
during general anaesthesia . Anesthesiology 1951; 1  
8.  Wycoff CC. Endotracheal intubation: Effect on blood pressure and 
pulse rate. Anaesthesiology 1960;21:153  
9.  Dingle HR. Antihypertensive drugs. Anaesthesia 1996; 21:1 51. 
 
 
108 
 
10.Bedford RF. Circulatory response to tracheal intubation: Erchnorn 
JH, Kirbv RB, Brown DL (Eds): Problems in Anaesthesia.  
Philadelphia JB Lippincott 1998: 2:203 -10.  
11.Takashima K, Nada k, Higaki M: Cardiovascular response to rapid 
anaesthesia induction and intubation. Anaesthesia Analgesia 1964; 
43: 201-208.  
12.Derbyshire DR, Chmielewki A, Fell  D, Smith G. Plasma 
catecholamine responses to tracheal intubation. Br J Anaesthesia 
1983; 55: 856-60.  
13.Derbyshire DR.Smith G, Achola KJ. Effect of topical lignocaine on  
the sympathoadrenal responses to tracheal intubation. Br J 
Anaesthesia 1987; 59:300-4. 
14.Ovassapian A, Yehch SJ, Dykes MH, Brunner EE. Blood pressure 
and heart  rate changes during awake fiberoptic nasotracheal 
intubation. Anaesth. Analg 1983;62:951-4. 
15.Shribman AJ, Smith G, Achola KJ. Cardiovascular and 
catecholamine responses to laryngoscopy with and without tracheal 
intubation. Br J Anaesth 1987; 59:295 -9. 
16.Finfer SR, MacKenzie SI,  Saddler JM, et al. Cardiovascular 
responses to tracheal intubation: a compari son of direct  
laryngoscopy and fiberoptic intubation. Anaesth Intensive Care 
(1989) 17:44-8.  
17.Roy WL, Edelist  G, Gilbert  B. Myocardial  ischemia during non -
cardiac surgical  procedures in patients with coronary artery disease. 
Anaesthesiology 1979;51:393-7. 
 
 
109 
 
18.Fox EJ, Sklar GS, Hill  CH.Vilanueva P, King BD. Complications 
related to the pressor response to endotracheal intubation.  
Anaesthesiology 1977; 47:524-5. 
19.Mangano DT. Perioperative cardiac morbidity.  Anaesthesiology 
1990;72:153-84. 
20.Mangano DT, Browner WS, Hollenberg M, Li J, Tateol M. Long 
term cardiac prognosis following non -cardiac surgery. The study of 
operative Ischemia Research Group JAMA 1992; 268:233 -9.  
21.Ross AF, Tinker JH. Evaluation of adult  patient with cardiac 
problems, In:  Gogers MC, Timken JA, Covino BG, Langnecker DE 
(ECS). Principles and practice of Anaesthesiology 1979; 50:285-9. 
22.Goldman L, Cakta QL. Risk of general anaesthesia and elective 
operation in the hypertensive patient. Anaesthesiology 1979; 
50:285-92. 
23.Raby KE, Goldman L, Creager MA et  al. Correlation between 
preoperative ischemia and major cardiac events after peripheral  
vascular surgery N.Engl J Med 1989;321:1296 -300.  
24.Mangano DT, Browner WS, Hollenberg M.London MJ, Tubau JF, 
Tateo IM. Association of perioperative myocardial ischemia w ith 
cardiac morbidity and mortality in men undergoing non -cardiac 
surgery. The study of perioperative ischemia Research Group. 
N.Engl.  JMed. 1990; 323:1931-5. 
25.Kleinman B, Henkin RE, Glisson S et  al . Qualitative evaluation of 
coronary flow during anaestheti c thall ium 201 perfusion scans. 
Anaesthesiology 1986; 64:157-64. 
 
 
110 
 
26.Slogoffs,  Keats AS. Does perioperative myocardial  ischemia lead to 
postoperative myocardial infarction. Anaesthesiology 1985; 62:107 -
14. 
27.Prys-Roberts C. Hypertension and Anaesthesia: 50 yrs o n 
anaesthesiology 1979; 50:281-4. 
28.Steen PA, Tinker JH, Tarhan S. Myocardial reinfarction after 
anaesthesia and surgery. JAMA 1978; 239:2566 -70. 
29.Stone JG, Foex P, SEAR JW, Johnson LL, Khambatta HJ, Triner L.  
Myocardial  ischemia in untreated hypertensive patients:  Effects of a 
single small  oral  dose of a beta -adrenergic blocking agent. 
Anaesthesiology 1988; 08:495-500.  
30.Kaplan JA. Haemodynamic monitoring. In:  Kaplan JA (Ed) Cardiac 
Anaesthesia.  Philadelphia. WB Saunders 1987:179 -225.  
31.Giles RW. Berger HJ, Barash PG et al. Continuous monitoring of 
left ventricular performance with the computerized nuclear probe 
during laryngoscopy and intubation before coronary artery bypass 
surgery. Am J Cardio 1982; 50:735 -41. 
32.Thomson IR. The haemodynamic response to intubat ion: a 
perspective.  Can J Anaesth 1989; 2:203 -10.  
33.Roelofse JA, Snipton EA, Joubent JJ, Grotepass FW. A comparison 
of labetalol , acebutalol and lidocaine for controlling the 
cardiovascular responses to endotracheal intubation for oral surgical  
procedures.  J  Oral  maxillofacial Surg 1987; 45:835-41. 
 
 
111 
 
34.Allberry RA. Drake HF. Preoperative beta blockade for patients 
undergoing craniotomy: A comparison between propranalol and 
atenolol. Can J Anaesthesia 1990; 37:448 -51.  
35.Achola KJ, Jones MJ, Mitchell  RW, Smith G. Ef fects of beta 
adrenoceptor antagonism on the cardiovascular and catecholamine 
responses to tracheal intubation. Anaesthesia 1998; 43:433 -6.  
36.Inada E, Culless DJ, Nemeskal AR, Teplicick R. Effect of labetalol  
or lidocaine on the haemodynamic response to intu bation. A 
controlled randomized double -blind study. J  Clin Anaesthesia 1989;  
1:201-13. 
37.Leslie JB, Kalayjian RW. McLoughlin TM, Palchetaka JR. 
Attenuation of the haemodynamic response to endotracheal 
intubation with preinduction intravenous labetalol . J  Cli n 
Anaesthesia 1989; 1:194-200.  
38.Liu PL, Gatt  S,  Guigino LD, Mallampati  SR, Convino BG. Esmolol 
for control  of increases in heart  rate and blood pressure during 
tracheal intubation after thiopentone and succinylcholine.  Can 
Anaesthesia Soc. J  1986; 33;556 -62. 
39.Watwill  M.Sundberg A, 01sson et al . Thoracolumbar epidural  
anaesthesia blocks the circulatory response to laryngoscopy and 
intubation. Acta. Anaesthesiol.Scand.l987; 529 -531.  
40.Thakker JM, Joshi GB, Shah RA. Sublingual nifedipine to attenuate 
response to laryngoscopy and intubation. Indian J Anaesthesia 1994; 
42:209.  
 
 
112 
 
41.Puri  GD, Batra YK. Effects of nifedipine on cardiovascular 
responses to laryngoscopy and intubation. Indian J Anaesthesia 
1993; 34:56.  
42.Reaves JG, Kissin L, Lell WA. Calcium entry blockers: Uses  and 
implications for anaesthesiologist.  Anaesthesiology 1983; 57; 504 - 
18. 
43.Lishajko F. Releasing effect of calcium and phosphate on 
catecholamines,  ATP and protein from Chromaffin cell  granules.  
Acta physiologica Scand 1970; 79; 575- 84.  
44.James MF, Beer RE, Esser JD. Intravenous magnesium sulfate 
inhibits catecholamine release associated with tracheal intubation,  
Anaesth Analg 1989; 68:772-6. 
45.Allen RW, James MF. Attenuation of the pressor response to 
tracheal intubation in hypertensive proteinuric pregnant patients by 
lignocaine, alfentanil and magnesium sulfate.  Br J Anaesthesia 
1991; 66:216-23. 
46.Stoelting RK. Attenuation of blood pressure to laryngoscopy and 
tracheal intubation with sodium nitroprusside.  Anaesth Analg 1979; 
58:116-9.  
47.Gallagher, Moore RA, Botors AB, Clark DL. Prophylactic  
nitroglycerine infusion during coronary artery bypasses surgery.  
Anaesthesiology 1986; 64;785-89. 
48.John D, Gallagher MD, Roger A, Moore MD. Prophylactic 
nitroglycerine infusions during CABG. Anaesthesiology 1986;  
64:785-789.  
 
 
113 
 
49.Kamra S, Sapru RP. Topical nitroglycerine a safeguard against 
pressor response to tracheal intubation. Anaesthesia 1986; 41:1087.  
50.Fassoulaki A and Kaniaris P.  Intranasal  administration of 
nitroglycerin attenuates the pressor response to laryngoscopy and 
intubation of the trachea. BrJAnaesth 1983; 55:49 -52  
51.Khan FA, Kamal RS. Effect  of buprenorphine on cardiovascular 
response to tracheal intubation. Anaesthesia 1989; 44:394 -7. 
52.Dahlgren N, Messiter K. Treatment of stress response to  
laryngoscopy and intubat ion with fentanyl. Anaesthesia 1981; 
36(11); 1022-1026.  
53.Black TE, Kay B, HealyTEJ. Reducing the haemodynamic responses  
to laryngoscopy and intubation: A comparison of alfentanil with 
fentanyl. Anaesthesia 1984; 39:883-7. 
54.Kay B, Nolan D, Mayall  R et  al.  The  effect of Sufentanil on 
cardiovascular response to tracheal intubation. Anaesthesia 1987; 
42:382-6. 
55.James TN. The chronotropic action of ATP and related compounds 
studied by direct perfusion of the sinus node. J  Pharmacol Exp 
1965; 149:233-47. 
56.Belardinelli L, Mattas EC, Berne RM. Evidence for adenosine 
mediation of atrioventricular block in the ischemic canine 
myocardium. J Cli  Tnvest 1981; 68:195-205.  
57.MiKawa KJ, Iegaki J, Mackwa N et  al . Effects of prostaglandin E on 
the cardiovascular response to tracheal intubation. J  Clin 
Anaesthesia 1990; 2:420-4. 
 
 
114 
 
58.Menkhaus PG, Reves JG, Kissin I et al.  Cardiovascular effects of 
esmolol in anaesthetized humans. Anaesth Analg 1985; 64:327 -34.  
59.Lev R, Rosen P. Prophylactic lidocaine use preintubation: a review . 
J Emerg Med. 1994; 12(4):499-506.  
60.Stoelting RK: Circulatory responses to laryngoscopy and tracheal  
intubation with or without prior oropharyngeal viscous l idocaine. 
Anaesth Analg 1977; 56:618.  
61.Delinker JK, Ellison N. Omnisky AJ. Effects of intratracheal 
lidocaine on the circulatory response to tracheal intubation. 
Anesthesiology 1974;41:409r 12.  
62.Kautto UM. Attenuation of the circulatory response to laryngoscopy 
and intubation by fentanyl.  Acta Anaesthesia Scand 1982 Jun;26(3):  
217-21.  
63.Thompson JP, Hall  AP, Russell J , Cagney B, Rowbotham DJ. 
Comparison of different doses of remifentanil on the cardiovascular 
response to laryngoscopy and tracheal intubation. BrJAnaesth 2000; 
84: 100-2 
64.Maze M, Tranquilli W: Alpha-2 adrenoreceptor agonists:  Defining 
the role in clinical  anaesthesia. Anaesthesiology 1991; 74: 581 -605.  
65.Kaukinen S, Kaukinen L, Eerola R: Preoperative and postoperative 
use of clonidine with neurolept anaesthesia. Acta Anaesthesiol  
Scandinavica 1979; 23:113-120.  
66.Bloor BC, Flacke WE: Reduction in hal othane anaesthetic 
requirement by clonidine, an alpha -adrenergic agonist . Anaesthesia 
Analgesia 1982; 61: 741-745.  
 
 
115 
 
67.Virtanen R, Savola JM, Saano V, Nyman L: Characterization of the 
selectivity,  specifici ty and potency of medetomidine as an alpha 2 - 
adrenoreceptor agonist.  European Journal of Pharmacology 1988; 
150: 9-14. 
68.Hall JE, Uhrich TD, Barney JA, Arain SR. Ebert TJ. Sedative, 
amnestic, and analgesic properties of small -dose Dexmedetomidine 
infusions. Anaesthesia Analgesia 2000; 90:699 -705 
69.Talke P, Richardson CA, Scheinin M, Fisher DM. Postoperative 
pharmacokinetics and sympatholytic effects of dexmedetomidine. 
Anaesthesia Analgesia 1997; 85:1136 -42 
70.Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr Opin 
Anaesthesiol 2005; 18: 412-8 
71.Ebert  TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects 
of increasing plasma concentrations of dexmedetomidine in humans. 
Anaesthesiology. 2000; 93:382-94  
72.Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, 
Heard S, Cheung A, Son SL, Kallio A. The he modynamic and 
adrenergic effects of perioperative dexmedetomidine infusion after 
vascular surgery. Anaesthesia Analgesia 2000; 90:834 -9  
73.Guler G, Akin Z, Tosun E, Eskitascoglu, Mizrak A, Boyaci A. 
Single-dose dexmedetomidine attenuates airway and circulato ry 
reflexes during extubation. Acta Anaesthesiol Scandinavica 2005; 
49:1088-91 
 
 
116 
 
74.Aantaa R, Jaakola ML, Kallio A, Kanto J.  Reduction of the 
minimum alveolar concentration of isoflurane by dexmedetomidine. 
Anaesthesiology 1997; 86:1055-60 
75.Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. 
Intraoperative infusion of dexmedetomidine reduces perioperative 
analgesic requirements.  Canada Journal Anaesthesia 2006; 53:646 -
52 
76.Gerlach AT, Dasta JF: Dexmedetomidine: An updated review. Ann 
Pharmacotherapy 2007; 41:245-252.  
77.Tobias JD: Dexmedetomidine: applications in pediatric critical  care 
and pediatric anaesthesiology. Paediatric Critical Care Medicine 
2007; 8:115-131.  
78.Bloor BC, Ward DS, Belleville JP, Maze M. Effects of IV 
Dexmedetomidine in Humans II.  Haemod ynamic changes.  
Anaesthesiology 1992; 77:1125-33. 
79.Bloor BC, Ward DS, Belleville JP, Maze M. Effects of IV 
Dexmedetomidine I. Sedation, Ventilation and Metabolic rate.  
Anaesthesiology 1991; 74:997-1002.  
80.Villela NR, Nascimento junior P. Dexmedetomidine in 
Anaesthesiology. Rev Bras Anestesiol  2003 Feb; 53(1):97 -l  13.  
81.Kallio A, Scheinin M, Koulu M, Riitta Ponkilainen, Heikki 
Ruskoaho, Osmo Viinamaki,  and Harry Scheinin. Effects of 
Dexmedetomidine, a selective α2 adrenergic agonist on 
haemodynamic control mechanism. Clinical pharmacology and 
therapeutics 1989; 46: 33 -42.  
 
 
117 
 
82.Yildiz M, Taylan A, Tuneer S, Reisli R, Yosunkaya A, Oteleioglu.  
Effect of Dexmedetomidine on hemodynamic responses to 
laryngoscopy and Intubation: Perioperative haemodynamic and 
anaesthetic requirements. Drugs RD. 2006; 7:  43 -52.  
83.Scheinin B, Lindgren L, Randell  T, et  al: Dexmedetomidine 
attenuates sympathoadrenal responses to tracheal intubation and 
reduces the need for thiopentone and perioperative fentanyl. Br J 
Anaesth 1992; 68:126-131.  
84.Hulya Basar,  Serpil  Akpinar; The effects of preanaesthetic,  single 
dose dexmedetomidine on induction, hemodynamic and 
cardiovascular parameters.  Journal of Clinical  Anaesthesia  2008; 
20:431-436.  
85.Jaakola ML, Ali -Melkkila T, Kanto J,  et al: Dexmedetomidine 
reduces intraocular pressure, intubation responses and anaesthetic  
requirements in patients undergoing ophthalmic surgery.  Br J 
Anaesth 1992; 68:570-575.  
86.Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates  
sympathoadrenal response to tracheal intubation and reduces 
perioperative anaesthetic  requirement. Indian J Anaesth 
2011;55:352-7 
87.Lawrence CJ, De Lange S. Effects of a single preoperative 
dexmedetomidine dose on isoflurane requirements and perioperative 
hemodynamic stabili ty,  Anaesthesia 1997; 52:736 -44 
 
 
118 
 
88.Bajwa SS, Kaur J, Singh G, Kulshrestha A, et  al.  Attenuation of 
pressor response and dose sparing of opioids and anaesthetics with 
pre-operative dexmedetomidine. Indian J Anaesth 2012; 56:123 -8. 
89.Turan G, Ozgultekin A, Turan C, Dincer E, Yuksel G. Adverse 
effect of dexmedetomidine on haemodynamic and recovery response 
during extubation for intracranial surgery. European journal of 
anaesthesia.  Oct 2008. Vol 25; issue 10: 816 -820.  
90.Alex Bekker, Mary Sturaitis , Marc Bloom, Mario Moric,  John 
Golfinos, Dexmedetomidine on perioperative Haemodynamic in 
patients undergoing Craniotomy. Anaesthesia Analgesia 2008; 
107:1340-7. 
91.Zerrin Ozkose, Figen Sunay Demir,  Kutluk Pamdal,  Sahn Yardim. 
Haemodynamic and Anaesthetic advantages of dexmedetomidine, an 
α2 Agonist , for surgery in prone position. Tohoku J. EXP. Med.,  
2006,210(2);  153-160.  
92.Menda F, et al.  Dexmedetomidine as an adjunct to anaesthetic  
induction to attenuate hemodynamic response to endotracheal 
intubation in patients undergoing fast -track CABG. Ann Card 
Anaesth.  2010;13:16-21.  
93.Pekka Talke, Richard Chen, Brian Thomas, Anil Agarwal,  
Alexandra Gottl ieb,  Per Thorberg, Stephen Heard, Albert  Cheung, 
Stan Lee Son. The Haemodynamic and Adrenergic effects of 
perioperative dexmedetomidine infusion after vascular surgery. 
Anaesthesia Analgesia 2000; 90: 834 -839. 
 
 
119 
 
94.Tufanogullari  B, White PF, Peixoto MP, Kianpour D, Lacour T, 
Griffin J, Skrivanek G, Macaluso A, Shah M, Provost DA. 
Dexmedetomidine infusion during laparoscopic bariatric surgery: 
the effect on recovery outcome vari ables. Anaesthesia & Analgesia 
June 2008; Vol 106,ino.6:1741-48.  
95.Hassan S Bakhamees, Yasser M el -Halafawy, Hala M El -Kerdawy,  
Nevien M Gouda, Sultan AITemyatt. Effects of dexmedetomidine in 
morbidly obese patients undergoing laparoscopic gastric bypass.  
M.E.J. ANAESTH 2007,19 (3).  
96.Stoelting RK. Circulatory response to laryngoscopy and tracheal 
intubation with or without prior oropharyngeal viscous lidocaine..  
Anesth Analg. 1977; 56(5):618 -21.  
97.Venus B, Polassani V, Pham CG. Effects of aerosolized lidocaine  on 
circulatory responses to laryngoscopy and tracheal intubation. Crit  
Care Med. 1984; 12(4):391-4. 
98.Mostafa SM, Murthy BV, Barrett PJ, McHugh P. Comparison of the 
effects of topical lignocaine spray applied before or after induction 
of anaesthesia on the pressor response to direct laryngoscopy and 
intubation. Eur J Anaesthesiol. 1999; 16(1):7 -10.  
99.Takita K, Morimoto Y, Kemmotsu O. Tracheal lidocaine attenuates 
the cardiovascular response to endotracheal intubation. Can J 
Anaesth.  2001; 48(8):732-6. 
100.  Sklar BZ, Lurie S, Ezri T, Krichelli  D, Savir I,  Soroker D. 
Lidocaine inhalation attenuates the circulatory response to 
 
 
120 
 
laryngoscopy and endotracheal intubation. J  Clin Anesth.  1992; 
4(5):382-5. 
101.  Yukioka H, Yoshimoto N, Nishimura K, Fujimori M. Intravenous 
lidocaine as a suppressant of coughing during tracheal intubation.  
Anesth Analg 1985; 64(12): 1189 -92. 
102.  Aouad MT, Sayyid SS, Zalaket MI, Baraka AS. Intravenous 
lidocaine as adjuvant to sevoflurane anaesthesia for endotracheal 
intubation in children. Anesth Analg. 2003 96(5): 1325-7. 
103.  Abou-Madi MN, Keszler H, Yacoub JM. Cardiovascular reactions 
to laryngoscopy and tracheal intubation following small and large 
intravenous doses of lidocaine. Can Anaesth Soc J. 1977; 24(1):  12 -
9.  
104.  Singh H, Vichitvejpaisal P, Gaines GY, W hite PF. Comparative 
effects of lidocaine, esmolol, and nitroglycerin in modifying the 
hemodynamic response to laryngoscopy and intubation. Clin Anesth.  
1995; 7(l):5-8.  
105.  Van den Berg AA, Savva D, Honjol NM. Attenuation of the 
haemodynamic responses to noxious st imuli in patients undergoing 
cataract surgery. A comparison of magnesium sulphate, esmolol, 
lignocaine, nitroglycerine and placebo given IV with induction of 
anaesthesia.  Eur J Anaesthesiol.  1997; 14(2): 134 -47.  
106.  Kindler CH, Schumacher PG, Schneider MC , Urwyler A. Effects 
of intravenous lidocaine and/or esmolol on hemodynamic responses 
to laryngoscopy and intubation: a double -blind, controlled clinical  
trial. Clin Anesth. 1996; 8(6):491 -6.  
 
 
121 
 
107.  Tam S, Chung F, Campbell  M. Intravenous lidocaine: optimal 
time of injection before tracheal intubation. Anesth Analg.1987; 
66:1036-8 
108.  Miller CD, Warren SJ. IV lignocaine fails to attenuate the 
cardiovascular response to laryngoscopy and tracheal intubation. Br 
J Anaesth. 1990; 65(2):216-9. 
109.  Wilson IG, Meiklejohn BH, Smith G. Intravenous lignocaine and 
sympathoadrenal responses to laryngoscopy and intubation. The 
effect of varying time of injection. Anaesthesia.  1991; 46(3):  177 -
80. 
110.  Bruder N, Ortega D, Granthil  C. Consequences and prevention 
methods of hemodynamic changes during laryngoscopy and 
intratracheal intubation Ann Fr Anesth Reanim. 1992; 11(1):  57 -71.  
111.  Aantaa R, Jalonen J: Perioperative use of alpha2 -adrenoceptor 
agonists and the cardiac patient. European Journal Anaesthesiol  
2006; 23:361-372.  
112.  Cooper J, Bloom F, Roth R. The Biochemical Basis of 
Neuropharmacology.  7th ed. 1996: 285 -287.  
113.  Duke P, Maze M, Morrison P. Dexmedetomidine: a general 
overview. International Congress and Symposium Series (221). 
1998(theme issue): 13.  
114.  De Wolf AM, Fragen RJ, Avram MJ, et  al :  The pharmacokinetics 
of dexmedetomidine in volunteers with severe renal impairment.  
Anesth Analg 2001; 93:1205-1209.  
 
 
122 
 
115.  Venn RM, Karol MD, Grounds RM: Pharmacokinetics of 
dexmedetomidine infusions for sedation of postoperative patients  
requiring intensive caret . Br JAnaesth 2002; 88:669-675.  
116.  Maier C, Steinberg GK, Sun GH, et  al:  Neuroprotection by the 
alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of 
cerebral ischemia. Anesthesiology 1993; 79:306 -312.  
117.  Ramsay MA, Luterman DL: Dexmedetomidine a s a total  
intravenous anaesthetic agent. Anesthesiology 2004; 101:787 -790. 
118.  Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer 
SL: Computer-controlled infusion of intravenous dexmedetomidine 
hydrochloride in adult human volunteers.  Anaesthesiology 1993; 78: 
821-28.  
119.  Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL: The 
pharmacokinetics and haemodynamic effects of intravenous and 
intramuscular dexmedetomidine hydrochloride in adult human 
volunteers.  Anaesthesiology 1993; 78: 813 -820.  
120.  De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Danesh FR: 
The pharmacokinetics of dexmedetomidine in volunteers with severe 
renal impairment. Anaesthesia Analgesia 2001; 93:1205 - 1209.  
121.  Guo TZ, Jiang JY, Buttermann AE, Maze M: Dexmedetomidine 
injection into the locus coeruleus produces antinociception. 
Anesthesiology 1996; 84:873-881.  
122.  Venn RM, Bradshaw CJ, Spencer R, et al: Preliminary UK 
experience of dexmedetomidine, a novel agent for postoperative 
 
 
123 
 
sedation in the intensive care unit.  Anaesthesia 1999; 54:1136 - 
1142.  
123.  Venn RM, Hell  J , Grounds RM: Respiratory effects of 
dexmedetomidine in the surgical patient requiring intensive care.  
Crit Care 2000; 4:302-308.  
124.  Kress JP, Pohlman AS, O'Connor MF, Hall JB: Daily interruption 
of sedative infusions in critically ill  patients u ndergoing mechanical 
ventilation. N Engl J Med 2000; 342:1471 -1477.  
125.  Nelson LE, Lu J, Guo T, et  al : The alpha2 -adrenoceptor agonist 
dexmedetomidine converges on an endogenous sleep -promoting 
pathway to exert its sedative effects. Anesthesiology 2003; 98:428 -
436. 
126.  Nacif-Coelho C, Correa-Sales C, Chang LL, Maze M: 
Perturbation of ion channel conductance alters the hypnotic 
response to the alpha 2 -adrenergic agonist dexmedetomidine in the 
locus coeruleus of the rat. Anesthesiology 1994; 81:1527 -1534. 
127.  Angst MS, Ramaswamy B, Davies MF, Maze M: Comparative 
analgesic and mental  effects of increasing plasma concentrations of 
dexmedetomidine and alfentanil in humans. Anesthesiology 2004; 
101:744-752.  
128.  Aho M, Erkola O, Kallio A, et  al : Comparison of 
dexmedetomidine and midazolam sedation and antagonism of 
dexmedetomidine with atipamezole. J  Clin Anesth 1993; 5:194 -203.  
129.  Reid K, Hayashi Y, Guo TZ, et  al : Chronic administration of an 
alpha 2 adrenergic agonist desensitizes rats to the anaesthetic  
 
 
124 
 
effects of dexmedetomidine. Pharmacol Biochem Behav 1994;  
47:171- 175.  
130.  Maccioli GA: Dexmedetomidine to facil itate drug withdrawal.  
Anesthesiology; 2003; 98:575-577.  
131.  Davies MF, Haimor F, Lighthall  G, Clark JD: Dexmedetomidine 
fails to cause hyperalgesia after cessation of chronic admi nistration. 
Anesth Analg 2003;96:195-200.  
132.  Hayashi Y, Guo TZ, Maze M: Hypnotic and analgesic effects of 
the alpha 2-adrenergic agonist dexmedetomidine in morphine -
tolerant rats. Anaesthesia Analgesia 1996; 83: 606 -610.  
133.  Asano T, Dohi S, Ohta S, et al: Antinociception by epidural and 
systemic alpha(2)-adrenoceptor agonists and their binding affinity 
in rat  spinal  cord and brain.  Anesth Analg 2000; 90:400 -407.  
134.  Tryba M, Gehling M: Clonidine—a potent analgesic adjuvant. 
Curr Opin Anaesthesiol 2002; 15:511-517. 
135.  Eisenach JC, De Kock M, Klimscha W: Alpha(2) -adrenergic 
agonists for regional anaesthesia: A clinical review of clonidine 
(1984-1995). Anesthesiology 1996; 85:655-674.  
136.  Eisenach JC, Shafer SL, Bucklin BA, et  al: Pharmacokinetics and 
pharmacodynamics of intraspinal dexmedetomidine in sheep. 
Anesthesiology 1994; 80:1349-1359.  
137.  Aho MS, Erkola OA, Scheinin H, et  al:  Effect  of intravenously 
administered dexmedetomidine on pain after laparoscopic tubal 
ligation. Anesth Analg 1991; 73:112 -118.  
 
 
125 
 
138.  Hall JE, Uhrich TD, Barney JA, et al:  Sedative,  amnestic, and 
analgesic properties of small -dose dexmedetomidine infusions.  
Anesth Analg 2000; 90:699-705.  
139.  Cortinez LI,  su YW, Sum-Ping ST, et al:  Dexmedetomidine 
pharmacodynamics,  part  II:  Crossover comparison of the analgesi c 
effect of dexmedetomidine and remifentanil  in healthy volunteers.  
Anesthesiology 2004; 101:1077-1083.  
140.  Hoffman WE, Kochs E, Werner C, et al: Dexmedetomidine 
improves neurologic outcome from incomplete ischemia in the rat:  
Reversal by the alpha 2 -adrenergic antagonist  atipamezole.  
Anesthesiology 1991; 75:328-332.  
141.  Kuhmonen J, Pokomy J, Miettinen R, et al: Neuroprotective 
effects of dexmedetomidine in the gerbil  hippocampus after 
transient global ischemia. Anesthesiology 1997; 87:371 -377.  
142.  Engelhard K, Werner C, Kaspar S, et al : Effect  of the alpha 2 - 
agonist  dexmedetomidine on cerebral  neurotransmitter 
concentrations during cerebral  ischemia in rats. Anesthesiology 
2002; 96:450-457.  
143.  Talke P, Bickler PE: Effects of dexmedetomidine on hypoxia -
evoked glutamate release and glutamate receptor activity in 
hippocampal slices. Anesthesiology 1996; 85:551 -557.  
144.  Talke P, Tong C, Lee HW, et al: Effect of dexmedetomidine on 
lumbar cerebrospinal fluid pressure in humans. Anesth Analg 
1997;85:358-364.  
 
 
126 
 
145.  Karlsson BR, Forsman M, Roald OK, et  al: Effect  of 
dexmedetomidine, a selective and potent alpha 2 -agonist, on 
cerebral blood flow and oxygen consumption during halothane 
anaesthesia in dogs. Anesth Analg 1990; 71:125-129.  
146.  Zornow MH, Fleischer JE, Scheller MS, et al:  Dexmedetomid ine, 
an alpha 2-adrenergic agonist , decreases cerebral blood flow in the 
isoflurane-anesthetized dog. Anesth Analg 1990; 70:624 -630.  
147.  Zornow MH, Maze M, Dyck JB, Shafer SL: Dexmedetomidine 
decreases cerebral blood flow velocity in humans. J  Cereb Blood 
Flow Metab 1993; 13:350-353.  
148.  Bekker A, Sturaitis  MK: Dexmedetomidine for neurological  
surgery. Neurosurgery 2005; 57:1 -10. 
149.  Drummond JC, Dao AV, Roth DM, et  al : Effect  of 
dexmedetomidine on cerebral blood flow velocity, cerebral  
metabolic rate, and carbon dioxide response in normal humans. 
Anesthesiology 2008; 108:225-232.  
150.  Mirski MA, Rossell LA, McPherson RW, Traystman RJ: 
Dexmedetomidine decreases seizure threshold in a rat model of 
experimental generalized epilepsy. Anesthesiology 1994; 81:1422 - 
1428.  
151.  Halonen T, Kotti T, Tuunanen J, et al : Alpha 2 -adrenoceptor  
agonist , dexmedetomidine, protects against kainic acid -induced 
convulsions and neuronal damage. Brain Res 1995; 693:217 -224.  
 
 
127 
 
152.  Weinger MB, Segal IS, Maze M: Dexmedetomidine, acting 
through central alpha-2 adrenoceptors,  prevents opiate -induced 
muscle rigidity in the rat. Anesthesiology 1989; 71:242 -249.  
153.  Schmucker P, van Ackern K, Franke N, et al: [Effect of the 
intravenous administration of lormetazepam on hemodynamics and 
arterial blood gases in patients wi th coronary heart disease].  
Anaesthetist  1982; 31:557-563.  
154.  Karhuvaara S, Kallio A, Koulu M, et al : No involvement of alpha 
2-adrenoceptors in the regulation of basal prolactin secretion in 
healthy men. Psychoneuroendocrinology 1990; 15:125 -129.  
155.  Ebert TJ, Hall JE, Barney JA, et al: The effects of increasing 
plasma concentrations of dexmedetomidine in humans. 
Anesthesiology 2000; 93:382-394.  
156.  Yung-Wei H, Robertson K, Young C, et al: Compare the 
respiratory effects of remifentanil  and dexmedetomidine. 
Anesthesiology 2001; 95:A1357.  
157.  Arain SR, Ebert TJ: The efficacy, side effects, and recovery 
characteristics of dexmedetomidine versus propofol when used for  
intraoperative sedation. Anesth Analg 2002; 95:461 -466.  
158.  Hsu YW, Cortinez LI,  Robertson KM, et al:  Dexmedetom idine  
pharmacodynamics, part 1;  Crossover comparison of the respiratory 
effects of dexmedetomidine and remifentanil  in healthy volunteers.  
Anesthesiology 2004; 101:1066-1076.  
159.  Lou YP, Franco-Cereceda A, Lundberg JM: Variable alpha 2 - 
adrenoreceptor-mediated inhibit ion of bronchoconstrict ion and 
 
 
128 
 
peptide release upon activation of pulmonary afferents.  Eur J 
Pharmacol 1992; 210:173-181.  
160.  Hogue Jr CW, Talke P, Stein PK, et  al:  Autonomic nervous 
system responses during sedative infusions of dexmedetomidine. 
Anesthesiology 2002; 97:592-598.  
161.  Riker RR, Fraser GL: Adverse events associated with sedatives,  
analgesics, and other drugs that  provide patient comfort in the 
intensive care unit . Pharmacotherapy 2005; 25:8S -18S. 
162.  Roekaerts P, Prinzen F, Willingers H: The effec t  of  
dexmedetomidine on systemic haemodynamics,  regional myocardial  
function and blood flow during coronary artery stenosis in acute 
anaesthetized dogs. J  Cardiothorac Anesth 1994; 8:58.  
163.  Willigers HM, Prinzen FW, Roekaerts PM, et  al: 
Dexmedetomidine decreases perioperative myocardial  lactate 
release in dogs. Anesth Analg 2003; 96:657 -664.  
164.  Nishina K, Mikawa K, Uesugi T, et  al : Efficacy of clonidine for 
prevention of perioperative myocardial ischemia: A critical  
appraisal and meta-analysis of the litera ture. Anesthesiology 2002; 
96:323-329.  
165.  Wallace AW, Galindez D, Saiahieh A, et  al: Effect of clonidine 
on cardiovascular morbidity and mortality after non -cardiac surgery.  
Anesthesiology 2004; 101 284-293.  
166.  Venn M, Newman J,  Grounds M: A phase 11 study to ev aluate 
the efficacy of dexmedetomidine for sedation in the medical  
intensive care unit . Intensive Care Med 2003; 29:201 -207.  
 
 
129 
 
167.  Grant SA, Breslin DS, MacLeod DB, et al: Dexmedetomidine 
infusion for sedation during fiberoptic intubation: A report  of three 
cases. J  Clin Anesth 2004; 16:124-126.  
168.  Aho M, Erkola O, Kallio A, et  al: Dexmedetomidine infusion for 
maintenance of anaesthesia in patients undergoing abdominal 
hysterectomy. Anesth Analg 1992; 75:940-946.  
169.  Feld JM, Hoffman WE, Stechert  MM, et al: Fentanyl or 
dexmedetomidine combined with desflurane for bariatric surgery. J  
Clin Anesth 2006; 18:24-28.  
170.  Bakhamees HS, El -Halafawy YM, El -Kerdawy HM, et al : Effects 
of dexmedetomidine in morbidly obese patients undergoing 
laparoscopic gastric bypass.  Middle East  J  An esthesiol 2007;  
19:537-551.  
171.  Dholakia C, Beverstein G, Garren M, et al: The impact of 
perioperative dexmedetomidine infusion on postoperative narcotic  
use and duration of stay after laparoscopic bariatric surgery. J  
Gastrointest  Surg 2007; 11:1556 -1559.  
172.  Bekker AY, Kaufman B, Samir H, Doyle W: The use of 
dexmedetomidine infusion for awake craniotomy. Anesth Analg 
2001; 92:1251-1253.  
173.  Bekker AY, Basile J , Gold M, et  al:  Dexmedetomidine for awake 
carotid endarterectomy: efficacy, hemodynamic profile,  and side 
effects. J  Neurosurg Anesthesiol 2004; 16:126 -135.  
 
 
130 
 
174.   Riker RR, Fraser GL: Adverse events associated with sedatives,  
analgesics and other drugs that provide patient comfort in the 
intensive care unit . Pharmacotherapy 2005; 25:8S -18S. 
175.  Gerlach AT, Dasta JF: Dexmedetomidine: An updated review. 
Ann Pharmacother 2007; 41:245-252 
176.   Aho M, Erkola O, Kallio A, et al: Comparison of 
Dexmedetomidine and midazolam sedation and antagonism of 
Dexmedetomidine with atipamezole. J  Clinical Anaesthesia 1993; 
5:194-203.  
177.   Maroof M: Evaluation of effect  of Dexmedetomidine in reducing 
shivering following epidural anaesthesia. ASA annual meeting. 
Abstract  A-49. Memis D, Turan A, Karamanlioglu B, Pamukcu Z, 
Kurt I: Adding Dexmedetomidine to l idocaine for intravenous 
regional anaesthesia.  Aneth Analg; 98(3):  835-40, 2004.  
178.   Kanazi GE, Aouad MT, Jabbour - Khoury SI,  AJ Jazzar MD, 
Alameddine MM, Al-Yaman R, Bulbul M, Baraka AS: Effect of 
Small Dose Dexmedetomidine or Clonidine on the Characteristics of 
Bupivacaine-Spinal Block. Acta Anaesthes iol Scand 2005; 50:222-7, 
2006.  
179.   Yildiz, Munise; Tavlan, Aybars; Tuncer, Sema; Reisli,  Ruhiye;  
Yosunkaya, Alper;  Otelcioglu,  Seref. Effect of Dexmedetomidine on 
Haemodynamic Responses to Laryngoscopy and Intubation: 
Perioperative Haemodynamics and Anaesthe tic Requirements. Drugs 
in R & D. 7(1):43-52, 2006.  
 
 
131 
 
180.   Sulaiman S, Karthikeyan RB, Vakamudi M, Sundar AS, 
Ravullapalli H, Gandham R. the effects of Dexmedetomidine on 
attenuation of stress response to endotracheal intubation in patients  
undergoing elective off-pump coronary artery bypass graft ing. Ann 
Card Anaesth 2012;15:39-43.  
181.  Jeongmin Kim, So Yeon Kim, Jae Hoon Lee, Young Ran Kang,  
and Bon-Nyeo Koo, Low-Dose Dexmedetomidine Reduces 
Emergence Agitation after Desflurane Anaesthesia in Children 
Undergoing Strabismus Surgery, Yonsei Med J. Mar 1, 2014; 55(2): 
508–516.  
182.  Dhara A. Vyas, Nikunj H. Hihoriya,  Rina A. Gadhavi.  A 
comparative study of dexmedetomidine vs midazolam for sedation 
and hemodynamic changes during tympanoplasty and modified 
radical mastoidectomy Int J  Basic Clin Pharmacol . 2013; 2(5): 562-
566 
183.  Tanuja,  Shobha Purohit ,  Amit Kulshreshtha, a study on effects of 
dexmedetomidine on intraocular pressure and haemodynamic 
changes in response to laryngoscopy and tracheal intubation. 
Journal of Neuroanaesthesiology and crit ical care.  2014;   1  ( 3)  :  
178-182.  
184.  Dalia Abdelhamid Nasr ,  Hadeel Magdy Abdelhamid, the efficacy 
of caudal dexmedetomidine on stress response and postoperative 
pain in pediatric cardiac surgery. Annals of Cardiac Anaesthesia.  
2013, 16  ( 2 ): 109-114. 
 
 
132 
 
185.  Kwon-Hui Seo1, et .al, Optimal dose of dexmedetomidine for 
attenuating cardiovascular response during emergence in patients 
undergoing total laparoscopic hysterectomy. Journal of International  
Medical Research.  July 8,  2014.  
186.  Ashraf M. Eskandra, Abd El -Azeem A. Elbakrya, Osama A.  
Elmorsy, Dexmedetomidine is an effective adjuvant to subtenon 
block in phacoemulsification cataract  surgery. Egyptian Journal of 
Anaesthesia.  2014;  30 (3): 261–266. 
187.  Fuhai Ji,  Zhongmin Li,   Hung Nguyen, Nilas Young,  Pengcai 
Shi,  Neal Fleming, Hong Liu, Perioperative Dexmedetomidine 
Improves Outcomes of Cardiac Surgery. Circulation.  2013; 127: 
1576-1584.  
188.  Rasha S Bondok, Nirvana A El-Shalakany, The equisedative 
effect of dexmedetomidine versus propofol on supraclavicular 
brachial  plexus block and recovery profile in patients with ischemic 
heart disease. Ains Shams Journal of Anaesthesiology, 2014; 7 (1):  
32-39.  
189.  Kanchan Gupta, Sunil Katyal, Sandeep Kaushal, Geeta Mittal,  
Randomised double-blind comparative study of dexmedetomidine 
and tramadol for post -spinal anaesthesia shivering.  Indian Journal 
of Anaesthesia, 2014, 58 (3) : 257 -262.  
190.  Mohamed Essam Abdel -Meguid, Dexmedetomidine as anaesthetic 
adjunct for fast tracking and pain control in off -pump coronary 
artery bypass. Saudi Journal of Anaesthesia; 2013, 7  (1): 6-8.  
 
 
133 
 
191.  Rayner SG, Weinert  CR, Peng H, et al . Dexmedetomidine as 
adjunct treatment forsevere alcohol withdrawal in the ICU. Ann 
Intensive Care,  .  2012; 2:12.  
192.  Shailesh Bhadla , Deepal Prajapati ,  Thaju Louis , Garima Puri ,  
Saurin Panchal ,  Mayur Bhuva, Comparison between 
dexmedetomidine and midazolam premedication in pediatric patients  
undergoing ophthalmic day-care surgeries. Anesth Essays Res 
2013;7:248-56 
193.  SS Harsoor, D Devika Rani , Bhavana Yalamuru, K Sudheesh, SS 
Nethra,  Effect  of supplementation of low dose intravenous 
dexmedetomidine on characteristi cs of spinal  anaesthesia with 
hyperbaric bupivacaine. Indian Journal of Anaesthesia,  
2013.  57  (3) : 265-269. 
194.  Annamalai A, Singh S, Singh A, Mahrous DE, Can Intravenous 
Dexmedetomidine Prolong Bupivacaine Intrathecal Spinal 
Anaesthesia? 2013;    J  Anesth Clin Resm 4:372.  
195.  Tarek Shams, Nahla S El Bahnasawe, Mohamed Abu-Samra, 
Ragaa El-Masry, Induced hypotension for functional endoscopic 
sinus surgery: A comparative study of dex medetomidine versus 
esmolol.   Saudi Journal of Anaesthesia; 2013, 7  ( 2):  175-180.  
196.  Hazra R, Manjunatha SM, Manuar MDB, Basu R, Chakraborty S.  
Comparison of the effects of intravenously administered 
dexmedetomidine with clonidine on hemodynamic responses du ring 
laparoscopic cholecystectomy. Anaesth Pain & Intensive Care 
2014;18(1):25-30 
 
 
134 
 
197.  Usta B, Gozdemir M, Demircioglu RI, Muslu B, Sert H, Yaldiz 
A. Study to evaluate the effect of dexmedetomidine on shivering 
during spinal anaesthesia.  Clinics (Sao Paulo).  2011;66(7):1187-91. 
198.  Kim YS, Kim YI, Seo KH, Kang HR. Optimal dose of 
prophylactic dexmedetomidine for preventing postoperative 
shivering. Int J  Med Sci. 2013;10:1327–1332.  
199.  Sen S, Chakraborty J, Santra S, Mukherjee P, Das B. The effect 
of dexmedetomidine infusion on propofol requirement for 
maintenance of optimum depth of anaesthesia during elective spine 
surgery. Indian J Anaesth 2013;57:358-63 
200.  S S Harsoor,  Devika D Rani ,  S Lathashree, S S Nethra, and K 
Sudheesh to evaluate the effect  of intravenous Dexmedetomidine 
infusion during general  anaesthesia for abdominal surgeries on 
blood glucose levels and on Sevoflurane requirements during 
anaesthesia.  J  Anaesthesiol  Clin Pharmacol.  2014 Jan -Mar; 30(1):  
25–30.  
201.  Yazbek-Karam VG, Aouad MA. Perioperative Uses of 
Dexmedetomidine. Middle East J  Anesthesiol 2006;18:1043 -58 
202.  Scheinin H, Aantaa R, Anttila M, Hakola P, Helminen A, 
Karhuvaara S. Reversal  of the sedative and sympatholytic effects of 
dexmedetomidine with a specific alpha2 -adrenoceptor antagonist 
atipamezole:  A pharmacodynamic and kinetic study in healthy 
volunteers.  Anesthesiology 1998;89:574 -84 
203.  DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A review 
of clinical  applications. Curr Opin Anaesthesiol 2008;21:457 -61 
 
 
135 
 
204.  J, Singer M. Importance of patient orientation and rousability as 
components of intensive care unit sedation. In:  Maze M, Morrison 
P, editors. Redefining sedation. London, UK: The Royal Society of 
Medicine Press Ltd.;  1998. p. 23 -9.    
205.  Andrew C. Kontak,  Ronald G. Victor,  Wanpen Vongpatanasin,  
Dexmedetomidine as a Novel Countermeasure for Cocaine -Induced 
Central Sympathoexcitation in Cocaine -Addicted Humans,  
Hypertension. 2013, 61: 388-394.  
206.  Byung Ju Ko, Jung-Hoon Jang, Jae Won Park,  Seung Cheol Lee,  
and So Ron Choi, Procedural sedation with dexmedetomidine for 
pediatric endoscopic retrograde cholangiopancreatography guided 
stone retraction. Korean J Anesthesiol. Dec 2012; 63(6): 567 –568. 
207.  Alka Shah, Ila Patel,  Rachana Gandhi, Haemodynamic effects of 
intrathecal dexmedetomidine added to ropivacaine intraoperatively 
and for postoperative analgesia. Int J  Basic Clin Pharmacol . 2013;  
2(1): 26-29.  
208.  Priyam Saikia ,  Anulekha Chakrabartty,  Shameem 
Ahmed,Successful  use of dexmedetomidine as an adju nct to 
multimodal analgesic regimen in a postoperative ventilated patient  
following transoral  odontoidectomy. Indian Journal of 
Neurosurgery, 2014, 3  (1):  60-61.  
209.  Mahima Gupta,  S.  Shailaja,  and K. Sudhir Hegde. Comparison of 
Intrathecal Dexmedetomidine with Buprenorphine as Adj uvant to 
Bupivacaine in Spinal Asnaesthesia.  J  Clin Diagn Res.  2014; 8(2):  
114–117.  
 
 
136 
 
210.  MS Saravana Babu, Anil  Kumar Verma, Apurva Agarwal, Chitra 
MS Tyagi, Manoj Upadhyay, Shivshenkar Tripathi. A comparative 
study in the post-operative spine surgeries: Epidural ropivacaine 
with dexmedetomidine and ropivacaine with clonidine for post -
operative analgesia.  Indian Journal of Anaesthesia. 2013, 57(4):  
371-376.  
211.  Dalia Abdelhamid Nasr , Hadeel Magdy Abdelhamid, The 
efficacy of caudal dexmedetomidine on stress response and 
postoperative pain in pediatric cardiac surgery. Annals of Cardiac 
Anaesthesia; 2013, 16 (2) : 109 -114.  
212.  Lili Jiang, Li Li, Jinmei Shen, Zeyou Qi,  and Liang Guo, Effect  
of dexmedetomidine on lung ischemia -reperfusion injury. Mol Med 
Rep. Feb 2014; 9(2):  419–426.  
213.  Friesen RH, Nichols CS, Twite MD, Cardwell KA, Pan Z, Pietra 
B, Miyamoto SD, Auerbach SR, Darst  JR, Ivy DD. The 
hemodynamic response to dexmedetomidine loading dose in children 
with and without pulmonary hypertension. Anesth Analg.  2013 
Oct;117(4):953-9.  
214.  Siddareddigari  Velayudha Reddy, Donthu Balaji ,  Shaik Nawaz 
Ahmed, Dexmedetomidine versus esmolol to attenuate the 
hemodynamic response to laryngoscopy and tracheal intubation: A 
randomized double-blind clinical study. International Jou rnal of 
Applied Basic Medical Research; 2014, 4  (2): 95-100 
215.  Yu Zhang, Chang-Song Wang, Jing-Hui Shi, Bo Sun, Shu-Jie 
Liu, Peng Li, En-You Li Perineural administration of 
 
 
137 
 
dexmedetomidine in combination with ropivacaine prolongs axillary 
brachial plexus block. Int J  Clin Exp Med 2014;7(3):680 -685.  
216.  Pant D, Sethi N and Sood J . Comparison of sublingual 
midazolam and dexmedetomidine for premedication in 
children.Minerva Anestesiol.  2014 Feb;80(2):167-75.  
217.  Na Young Kim, So Yeon Kim, Hye Jin Yoon, and Hae Keum Kil,  
Effect  of Dexmedetomidine on Sevoflurane Requirements and 
Emergence Agitation in Children Undergoing Ambulatory Surgery. 
Yonsei Med J. 2014 Jan;55(1):209-215.  
218.  Shan-Shan Wang, Ma-Zhong Zhang, Ying Sun, Chi Wu, Wen -Yin 
Xu, Jie Bai, Mei -Hua Cai and Lin Lin.  The sedative effects and the 
attenuation of cardiovascular and arousal responses during 
anaesthesia induction and intubation in pediatric patients: a 
randomized comparison between two different doses of preoperative 
intranasal dexmedetomidine  Pediatric Anaesthesia. 2014; 24(3):  
275–281.  
219.  Gaurav Jain, Pranav Bansal , Bashir Ahmad, Dinesh K Singh,  
Ghanshyam Yadav, Effect  of the perioperative infusion of 
dexmedetomidine on chronic pain after breast surgery. Indian 
Journal of Palliative Care;  2012, 18  (1):  45-51.  
220.  Sukhminder Jit Singh Bajwa 1 ,  Sukhwinder Kaur Bajwa2 ,  Jasbir 
Kaur
1
,  Gurpreet Singh
1
,  Vikramjit Arora
1
,  Sachin Gupta
1
,  Ashish 
Kulshrestha
1
,  Amarjit Singh
1
,  SS Parmar
1
,  Anita Singh
2
,  SPS 
Goraya, Dexmedetomidine and clonidine in epidural anaesthesia: A 
 
 
138 
 
comparative evaluation. Indian Journal of Anaesthesia;  2011, 55( 2):  
116-121.  
221.  Eike Martin , Graham Ramsay, Jean Mantz, S.  T. John Sum-Ping, 
The Role of the α 2-Adrenoceptor Agonist Dexmedetomidine in 
Postsurgical Sedation in the Intensive Care Unit;  J  Intensive Care 
Med;  2003, 18(1):  29-41.  
 
 
 
 
 
 
 
 
 
 
i 
 
APPENDIX I 
INSTITUTIONAL HUMAN ETHICS COMMITTEE CLEARANCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
APPENDIX II 
INFORMED WRITTEN CONSENT FORM 
PART 1 OF 2 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
Dear Volunteers, 
 We welcome you and thank for your keen interest in participation in this research 
project. Before you participate in this study, it is important for you to understand why this 
research is being carried out. This form will provide you all the relevant details of this 
research. It will explain the nature, the purpose the benefits, the risks, the discomforts, the 
precautions and the information about how this project will be carried out. It is important 
that you can read and understand the contents of the form carefully. This form may 
contain certain scientific terms and hence, if you have any doubts or if you want more 
information, you are to ask the study personnel or the contact person mentioned below 
before you give your consent and also at any time during the entire course of the project. 
1. Name of the Principal Investigator:  Dr.Rakhi S.P. 
Junior Resident 
Department of Anaesthesiology 
Sree Mookambika Institute of  
    Medical Sciences, Kulasekharam. 
2. Name of the Guide:   : Dr.V.G.Jayaprakash 
   Professor, 
   Department of Anaesthesiology, 
   Sree Mookambika Institute of  
   Medical Sciences, Kulasekharam. 
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3. Institute : Details with Address 
Sree Mookambika Institute of Medical Sciences, 
Kulasekharam, Kanyakumari district – 629161 
Tamil Nadu. 
4. Title of the study:  
Effects of intravenous Dexmedetomidine on the haemodynamic stress 
response to Laryngoscopy and Endotracheal intubation during general 
anaesthesia. 
5. Back ground Information:-  
Laryngoscopy and endotracheal intubation is to be done during general 
anesthesia. This can lead to an increase in heart rate and blood pressure. Various 
drugs have been used to reduce this stress response. Dexmedetomidine is an 
alpha2 adrenergic agonist which has sedative, anxiolytic and analgesic properties. 
6. Aims and Objectives: 
a. To know if Dexmedetomidine can reduce the haemodynamic stress 
response to laryngoscopy and intubation during general anesthesia. 
b. To assess the haemodynamic stability throughout surgery when 
Dexmedetomidine is used. 
7. Scientific justification of the study: 
Maintenance of stable haemodynamics throughout the surgery is very 
important. The haemodynamic stress response to laryngoscopy and intubation is 
iv 
 
dangerous especially in patients with cardiovascular disease. Increase in heart rate 
and blood pressure will increase the myocardial contractility and myocardial 
oxygen consumption. This stress response can be reduced using various drugs like 
lignocaine, Beta blockers, nifedipine etc. Dexmedetomidine is an alpha2 agonist 
with additional sedative, anxiolytic and analgesic properties which are useful in 
anaesthesia. 
8. Procedure for the study: 
General anesthesia has different steps. Premedication will be given with 
Inj. Midazolam, Inj .Fentanyl, Inj. Glycopyrrolate. Dexmedetomidine 1 
microgram/kg iv over 10 minutes will be started before induction of anesthesia 
and will be continued as a continuous infusion at the rate of 0.4 
microgram/kg/hour throughout the surgery. Induction of anesthesia will be done 
with Inj. Propofol 2mg/kg. Inj. Succinyl choline 1.5-2mg/kg will be used as the 
muscle relaxant for intubation. Anaesthesia will be maintained with intermittent 
positive pressure ventilation with 02, N20 and isoflurane. Inj. Atracurium 
0.6mg/kg will be given for maintenance of muscle relaxation. The selected 
patients for the study will be divided in to 2 groups of 35 pts each. Patients of 
Group I will receive Dexmedetomidine while patients of Group II will receive 
distilled water as placebo instead of Dexmedetomidine.  All other steps of 
anesthesia are similar in both groups. 
9. Expected risks for the participants: 
Hypotension and bradycardia may occur. 
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10. Expected benefits of research for the participants: 
There may not be any personal benefits, but this study will be beneficial 
for the betterment of the Health Sector. 
11. Maintenance of Confidentiality: 
All data collected for the study will be kept confidentially and would 
reflect on general statistical evaluation only and would not reveal any personal 
details. 
12. Why have you been chosen to be in the study?  
You are undergoing general anaesthesia and fulfill the criteria of selection. 
13. How many people will be in the study? :  
70 
14. Agreement of compensation to the participant:  
Yes. 
15. Anticipated prorated payment, if any, to the participant(s) of the study:  
 Nil 
16. Can I withdraw from the study at any time during the study period? :  
Yes  
17. If there is any new findings/information, would I be informed? :  
Yes 
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18. Expected duration of Participant’s participation in the study:   
Throughout the surgery. 
19. Any other pertinent information: 
No 
20. Whom do I contact for further information?: Dr. Rakhi S.P 
For any study related queries, you are free to contact 
Dr.Rakhi S.P. 
Junior Resident 
Department of Anaesthesiology 
Sree Mookambika Institute of Medical  Sciences, 
Kulasekharam 
Mobile No.9626124177 
Email ID -  rakhispk@gmail.com
 
Place:  
Date:        Signature of Principal Investigator 
       
    Signature of the Participant 
 
 
 
vii 
 
CONSENT FORM 
PART 2 OF 2 
PARTICIPANTS CONSENT FORM 
 The details of the study have been explained to me in writing and the details have 
been fully explained to me. I am aware that the results of the study may not be directly 
beneficial to me but will help in the advancement of medical science. I confirm that I 
have understood the study and had the opportunity to ask questions. I understand that my 
participation in the study is voluntary and that I am free to withdraw at any time, without 
giving any reason. Without the medical care that will normally be provided by the 
hospital being affected. I agree not to restrict the use of any data or results that arise from 
this study provided such a use is only for scientific purpose(s). I have been given an 
information sheet giving details of the study. I fully consent to participate in the study 
titled “Effects of intravenous Dexmeditomidine on the haemodynamic stress response to 
laryngoscopy and endotracheal intubation during general anesthesia”. 
Name of the Participant:     Address of the Participant: 
Contact Number of the Participant: 
 
Signature/ Thumb impression of the participant/ Legal guardian 
Witnesses: 
1.   
2.  
Date: 
Place: 
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APPENDIX III 
PROFORMA FOR THE STUDY 
 
Name of the patient: 
Age: 
Sex: 
IP Number: 
Surgical Diagnosis: 
Proposed Surgery: 
Relevant history: 
History of drug allergy, drug reaction, previous surgeries: 
GENERAL EXAMINATION  
Height:                                                                      Weight: 
Pallor:                  Icterus:               Cyanosis:                                    Clubbing:    
Lymphadenopathy:                            
Edema: 
Any other relevant findings: 
Pulse rate: 
Blood pressure: 
Temperature: 
SYSTEMIC EXAMINATION 
Examination of Cardiovascular system: 
 
Examination of Respiratory system: 
 
Examination of Gastrointestinal system: 
 
Examination of Central Nervous system: 
ASSESSMENT OF AIRWAY 
Mallampati grade: 
ix 
 
Thyro-mental distance: 
Mouth opening distance: 
Neck – range of motion: 
Teeth: 
Facial hair: 
Morbid obesity: 
Short muscular neck: 
Micrognathia: 
INVESTIGATIONS                               
Haematological: 
  Haemoglobin, total count, differential count, ESR 
  Bleeding time, Clotting time 
  Blood sugar 
  Blood urea, Serum creatinine 
  HIV, HBsAg 
Urine examination for sugar, albumin and microscopy 
ECG 
Chest X-ray- PA view if needed. 
ASA physical status 
Premedication: 
Intra-operative monitoring: pulse rate, blood pressure, peripheral oxygen saturation, end 
tidal carbondioxide. 
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APPENDIX IV 
CASE RECORD FORM 
 
Name :                                                                        Age:                              Sex:                    
Weight: 
I.P No: 
Diagnosis : 
 
Procedure: 
 
American Society of Anaesthesiologists Class:  
Drugs given:  
          Tab. Ranitidine 150mg at 10pm & 6am. 
          Tab. Metoclopramide 10mg at 10pm & 6am. 
           Inj. Midazolam 2mg iv 
           Inj. Glycopyrrolate 0.2mg iv 
           Inj. Fentanyl         mcg iv 
           Inj. Dexmedetomidine             mcg (1mcg/kg ) iv over 10 minutes started at                  
           Inj. Dexmedetomidine             mcg(0.4mcg/kg) as continuous iv infusion started at 
           Inj. Propofol           mg iv 
           Inj. Succinyl choline              mg iv 
           Inj. Atracurium                mg iv at     
           Oxygen       : Nitrous oxide  
           Isoflurane 
           Inj. Neostigmine                 mg iv 
           Inj. Glycopyrrolate             mg iv 
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Time Heart Rate 
(/min) 
Blood Pressure SpO2(%) EtCO2(mmHg) 
 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
xii 
 
APPENDIX V 
 
Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 94 82 86 84 83 80 76 78 80 82 82 80 78 80 81 82
2 106 82 92 94 86 84 82 80 80 78 78 80 82 78 72 84
3 76 60 78 72 70 66 64 66 68 68 66 64 64 66 64 66
4 86 70 84 82 76 74 72 70 70 72 72 70 70 70 71 72
5 66 52 68 66 64 58 58 60 58 59 60 60 58 59 60 60
6 74 62 70 68 68 66 60 62 62 63 62 64 64 65 66 66
7 68 52 64 62 61 58 54 58 58 60 58 59 60 62 62 60
8 80 66 74 72 70 66 62 62 64 64 61 62 62 60 62 64
9 94 76 86 82 80 74 72 74 72 72 74 72 74 75 75 76
10 80 64 76 74 72 68 66 66 68 66 66 67 67 65 65 66
11 72 62 74 72 70 66 64 66 68 68 66 68 66 68 69 68
12 78 62 68 66 66 64 64 66 66 68 68 68 66 65 67 68
13 72 60 66 64 64 62 62 62 60 60 61 62 62 63 63 64
14 78 64 72 70 68 64 68 68 66 67 67 68 68 66 66 68
15 74 62 70 68 66 64 68 70 68 68 67 67 68 67 68 66
16 90 74 82 84 82 76 74 74 72 72 73 74 75 76 78 77
17 80 66 72 76 72 68 64 66 69 68 67 69 68 66 66 68
18 102 84 92 90 86 84 82 80 80 82 81 82 82 80 82 80
19 80 68 74 72 70 74 70 72 72 72 70 70 68 70 72 71
20 100 78 84 86 83 78 74 76 74 74 75 76 76 78 78 76
21 80 64 76 74 70 66 64 66 66 65 64 64 65 66 66 68
22 92 74 86 84 78 76 70 70 71 71 72 73 72 73 74 74
23 74 62 72 74 71 68 68 70 70 70 68 68 70 70 72 72
24 94 74 82 84 76 74 70 72 72 72 70 70 71 71 72 71
25 80 66 74 72 68 66 64 64 65 65 66 66 65 65 66 66
26 94 74 84 86 84 82 80 80 82 82 80 80 82 82 81 82
27 80 60 66 68 66 64 64 66 64 65 66 66 67 66 67 67
28 90 74 84 86 82 78 72 74 72 72 73 74 74 73 73 72
29 84 66 84 86 80 76 74 74 76 76 75 75 74 76 74 74
30 86 72 80 78 78 75 76 76 75 75 76 77 77 76 75 75
31 98 68 80 78 80 76 74 74 74 76 76 75 75 76 76 74
32 92 75 78 80 82 82 78 80 80 78 78 77 77 78 78 72
33 72 65 67 68 72 70 70 70 68 68 70 70 68 67 78 70
34 70 65 68 70 68 69 68 68 66 66 68 68 66 65 86 64
35 88 68 74 72 72 70 72 70 71 71 72 72 70 70 70 72
HEART RATE - DEXMEDETOMIDINE GROUP
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 94 105 114 110 104 104 96 76 94 90 92 98 94 90 86 86
2 72 80 98 96 95 88 83 82 80 82 84 82 80 78 78 76
3 67 80 90 94 88 80 76 76 74 75 72 72 74 76 74 74
4 74 85 106 102 96 84 78 80 82 80 88 88 86 84 84 86
5 112 116 130 128 120 116 112 112 110 110 108 106 100 106 108 110
6 69 78 96 94 88 84 76 78 80 84 80 78 96 76 75 78
7 76 86 95 93 88 84 78 80 82 82 80 88 92 90 84 82
8 78 90 106 108 96 88 88 86 86 86 84 90 88 86 82 82
9 76 84 97 96 88 84 80 78 76 76 80 82 84 82 82 78
10 84 90 113 112 104 96 96 84 82 84 90 98 94 90 86 88
11 86 93 112 98 96 94 92 92 92 98 94 92 88 88 86 86
12 92 100 126 124 106 96 92 90 94 98 98 104 102 98 96 90
13 70 86 98 94 92 90 82 80 80 84 84 82 82 80 82 84
14 88 94 102 98 96 94 92 90 88 86 90 96 94 90 86 86
15 82 98 116 110 104 98 88 90 86 86 90 94 90 88 86 84
16 86 93 106 98 96 92 86 88 88 86 88 88 86 94 84 84
17 64 76 86 84 78 74 72 74 76 78 82 84 86 78 78 76
18 72 80 94 90 86 84 82 82 80 80 84 88 88 84 82 82
19 88 94 110 106 102 94 90 90 94 98 94 92 92 88 88 86
20 102 104 112 110 104 102 104 102 100 98 104 102 106 108 106 104
21 72 75 86 84 80 78 76 76 74 72 76 78 82 84 80 78
22 86 88 96 94 92 90 92 90 90 98 90 92 88 88 86 86
23 78 86 88 82 80 78 70 74 74 76 80 78 76 74 78 82
24 72 78 86 83 80 76 77 80 82 88 86 82 78 78 76 76
25 108 112 126 124 118 104 100 104 104 98 96 10 102 98 96 94
26 64 76 88 84 82 76 70 72 72 74 70 74 78 76 74 72
27 68 72 84 82 76 74 68 88 70 68 66 66 68 72 74 60
28 72 76 82 86 84 82 76 76 78 82 86 82 80 80 78 78
29 78 82 96 94 90 83 80 84 86 88 86 86 82 82 80 78
30 72 82 88 85 82 78 75 76 76 78 88 90 86 84 82 80
31 90 88 94 100 102 102 100 102 98 96 92 90 96 92 88 88
32 84 86 96 99 104 104 102 100 98 96 96 94 94 90 96 90
33 104 108 112 116 118 118 114 112 110 112 108 106 104 112 108 102
34 97 96 106 108 110 110 106 104 102 98 98 96 102 108 102 98
35 70 70 78 80 82 80 82 80 82 80 78 84 88 84 86 80
HEART RATE - CONTROL GROUP
 
xiv 
 
Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 140 118 122 124 122 120 120 120 120 120 116 116 118 118 114 116
2 130 110 116 118 118 120 118 118 122 118 116 116 114 116 118 118
3 130 106 116 118 118 120 116 118 118 114 116 112 114 112 114 116
4 122 98 104 106 106 106 106 108 110 108 108 106 104 106 108 108
5 140 112 120 122 120 120 120 118 112 116 118 120 128 122 118 116
6 110 92 104 104 104 104 102 100 98 100 102 102 100 98 100 98
7 120 100 110 110 110 108 106 106 106 104 102 102 104 104 106 108
8 118 102 108 110 110 106 104 106 104 102 104 100 100 102 104 106
9 124 104 110 112 112 112 110 110 110 108 106 103 104 106 106 110
10 142 118 126 128 128 128 128 124 122 120 118 122 124 124 126 124
11 128 100 106 108 108 108 108 106 106 110 108 106 104 106 104 106
12 132 104 112 112 112 114 114 112 116 114 114 112 110 110 108 110
13 134 114 120 122 124 124 124 124 124 123 120 118 118 116 118 116
14 138 102 128 126 128 128 124 124 126 123 122 120 118 120 118 120
15 124 98 110 110 110 110 112 112 112 110 10 104 102 102 106 108
16 118 98 104 104 106 106 106 104 104 102 100 100 98 96 96 98
17 112 92 108 108 108 104 106 106 104 100 100 102 98 98 100 102
18 110 100 98 100 100 100 100 100 100 98 96 94 94 94 96 98
19 120 118 108 108 108 110 106 108 106 104 104 102 102 104 108 114
20 142 102 126 128 128 128 130 130 124 124 136 130 126 124 120 124
21 124 96 108 108 108 110 110 108 108 104 104 106 102 104 106 104
22 118 98 102 102 104 100 100 98 98 94 94 96 98 98 100 98
23 120 122 106 106 102 100 104 106 106 106 100 100 98 96 98 102
24 148 130 128 130 130 130 128 126 120 118 128 136 130 126 124 126
25 124 100 110 106 104 104 100 102 102 100 100 98 102 102 104 106
26 132 104 112 112 114 116 110 112 110 114 120 126 120 118 112 112
27 136 106 112 112 114 116 114 116 118 114 114 110 108 108 110 112
28 134 108 116 116 116 116 114 112 112 110 106 104 106 108 112 114
29 126 100 108 108 110 110 108 108 104 102 100 100 102 104 100 102
30 128 100 108 108 108 110 106 104 104 102 100 108 100 100 100 102
31 124 98 108 112 112 102 112 112 112 110 110 108 110 112 118 120
32 118 96 102 104 105 104 102 106 110 110 102 100 96 96 98 98
33 150 126 130 132 128 128 126 128 122 118 118 116 122 122 120 118
34 138 112 120 120 120 122 122 124 120 118 120 116 114 114 114 112
35 132 110 122 120 124 122 124 124 120 118 118 118 116 120 120 118
SYSTOLIC BLOOD PRESSURE - DEXMEDETOMIDINE GROUP
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 90 76 86 80 80 80 80 80 82 80 78 78 80 78 80 80
2 86 70 78 78 78 80 80 82 80 78 78 76 74 74 72 74
3 84 72 80 80 80 82 82 82 80 80 78 76 74 72 70 72
4 80 68 76 78 76 78 76 76 74 72 72 70 70 68 68 68
5 86 70 78 78 76 78 76 76 80 78 78 76 74 76 78 78
6 72 62 68 68 68 70 70 70 70 68 66 66 64 64 66 66
7 82 64 68 68 70 70 70 70 70 70 68 70 68 68 70 70
8 82 68 74 74 74 74 74 74 80 76 78 80 80 80 78 80
9 86 70 78 78 78 80 80 80 80 76 78 76 74 74 74 76
10 86 72 80 80 82 80 82 82 80 78 80 78 78 76 78 80
11 72 62 68 70 70 72 70 70 68 66 66 64 64 66 68 70
12 86 72 78 78 78 80 82 80 78 78 80 82 78 76 78 78
13 82 64 70 70 70 70 70 70 78 70 76 74 72 72 74 74
14 86 68 74 74 72 72 72 70 80 68 76 70 70 80 80 80
15 82 66 72 72 72 74 70 70 78 70 74 74 70 70 68 68
16 84 66 70 70 70 70 70 70 76 66 70 70 70 68 68 70
17 82 68 76 70 70 70 70 70 68 66 66 64 62 64 64 68
18 74 64 70 70 70 70 70 68 68 66 66 66 68 70 70 70
19 80 64 72 74 74 74 76 76 76 74 74 72 70 70 72 72
20 86 70 78 78 80 80 84 78 80 80 84 78 78 76 78 80
21 84 70 78 80 80 80 80 78 78 76 76 74 74 72 72 70
22 78 70 78 70 70 72 72 72 74 72 70 70 68 70 70 72
23 70 62 72 72 72 68 68 68 66 66 64 68 70 66 64 62
24 86 64 70 72 68 70 72 70 78 70 76 72 68 72 70 72
25 82 68 78 78 78 78 80 78 78 76 76 74 72 72 72 70
26 78 62 68 70 70 70 70 70 74 74 72 70 68 64 66 66
27 92 70 78 78 76 78 78 76 84 72 82 70 72 72 72 70
28 90 72 78 78 78 70 70 70 78 72 78 76 70 70 78 80
29 86 70 76 74 76 78 78 78 76 76 74 74 70 70 72 72
30 86 72 74 78 78 78 80 80 76 76 74 80 78 78 76 74
31 90 74 78 78 76 76 72 70 76 74 74 74 72 70 70 72
32 70 66 78 72 72 70 64 68 66 62 62 64 64 64 68 68
33 98 78 74 84 76 86 74 74 76 78 76 74 74 74 70 70
34 72 62 70 70 70 72 72 70 78 66 74 70 70 70 72 74
35 82 70 76 76 76 74 74 70 78 74 74 74 72 72 74 76
DIASTOLIC BLOOD PRESSURE - DEXMEDETOMIDINE GROUP
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 106.67 90.00 98.00 94.67 94.00 93.33 93.33 93.33 94.67 93.33 90.67 90.67 92.67 91.33 91.33 92.00
2 100.67 83.33 90.67 91.33 91.33 93.33 92.67 94.00 94.00 91.33 90.67 89.33 87.33 88.00 87.33 88.67
3 99.33 83.33 92.00 92.67 92.67 94.67 93.33 94.00 92.67 91.33 90.67 88.00 87.33 85.33 84.67 86.67
4 94.00 78.00 85.33 87.33 86.00 87.33 86.00 86.67 86.00 84.00 84.00 82.00 81.33 80.67 81.33 81.33
5 104.00 84.00 92.00 92.67 90.67 92.00 90.67 90.00 90.67 90.67 91.33 90.67 92.00 91.33 91.33 90.67
6 84.67 72.00 80.00 80.00 80.00 81.33 80.67 80.00 79.33 78.67 78.00 78.00 76.00 75.33 77.33 76.67
7 94.67 76.00 82.00 82.00 83.33 82.67 82.00 82.00 82.00 81.33 79.33 80.67 80.00 80.00 82.00 82.67
8 94.00 79.33 85.33 86.00 86.00 84.67 84.00 84.67 88.00 84.67 86.67 86.67 86.67 87.33 86.67 88.67
9 98.67 81.33 88.67 89.33 89.33 90.67 90.00 90.00 90.00 86.67 87.33 85.00 84.00 84.67 84.67 87.33
10 104.67 87.33 95.33 96.00 97.33 96.00 97.33 96.00 94.00 92.00 92.67 92.67 93.33 92.00 94.00 94.67
11 90.67 74.67 80.67 82.67 82.67 84.00 82.67 82.00 80.67 80.67 80.00 78.00 77.33 79.33 80.00 82.00
12 101.33 82.67 89.33 89.33 89.33 91.33 92.67 90.67 90.67 90.00 91.33 92.00 88.67 87.33 88.00 88.67
13 99.33 80.67 86.67 87.33 88.00 88.00 88.00 88.00 93.33 87.67 90.67 88.67 87.33 86.67 88.67 88.00
14 103.33 79.33 92.00 91.33 90.67 90.67 89.33 88.00 95.33 86.33 91.33 86.67 86.00 93.33 92.67 93.33
15 96.00 76.67 84.67 84.67 84.67 86.00 84.00 84.00 89.33 83.33 52.67 84.00 80.67 80.67 80.67 81.33
16 95.33 76.67 81.33 81.33 82.00 82.00 82.00 81.33 85.33 78.00 80.00 80.00 79.33 77.33 77.33 79.33
17 92.00 76.00 86.67 82.67 82.67 81.33 82.00 82.00 80.00 77.33 77.33 76.67 74.00 75.33 76.00 79.33
18 86.00 76.00 79.33 80.00 80.00 80.00 80.00 78.67 78.67 76.67 76.00 75.33 76.67 78.00 78.67 79.33
19 93.33 82.00 84.00 85.33 85.33 86.00 86.00 86.67 86.00 84.00 84.00 82.00 80.67 81.33 84.00 86.00
20 104.67 80.67 94.00 94.67 96.00 96.00 99.33 95.33 94.67 94.67 101.33 95.33 94.00 92.00 92.00 94.67
21 97.33 78.67 88.00 89.33 89.33 90.00 90.00 88.00 88.00 85.33 85.33 84.67 83.33 82.67 83.33 81.33
22 91.33 79.33 86.00 80.67 81.33 81.33 81.33 80.67 82.00 79.33 78.00 78.67 78.00 79.33 80.00 80.67
23 86.67 82.00 83.33 83.33 82.00 78.67 80.00 80.67 79.33 79.33 76.00 78.67 79.33 76.00 75.33 75.33
24 106.67 86.00 89.33 91.33 88.67 90.00 90.67 88.67 92.00 86.00 93.33 93.33 88.67 90.00 88.00 90.00
25 96.00 78.67 88.67 87.33 86.67 86.67 86.67 86.00 86.00 84.00 84.00 82.00 82.00 82.00 82.67 82.00
26 96.00 76.00 82.67 84.00 84.67 85.33 83.33 84.00 86.00 87.33 88.00 88.67 85.33 82.00 81.33 81.33
27 106.67 82.00 89.33 89.33 88.67 90.67 90.00 89.33 95.33 86.00 92.67 83.33 84.00 84.00 84.67 84.00
28 104.67 84.00 90.67 90.67 90.67 85.33 84.67 84.00 89.33 84.67 87.33 85.33 82.00 82.67 89.33 91.33
29 99.33 80.00 86.67 85.33 87.33 88.67 88.00 88.00 85.33 84.67 82.67 82.67 80.67 81.33 81.33 82.00
30 100.00 81.33 85.33 88.00 88.00 88.67 88.67 88.00 85.33 84.67 82.67 89.33 85.33 85.33 84.00 83.33
31 101.33 82.00 88.00 89.33 88.00 84.67 85.33 84.00 88.00 86.00 86.00 85.33 84.67 84.00 86.00 88.00
32 86.00 76.00 86.00 82.67 83.00 81.33 76.67 80.67 80.67 78.00 75.33 76.00 74.67 74.67 78.00 78.00
33 115.33 94.00 92.67 100.00 93.33 100.00 91.33 92.00 91.33 91.33 90.00 88.00 90.00 90.00 86.67 86.00
34 94.00 78.67 86.67 86.67 86.67 88.67 88.67 88.00 92.00 83.33 89.33 85.33 84.67 84.67 86.00 86.67
35 98.67 83.33 91.33 90.67 92.00 90.00 90.67 88.00 92.00 88.67 88.67 88.67 86.67 88.00 89.33 90.00
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 102.66 100 117.33 118 83.33 106.66 102.66 106.66 104 101.33 97.33 98.66 104.67 100.67 98 99.33
2 99.33 99.33 112 109.33 80 104.66 100 100.66 96.67 96 100.67 94.66 92.67 95.33 95.33 96
3 101.33 94.66 112 110 76.66 100.66 101.33 100.66 98 100.67 98.67 96.67 98 98.67 96 95.33
4 96 98 109.33 107.33 78.66 102.66 99.33 102.66 102 102 104 98 100.67 102.67 95.67 96
5 101.3 94 115.33 113.33 80.66 102.66 101.33 101.33 98.67 96.67 94 92.67 98.67 102 101.33 100
6 96.6 93.33 106 101.33 72.66 100 96 96.66 93.33 101.33 98.67 96.67 98.67 100 98 96.67
7 100 98 108 103.33 74 99.33 100 98.66 96.67 96 94 94 94.67 96 99.33 98.67
8 98 98.66 112.66 109.33 73.33 102.66 97.33 100 98 95.33 94.67 95.33 94.67 94.66 96.67 99.33
9 100 92 108 105.33 74.66 101.33 100 100.66 96.67 95.33 94 94.67 101.33 103.33 100 98
10 96 94 111.33 101.33 74 99.33 96.66 98.66 96 94.66 93.33 94.67 96.67 96 96.67 98.67
11 102.66 96.33 114.67 110 79.33 106 101.33 102.66 100 98.66 96.67 104.67 108.67 104 102 100.67
12 101.33 96 114.67 108 76 111.33 100 96 98 96 94.6794.67 96 98.67 100 98 98.67
13 91.33 82 106 103 70.68 98.66 93.33 100.66 94.67 93.33 94 98 96 91.33 100 98
14 98.66 94 111.33 106 74.66 102 103.33 98.66 98 96.66 94.67 94.67 96 102.67 100 98
15 96.33 88 103.13 100 72 99.33 94.66 92 96.67 94 93.33 92 96 98.67 98.67 96.67
16 88 86 102.66 98.66 68.66 91.33 88.66 94.66 92.67 90 88.67 89.33 98.67 96.67 93.33 90.67
17 93.33 89.33 102.66 100 69.33 96.66 92.66 96 94.67 98.67 97.33 98.67 100 98.67 99.33 97.67
18 80.66 90.66 107.33 100.66 70 98 92 96.66 96 93.33 94 94 102.67 106.67 100.67 98.67
19 93.33 88 108 105.33 74 95.33 94 94 94 91.33 89.33 92 94.67 95.33 96.67 105.33
20 88.33 87.33 100.66 94.66 68.66 93.33 92.66 89.33 91.33 88.67 87.33 85.33 85.33 87.33 90.67 92.67
21 87.33 86 96 96.33 68 89.33 89.33 92 89.33 92.67 95.33 92 92 93.33 93.33 94.67
22 102 93.33 98 98 69.33 90 89.66 100 94 90 90 89.33 91.33 94 92 89.33
23 106 101.33 106.66 103.33 73.33 100.66 100.66 102.66 97.33 94.67 92 92.67 96 94.66 93.33 98
24 96.66 89.33 117.33 106.66 75.66 101.33 104 98.66 100 100 99.33 100.67 105.33 103.33 100 101.33
25 96 91.33 107.33 102.66 72 98.66 98 96 96.67 95.33 96 97.33 97.33 102.67 99.33 96.67
26 96.33 96 106.66 103.33 72 96.66 94.66 98 96.67 96.67 101.33 96.67 99.33 97.33 98.67 97.33
27 101.33 96 110.66 105.33 74.66 97.33 98 100.66 98 96.67 94.67 97.33 101.33 102 102.67 100
28 96 93.33 110 101.33 73.33 101.33 101.33 92.33 100.67 100 100.67 100.67 104.67 103.33 102 102
29 100 94.66 108 101.33 70 97.33 94.66 99.33 94.67 94.67 95.33 93.67 101.67 94 94 95.33
30 109 98.66 108.66 106 45.33 99.33 98 117.33 99.33 99.33 99.33 97.33 89.67 99 98 96
31 109.33 104 119.33 121.33 12.66 119.33 119.33 116.33 114 111.33 109.33 110 116 112.83 94.44 105.33
32 106.68 101.33 106.66 117.33 119.33 118.66 116.66 105.33 114 108 112.67 109.33 112.33 110 100.67 108
33 89.33 84.66 106 108 108 107.33 106 116.33 100.67 100.66 100 98 101.33 97.33 94 92
34 81.33 83.33 104 106 106 104.66 103.33 105 102.67 101.33 99.33 98.67 99.33 99.33 98 96
35 108.66 102 121.33 123.33 123.33 122.66 120.66 120 114 103.33 103.33 113.33 108 103.33 110 112.67
MEAN ARTERIAL PRESSURE - CONTROL GROUP
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 140 144 164 166 160 152 150 144 140 132 128 136 134 130 126 134
2 134 130 160 164 156 146 146 138 130 128 126 120 118 126 130 132
3 132 124 156 154 144 134 134 134 130 126 124 122 126 132 128 126
4 124 126 152 154 150 148 148 144 138 130 128 122 134 140 132 128
5 132 126 166 164 156 144 144 140 136 130 126 122 128 134 136 136
6 126 120 142 136 134 136 134 130 124 124 120 122 128 136 134 130
7 132 130 148 138 138 134 136 136 130 124 126 122 120 128 134 132
8 126 124 152 156 144 140 138 136 130 126 128 130 128 124 126 130
9 124 120 138 132 134 132 132 130 122 118 118 124 132 130 128 126
10 124 118 142 132 136 136 134 132 128 124 120 128 134 128 122 120
11 136 126 156 150 146 146 144 140 136 132 130 138 142 140 138 134
12 136 132 160 156 142 138 140 138 130 128 124 124 128 132 134 136
13 110 106 138 130 126 126 116 124 124 120 118 118 116 120 124 126
14 120 126 146 138 134 124 138 134 130 126 124 120 120 128 132 130
15 126 116 138 132 134 138 134 132 130 126 124 120 128 132 136 130
16 116 110 140 136 124 118 118 120 122 118 118 124 128 130 124 120
17 124 120 136 132 128 126 126 124 120 120 124 128 128 124 122 120
18 128 120 142 138 132 130 130 128 124 120 124 126 132 136 130 128
19 132 124 156 152 146 146 144 142 158 130 118 128 132 130 130 140
20 122 118 142 136 132 136 136 134 130 126 124 120 120 122 128 130
21 114 118 132 134 132 128 124 124 120 118 122 116 116 120 120 124
22 118 116 134 130 124 114 122 120 122 118 128 120 126 130 128 124
23 142 136 148 142 144 142 142 140 136 132 122 130 136 140 140 138
24 142 130 156 148 144 144 140 140 136 136 118 126 128 134 132 128
25 118 114 142 136 132 130 130 128 126 126 118 120 120 128 122 118
26 124 120 136 138 132 138 130 128 122 122 128 118 126 130 132 128
27 126 124 148 144 138 130 136 134 130 126 130 120 120 126 132 128
28 128 120 142 132 136 136 134 134 130 128 120 122 126 130 134 130
29 124 120 144 132 130 130 128 128 124 124 124 134 134 130 128 126
30 128 124 138 134 134 132 132 130 126 126 122 124 130 134 130 128
31 148 140 162 164 162 142 160 160 154 150 148 144 140 138 142 144
32 136 128 150 152 154 152 150 150 146 140 138 142 148 150 150 148
33 112 110 138 140 140 138 138 136 130 130 128 126 124 120 118 116
34 122 115 144 146 146 144 146 144 140 136 134 130 138 130 126 128
35 142 138 168 170 170 168 166 164 158 150 146 142 136 130 142 146
SYSTOLIC BLOOD PRESSURE - CONTROL GROUP
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Sl. 
No
Baseline
Before 
Intubati
on.
After 
Intubati
on.
1 
min.
2 
min.
3 
min.
4 
min.
5 
min.
10 
min.
15 
min.
20 
min.
25 
min.
30 
min.
35 
min.
40 
min.
45 
min.
1 84 78 94 94 90 90 90 88 86 86 82 80 90 86 84 82
2 82 78 88 82 84 84 82 82 80 80 88 82 80 80 78 78
3 86 84 90 88 86 84 86 84 82 88 86 84 84 82 80 80
4 82 80 88 84 86 84 84 82 84 88 92 86 84 84 82 80
5 89 84 90 88 86 84 84 82 80 80 78 78 84 86 84 82
6 82 78 88 84 84 82 82 80 78 90 88 84 84 82 80 80
7 84 80 88 86 84 82 82 80 80 82 78 80 82 80 82 82
8 84 82 92 86 84 84 82 82 82 80 78 78 78 80 82 84
9 88 86 94 92 90 90 86 86 84 84 82 80 86 90 86 84
10 82 78 96 86 86 84 82 82 80 80 80 78 78 80 84 88
11 86 82 94 90 92 88 84 84 82 82 80 88 92 86 84 84
12 84 80 92 84 86 84 84 84 82 80 80 82 84 84 80 80
13 82 78 90 90 86 86 82 82 80 80 82 88 86 86 88 84
14 88 86 94 90 90 86 86 84 82 82 80 82 84 90 84 82
15 80 7874 86 84 82 80 80 82 80 78 78 78 80 82 80 80
16 74 74 84 80 82 78 76 78 78 76 74 72 84 80 78 76
17 78 74 86 84 80 82 80 80 82 88 84 84 86 86 88 86
18 72 74 90 82 78 82 80 80 82 80 80 78 88 92 86 84
19 74 76 84 82 76 76 74 74 92 72 70 84 76 78 80 88
20 72 70 80 74 74 72 74 74 72 70 70 68 68 70 72 74
21 74 72 78 76 72 74 72 72 74 80 84 80 80 80 80 80
22 72 70 80 82 84 80 76 78 80 76 76 74 74 76 74 72
23 82 82 86 84 82 80 80 80 78 76 74 74 76 72 70 78
24 88 84 98 86 86 82 86 84 82 82 84 88 94 88 84 88
25 86 84 90 86 84 86 86 84 82 80 84 86 86 90 88 86
26 82 80 92 86 84 80 80 80 84 84 92 86 86 84 82 82
27 86 84 92 86 86 82 82 80 82 82 80 86 92 90 88 86
28 88 82 94 88 84 86 86 84 86 86 90 90 92 90 86 88
29 82 80 90 86 86 84 84 84 80 80 78 78 76 76 78 80
30 86 82 94 92 94 86 84 82 86 86 88 84 84 82 82 80
31 90 86 98 100 100 98 98 96 94 92 90 98 104 100 92 86
32 92 88 100 100 102 102 100 100 98 92 100 96 94 90 88 88
33 78 72 90 92 92 92 90 90 86 86 86 84 90 86 82 80
34 70 66 84 86 86 88 86 86 84 84 82 80 80 84 84 80
35 92 84 98 100 100 100 98 98 92 80 82 98 94 90 94 96
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PATIENTS LIST DEXMEDETOMIDINE GROUP 
Sl. No Name
IP 
Number
Age in 
Years
Sex
Weight 
in Kg
ASA 
Physical 
Status
Surgery
1 Valsala 167826 52 F 78 II Laparotomy 
2 Chandran 168654 55 M 65 I Orthopaedic Surgery
3 Kanija 280059 28 F 57 I Laparoscopic Surgery
4 Jayasree 152225 28 F 55 I Head & Neck Surgery
5 Muthurani 169557 54 F 70 II Head & Neck Surgery
6 Khalil Raz 138941 16 M 50 I Orthopaedic Surgery
7 Maria Azhagan 174202 53 M 61 I Head & Neck Surgery
8 Kavitha 170676 27 F 49 I Laparoscopic Surgery
9 Ramakrishnan 170675 52 M 64 II Orthopaedic Surgery
10 Sunitha Rani 169870 50 F 58 II Head & Neck Surgery
11 Jayalekshmi 169544 36 F 57 I Laparoscopic Surgery
12 Pathrose 167613 38 M 77 I Urology
13 Mani 174724 50 M 55 I Lower Abdominal  Surgery
14 Rajayyan 18078 54 M 72 II Breast Surgery
15 Sunitha  170068 35 F 60 I Head & Neck Surgery
16 Siva Priya 178434 29 F 56 I Laparoscopic Surgery
17 Sreekumar 177084 48 M 74 I Orthopaedic Surgery
18 Ratheesh 180557 18 M 53 I Orthopaedic Surgery
19 Christurajah 181159 45 M 58 I Orthopaedic Surgery
20 Vishnu 178243 25 M 62 I Laparotomy 
21 Mariya 178597 46 F 75 I Head & Neck Surgery
22 Vimala Devi 181997 45 F 80 I Lower Abdominal  Surgery
23 Shanthi 178888 48 F 88 II Lower Abdominal  Surgery
24 Murukesan 180743 50 M 61 II Orthopaedic Surgery
25 Paul Raj 181422 52 M 48 II Lower Abdominal  Surgery
26 Kannan 198418 27 M 80 I Head & Neck Surgery
27 Haneeshraj 198657 38 M 80 II Laparotomy
28 Binu kumari 198220 41 F 76 I Laparoscopic Surgery
29 Rajayyan 187739 47 M 45 I Orthopaedic Surgery
30 Ayyappan 188101 53 M 65 II Orthopaedic Surgery
31 Thankamma 201812 40 F 60 I Breast Surgery
32 Anitha 201543 18 F 56 I Head & Neck Surgery
33 Shalika 202692 29 F 50 I Laparoscopic Surgery
34 Shaji 202906 25 M 61 I Urology
35 Antony 203778 35 M 44 I Head & Neck Surgery  
xxi 
 
Sl. No Name
IP 
Number
Age in 
Years
Sex
Weight 
in Kg
ASA 
Physical 
Status
Surgery
1 Radhamani 165231 37 F 62 II Urology
2 Vinod 167530 30 M 70 I Head & Neck Surgery
3 Chandran 168063 42 M 49 I Head & Neck Surgery
4 Satheesh 168945 41 M 60 I Head & Neck Surgery
5 Simi Jose 169273 26 M 67 I Head & Neck Surgery
6 Jameela 169359 24 F 52 I Laparoscopic Surgery
7 Vincent 170584 26 M 64 I Orthopaedic Surgery
8 Raveendran 176272 30 M 68 I Orthopaedic Surgery
9 Jayan 170488 55 M 56 I Head & Neck Surgery
10 Viji 171705 28 F 58 I Laparoscopic Surgery
11 Moses 173517 55 M 58 II Lower Abdominal Surgery
12 Unni 173793 47 M 65 I Orthopaedic Surgery
13 Archana 174114 22 F 60 I Laparoscopic Surgery
14 Reenamol 174098 26 F 62 I Laparoscopic Surgery
15 Shobha 174118 33 F 60 I Head & Neck Surgery
16 Latha 173880 38 F 64 I Lower Abdominal Surgery
17 Krishnaveni 175083 50 F 72 II Laparotomy 
18 Usha 176124 34 F 65 II Laparoscopic Surgery
19 Absukhan 176715 33 M 58 I Head & Neck Surgery
20 Sinthiya 176874 22 F 64 II Head & Neck Surgery
21 Jessy 177161 42 F 57 I Breast Surgery
22 Thankabhai 187036 54 F 45 II Orthopaedic Surgery
23 Prasanna Kumari 170668 49 F 66 II Urology
24 Esther 18754 55 F 70 I Orthopaedic Surgery
25 Murugayyan 188222 60 M 65 I Orthopaedic Surgery
26 Prasad 193008 28 M 60 I Orthopaedic Surgery
27 Subha 187831 32 F 65 I Head & Neck Surgery
28 Rekha 186940 24 F 54 I Laparoscopic Surgery
29 Lally 187575 39 F 71 I Laparoscopic Surgery
30 Jeba 187740 28 F 56 II Laparoscopic Surgery
31 Arumugan 187548 43 M 54 I Head & Neck Surgery
32 Nabisha 190301 40 F 56 I Breast Surgery
33 Divya 202042 23 F 47 I Head & Neck Surgery
34 Sreekumari 202145 50 F 60 II Orthopaedic Surgery
35 Thankarajan 202338 53 M 60 I Orthopaedic Surgery
PATIENT DETAILS - CONTROL GROUP
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Sl. 
No
Concentration of 
Isoflurane
Sl. 
No
Concentration of 
Isoflurane
1 1% 1 0.80%
2 0.40% 2 1%
3 0.40% 3 1%
4 0% 4 0.80%
5 0% 5 1%
6 0.40% 6 0.60%
7 1% 7 1.20%
8 0% 8 1.60%
9 0% 9 0%
10 0% 10 1.20%
11 0% 11 2%
12 0.80% 12 1.80%
13 0.40% 13 1%
14 0.40% 14 0.80%
15 0.40% 15 0.40%
16 0% 16 1.80%
17 0.60% 17 1.60%
18 0.40% 18 1.20%
19 0% 19 0.80%
20 0% 20 1%
21 0.60% 21 1%
22 0.40% 22 1%
23 0.40% 23 0.80%
24 0% 24 0.60%
25 0% 25 1.80%
26 0% 26 1.20%
27 0.40% 27 2%
28 0.80% 28 1.20%
29 0.40% 29 1.20%
30 0% 30 1.20%
31 0.40% 31 0.80%
32 0.40% 32 1.40%
33 0.40% 33 1.40%
34 0% 34 1.20%
35 0% 35 1.40%
MAXIMUM CONCENTRATIONS OF ISOFLURANE USED FOR EACH 
PATIENT DURING SURGERY
CONTROL GROUPDEXMEDETOMIDINE GROUP
 
